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Pseudomonas aeruginosa is a dreaded opportunistic pathogen that causes severe and 
often intractable infections in immunocompromised and critically ill patients. This 
bacterium is also the primary cause of fatal lung infections in patients with cystic fibrosis 
and a leading nosocomial pathogen responsible for nearly 10% of all hospital-acquired 
infections. P. aeruginosa is intrinsically recalcitrant to most classes of antibiotics and has 
the ability to acquire additional resistance during treatment. In particular, resistance to the 
widely used β-lactam antibiotics is frequently mediated by the expression of AmpC, a 
chromosomally encoded β-lactamase that is ubiquitously found in P. aeruginosa strains. 
This dissertation delved into the role of a recently reported chromosomal β-lactamase in 
P. aeruginosa called PoxB. To date, no detailed studies have addressed the regulation of 
poxB expression and its contribution to β-lactam resistance in P. aeruginosa. In an effort 
to better understand the role of this β-lactamase, poxB was deleted from the chromosome 
and expressed in trans from an IPTG-inducible promoter. The loss of poxB did not affect 
susceptibility. However, expression in trans in the absence of ampC rendered strains 
 vi 
more resistant to the carbapenem β-lactams. The carbapenem-hydrolyzing phenotype was 
enhanced, reaching intermediate and resistant clinical breakpoints, in the absence of the 
carbapenem-specific outer membrane porin OprD. As observed for most class D β-
lactamases, PoxB was only weakly inhibited by the currently available β-lactamase 
inhibitors. Moreover, poxB was shown to form an operon with the upstream located 
poxA, whose expression in trans decreased pox promoter (Ppox) activity suggesting 
autoregulation. The transcriptional regulator AmpR negatively controlled Ppox activity, 
however no direct interaction could be demonstrated. A mariner transposon library 
identified genes involved in the transport of polyamines as potential regulators of pox 
expression. Unexpectedly, polyamines themselves were able induce resistance to 
carbapenems. In summary, P. aeruginosa carries a chromosomal-encoded β-lactamase 
PoxB that can provide resistance against the clinically relevant carbapenems despite its 
narrow spectrum of hydrolysis and whose activity in vivo may be regulated by 
polyamines.  
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1.1 Preface 
 
 Pseudomonas aeruginosa is one of the most dreaded pathogens in the clinical 
setting.  It is one of the leading causes of nosocomial infections and one of the most 
troublesome and intractable organisms colonizing the lungs of patients with cystic 
fibrosis (CF), a deadly genetic disease. Although there are antibiotics and treatment 
strategies to combat such infections, the organism’s inherent and acquired resistance 
renders many such antipseudomonal treatments ineffective. One important mechanism of 
resistance, the expression of β-lactamases, is the leading cause of β-lactam resistance in 
the clinical setting and is the subject of this dissertation.  The following introduction is a 
review of the relevant literature on this important organism and its mechanisms of 
resistance, with special attention to β-lactam antibiotics and the expression of β-
lactamases.  
1. 2 Pseudomonas aeruginosa  
 
P. aeruginosa is an aerobic, non-spore forming, monoflagellated, Gram-negative 
rod ubiquitously found in the environment (Figure 1.1) (1).  It is positive for catalase and 
oxidase, and produces a fruity or grape-like odor due to the production of 2-
aminoacetophenone (2). Although it is unable to ferment lactose and its metabolism is 
mostly respiratory, it can also grow under anaerobic conditions by using nitrate as a 
terminal electron acceptor or by fermenting arginine (3, 4).   
Like other pseudomonads, renowned for their nutritional versatility, P. 
aeruginosa has very simple nutritional needs and can use a multitude of organic 
compounds for growth (3).  As a chemoorganotroph, it can metabolize a variety of simple 
3 
 
and complex organic substrates as a sole source of carbon and energy.  It is also a very 
versatile, adaptable microbe that is able to tolerate a variety of physical conditions.  It has 
an optimum growth temperature of 37°C, but it is also able to grow at 42°C, unlike some 
other species of the same genera (3). Most notably, P. aeruginosa is inherently resistant 
to many commonly used antibiotics and chemotherapeutic agents (1, 5). 
 
 
 
 
 
 
 
 
 
Figure 1.1. Colored scanning electron micrograph of P. aeruginosa. 
(http://www.visualphotos.com/image/1x6040105/coloured_sem_of_pseudomonas_aerugi
nosa_bacteria) 
 
Most strains of P. aeruginosa produce pyocyanin, a blue-green, water-soluble, 
non-fluorescent phenazine pigment (3). Phenazine compounds are commonly found in 
nature and are produced by bacteria such as the Streptomyces and Pseudomonas spp. 
Pyocyanin (1-hydroxy-5-methyl-phenazine) is derived from chorismate, an intermediate 
in the biosynthesis of aromatic amino acids in plants and microorganisms (3). Pyocyanin 
and other phenazine compounds appear to contribute to the virulence and competitive 
fitness of the producing organisms (3, 6). For instance, in  P. aeruginosa pyocyanin 
contributes to its ability to colonize the lungs of patients with CF as it has been shown to 
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disrupt the beating of human cilia and inhibit mammalian cell respiration (7, 8). 
Additionally, this pigment inhibits lymphocyte proliferation and epidermal cell growth 
(9, 10). Pyocyanin can also act as an antibiotic agent against other bacterial cells by the 
generation of reactive oxygen intermediates (6). This antimicrobial activity is oxygen-
dependent and involves the oxidation of NADH to produce superoxide and hydrogen 
peroxide (6).  
Some strains also produce pyoverdin, a water-soluble, fluorescent pigment that 
gives P. aeruginosa a yellowish-green appearance (1). Pyoverdin functions as a 
siderophore or iron-scavenging compound, and as such it is known to increase the rate of 
bacterial iron transport. Siderophores, in general, are extracellular compounds that have a 
high affinity for iron; they are produced under iron-deficient conditions, and have been 
known to stimulate and increase bacterial growth rate (1, 11).  Production of siderophores 
during infection has been implicated with bacterial virulence as a consequence of  
increased growth rate; it also appears to be a factor that can limit the growth of other 
bacteria as P. aeruginosa can effectively compete for iron with other microorganisms (1, 
11).  
Besides pyocyanin and pyoverdin, P. aeruginosa can produce and secrete a 
myriad of other virulence factors that contribute to its success as a pathogen and allow it 
to compete against other microorganisms. These include elastase, a zinc protease that 
destroys immunoglobulins and eukaryotic proteins responsible for maintaining cell 
structure; exotoxin A, a very toxic protein that inhibits the host cell protein synthesis;  
exoenzymes S and T, proteins with cytotoxic activity secreted by the type III secretion 
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system; LasA protease, a staphylolytic enzyme that can destroy β-casein, and 
rhamnolipids (1, 12). Rhamnolipids, in particular, are very powerful virulence factors 
capable of destroying polymorphonuclear leukocytes, inhibiting phagocytosis by 
macrophages, and causing disruption of the mucociliary clearance and of epithelial tight 
junctions leading to paracellular infiltration of P. aeruginosa (13-16). Rhamnolipids have 
also been shown to have antibacterial activity against a number of microbes including 
Staphylococcus aureus, Enterobacter aerogenes, Streptococcus faecalis, Serratia 
marcescens, Klebsiella pneumoniae and Proteus vulgaris to name a few (17, 18).  
 
1.2.1 Habitat  
P. aeruginosa is a ubiquitous microorganism commonly found in water, soil, and 
sewage as well as on the surfaces of plants, animals, insects, fruits and vegetables (1, 19).  
Natural bodies of water such as lakes and rivers, are also natural sources of the 
bacterium, especially near sites of urban drainage. It is sometimes part of the human 
microbial flora infrequently colonizing the skin especially in areas that are moist, and the 
intestine after ingestion with contaminated foods or fluids (20-23). Its prevalence and 
colonization in healthy individuals is often low (2.6-25%) with intestinal loads being 
reported at 3% (24-26). 
Its ability to thrive in aqueous environments has made it a problem in the hospital 
setting where it is often isolated from soaps, ointments, disinfectants, irrigation fluids, 
and eye drops (27). Its very simple nutritional needs allow it to grow even on the 
negligible impurities contained in aqueous solutions found in hospitals. Specifically, a 
study found P. aeruginosa was able to not only grow but thrive in the distilled water of 
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several mist therapy units (28). Tap water is also a major source of nosocomial infections 
when it is inadvertently used for the preparation of solutions to be used in that setting 
(29-33). The prevalence of P. aeruginosa in tap water likely results from the colonization 
of showerheads, faucets, and sinks from which it has also been detected (32, 34-38).  
Additionally, P. aeruginosa has also been isolated from holy water, aerators, baby baths, 
hot tubs, swimming pools, contact lens solutions, cosmetics and even the innersole of 
sneakers (39-46). In short, aqueous and moist environments seem to be the natural and 
preferred reservoirs for P. aeruginosa and such environments, when contaminated, can be 
potential sources of infection.  
 
1.2.2 P. aeruginosa infections in healthy individuals 
 P. aeruginosa is rarely a cause for concern in healthy individuals with such 
infections often resulting from contact with contaminated water or solutions or after 
sustaining some form of external trauma like a puncture wound (19). Folliculitis, for 
example, is an infection of the hair follicles caused by bacteria such as P. aeruginosa, and 
can occur after bathing in swimming pools, hot tubs, and whirlpools that are not 
adequately treated with chlorine (43, 44, 47, 48). Individuals involved in aquatic sports as 
well as those swimming and bathing in contaminated waters can also develop superficial 
infections of the ear canal known as external otitis (49-52).  
 Minor injury to the eye or cornea, often related to the use of contacts lens, 
especially extended wear lenses, can predispose an individual to eye infections, or 
keratitis, with P. aeruginosa (53-57). Contact lens solutions that are contaminated, or 
even tap water used for the handling of contact lens, can all serve as potential sources of 
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infection (19). Osteomyelitis, or infection of the bone, has also been reported, especially 
in children after incurring puncture wounds in the feet, with the source of the infection 
often being the sole or inner pad of the sneaker that was worn at the time of the injury 
(46, 58). Osteomyelitis can also occur in intravenous drug users (59, 60).  
 One of the most severe P. aeruginosa infections that can affect an otherwise 
healthy person is endocarditis, or inflammation of the inner lining of the heart, often 
requiring replacement of the affected valve (19). The majority of P. aeruginosa 
endocarditis occurs in intravenous drug users, as the drugs are often mixed with 
contaminated water leading to bacteremia and endocarditis (61-63). P. aeruginosa-related 
endocarditis, however, can also occur in burn and open heart surgery patients (64-66). 
 
1.2.3 P. aeruginosa in nosocomial or healthcare-associated infections 
 P. aeruginosa is one of the leading causes of hospital-acquired infections 
accounting for as much as 10-13% of all nosocomial infections with incidences as high as 
22% reported in intensive care units (ICUs) (67-71). P. aeruginosa was the sixth most 
frequently isolated pathogen accounting for 7.1% of all healthcare-associated infections 
in a recent survey of 183 US hospitals from 10 different states (72).  Similarly, the latest 
hospital reporting to the CDC ranks P. aeruginosa as the fifth most commonly reported 
pathogen in nosocomial infections accounting for 7.5% of all healthcare-associated 
infections (73).  
 Pneumonia accounts for the majority of nosocomial diseases caused by P. 
aeruginosa (72, 73). P. aeruginosa can easily colonize endotracheal tubes and 
mechanical ventilators and as such has been reported as one of the leading causes of 
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ventilator-associated pneumonia (VAP), second only to S. aureus (73-75).  VAP has been 
associated with high mortality rates that exceed those of other types of pneumonia such 
as community-acquired, healthcare-associated or hospital-acquired pneumonia (75, 76).  
Mortality rates have been reported as high as or higher than 70% when P. aeruginosa or 
Acinetobacter spp. are the causative agents (74, 76-78). About 11% of nosocomial 
urinary tract infections (UTIs) are caused by P. aeruginosa (72, 73).  A higher incidence 
of infection is associated with the use of urinary catheters, P. aeruginosa being the 
second most commonly identified pathogen in catheter-associated UTIs (73, 79).  
 P. aeruginosa is also a leading cause of nosocomial infections in burn units 
primarily colonizing burn wounds but also responsible for pneumonia, bacteremia and 
UTIs in that setting (80-84). On admission, generally S. aureus and coagulase-negative 
staphylococci predominate the wounds of burn patients but the incidence of P. 
aeruginosa quickly increases during the first week of admission and continues to rise 
with time, often surpassing the incidence of other microorganisms (82, 85, 86). Burn 
wound infections with P. aeruginosa are especially worrisome since they are correlated 
with bacteremia, a high rate of sepsis and mortality (81, 82, 87, 88). Other nosocomial 
infections caused by P. aeruginosa include endocarditis, meningitis, bacteremia, 
gastrointestinal and surgical site infections (72, 73, 89).   
 
1.2.4 P. aeruginosa in immunocompromised patients 
 P. aeruginosa is an opportunistic human pathogen that readily exploits any 
deficiency in the host immune system to mount an infection. Since it is often intractable 
and resistant to a wide range of antibiotics, it represents a very serious problem not only 
9 
 
for critically ill individuals, such as those in the hospital setting and ICUs, but also for 
immunocompromised patients.  P. aeruginosa has often been isolated as one of the most 
common pathogens causing septicemia in patients with primary immunodeficiencies (90, 
91).  A number of other conditions can predispose the host to P. aeruginosa bacteremia 
including taking broad spectrum antibiotics, receiving chemotherapy, as well as being an 
HIV, leukemia, cancer, diabetes, bone marrow or organ transplant patient (92-99).   
 Although P. aeruginosa bacteremia has been reported in patients with AIDS (100, 
101), a number of studies agree that pathogens other than P. aeruginosa are the most 
common cause of bacteremia in that population (95, 102).  P. aeruginosa however, is one 
of the leading causes of pneumonia in HIV patients (103-106) and a common respiratory 
pathogen in patients with AIDS, where pulmonary and respiratory disease infections are 
often chronic and intractable (107-111).   
 Before 1968, P. aeruginosa bacteremia in cancer patients resulted in ∼80-90% 
fatalities (112-115). The development of more potent antipseudomonal drugs has greatly 
improved outcomes and survival rates in these patients, provided that the bacteremia is 
treated rapidly, with studies from the 1980s and 2000s showing a 60 and 80% cure rate, 
respectively (92, 98, 116, 117). Although prognosis has improved, the incidence of P. 
aeruginosa infections in cancer patients for the decade of the ‘90s was found to range 
from 5-12% (118), while in a report from 2008, carbapenem-resistant P. aeruginosa 
infections were documented in 20% of the cancer patients (119). A recent study found 
that P. aeruginosa was the leading causative agent of bloodstream infections (42%) and 
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pneumonia in patients with solid tumors, with 22% incidence of bloodstream infections 
in patients with haematological malignancies (120).  
 
1.2.5 P. aeruginosa and cystic fibrosis 
 P. aeruginosa is the most common and clinically relevant pathogen found in 
patients with CF (121-123).  It is estimated that over 80% of CF patients will be infected 
with this bacterium by the time they reach adulthood (122). Infection of the airways with 
P. aeruginosa, and the inflammation that follows, represent a major problem for CF 
patients as the lungs steadily deteriorate auguring very poor overall prognosis and high 
mortality rates (124-126).  As of 2012, the life expectancy for a patient with CF in the 
United States was around 37.8 years (122). 
 CF is an autosomal, recessive genetic disease affecting about 30,000 people in the 
US and about 70,000 worldwide (122). This disease mainly affects Caucasian 
populations of European descent and is caused by mutations in the cystic fibrosis 
transmembrane conductance regulator (CFTR) gene located in the long arm of 
chromosome VII (127-129). The CFTR protein is a cAMP-regulated chloride channel 
found on the apical surface of various epithelial cells and responsible for the transport of 
chloride ions into and out of the cell (130-136). Additionally, the CFTR protein is known 
to regulate other membrane conductance channels including the outwardly rectifying 
chloride channel (137-139) and the epithelial sodium channel, ENaC (140-143). 
 More than 1800 CFTR mutations have been reported so far, the majority being 
rare and not yet well understood (122, 144). Most mutations can be grouped into one of 
six classes according to the level of disruption or impairment of CFTR function (Figure 
11 
 
CFTR
x
x
CFTR
x
Class I
Nucleus
Class V
Endoplasmic
reticulum
Proteosome
Golgi
complex
Class II
Accelerated
turnover
Class VIClass IV
Class III
Cl¯
1.2). Classes I, II and III are associated with a more severe form of the disease including 
pancreatic insufficiency and defective pulmonary function (145-147). Patients with class 
IV, V and VI mutations, on the other hand, generally exhibit a milder presentation and 
have a functional pancreas (146, 148, 149). The most common mutation, a class II 
mutation present in 86.7% of the CF patients worldwide, is a deletion in phenylalanine at 
position 508 (ΔF508) resulting in misfolding of the protein and subsequent degradation 
by proteasomes (122, 147).  
  
 
 
 
 
 
 
 
 
 
 
Figure 1.2. Classes of CFTR mutations. CFTR mutations can result in no CFTR protein 
being expressed (class I), misfolded protein that is degraded by proteasome (class II), a 
CFTR protein that does not respond to cAMP (class III), defective chloride conductance 
or channel gating (class IV), a reduced number of CFTR transcripts due to a promoter or 
splicing abnormality (class V) and accelerated turnover from the cell surface (class VI) 
(148, 150-153). Reproduced with permission from (153), Copyright Massachusetts 
Medical Society. 
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 There is an ongoing debate as to how CFTR mutations cause lung disease in 
patients with CF but most proposed models converge on one point: the imbalance of 
water and ions created by a malfunctioning CFTR protein in the apical surfaces of airway 
epithelium ultimately leads to abnormal or defective mucociliary clearance (MCC) (154-
159). MCC is an important defense mechanism against inhaled particles, allergens, 
bacteria and viruses (160-162). Normal airway epithelium is ciliated and covered with a 
layer of liquid known as the airway surface liquid (ASL) (163-165). The ASL itself is 
divided into a fluid layer of low viscosity known as the periciliary liquid (PCL) or sol 
layer that keeps the cilia hydrated and facilitates its beating, and a more viscous upper gel 
or mucus layer that is responsible for trapping foreign particles (Figure 1.3A) (164-167). 
The beating of the cilia continuously propels the mucus layer with its trapped particles 
upwards towards the nasopharynx and the mouth where foreign substances can be then 
swallowed or expectorated (161, 166, 168, 169).  
 The most strongly supported and generally accepted hypothesis of pathobiology 
in CF is that abnormal transport of chloride ions across epithelial membranes coupled 
with the increased absorption of sodium and water through the epithelial sodium channel, 
ENaC, leads to dehydration of the ASL layer (Figure 1.3B) (170-174). This hypothesis, 
known as the low-volume hypothesis, states that the depletion of the airway surface 
liquid reduces the volume or height of the PCL layer and increases the viscosity of the 
mucus layer leading to compression and impaction of the cilia (170, 174-176). Impaction 
of the cilia is thought to compromise its proper functioning and to diminish its capacity to 
work in concert with the mucus layer to remove foreign particles (154, 156). The end 
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result is impairment of the MCC apparatus setting up the stage for the persistent and 
chronic bacterial infections that are a hallmark of airway disease in CF patients (Figure 
1.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3. ASL layer and MCC in the normal and CF airways. A. Normal CFTR 
function. Under normal conditions, the PCL layer is hydrated and the cilia beat normally 
allowing MCC from the mucus layer. B. Abnormal or nonfunctioning CFTR leads to 
dehydration and reduction in volume of the PCL layer resulting in impacted and 
improperly beating cilia that hinders MCC (177). Reproduced from (177) with 
permission from Elsevier.  
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Figure 1.4. Pathobiology of CF lung disease. In the most widely accepted hypothesis of 
pathobiology of CF lung disease, reduced airway surface liquid results in impairment of 
MCC leading to successive cycles of infection and inflammation eventually resulting in 
obstruction of the airways, chronic deterioration of the lungs and death. Reproduced from 
(154) with permission from John Wiley and Sons. 
 
 CF, however, is a multi-organ disease not just limited to the lungs, as the CFTR 
protein is expressed in the epithelium of several other organs including the pancreas, 
sweat ducts, intestine, biliary tree and the vas deferens (178-184). For example, in the 
intestine it can lead to meconium illium, a condition where the first stool of the newborn 
15 
 
is impacted in the intestine (182, 185).  Additionally, more than 95% of men with CF are 
usually infertile (186-188). Lung disease, however, remains one of the main concerns for 
patients with CF as continuous cycles of infection and inflammation herald gradual lung 
deterioration and eventual pulmonary failure (Figure 1.4).     
 The conditions present in CF airways, namely dehydrated, thick mucus coupled 
with impaired mucociliary clearance, provide the ideal environment that is conducive to 
colonization by a number of pathogens (123, 189).  S. aureus, for example, often the first 
to colonize the respiratory tract of CF patients, is common in children less than 10 years 
old, and responsible for infant morbidity and mortality in the preantibiotic era (Figure 
1.5) (122, 123). Haemophilus influenzae is another common pathogen and is 
predominantly found in young children (123, 189). Other less common pathogens such as 
Stenotrophomonas maltophilia (previously Xanthomonas maltophilia), Alcaligenes 
xylosoxidans and Burkholderia cepacia complex, have also been isolated from the 
respiratory tract of CF patients, the latter having the poorest prognosis, although found in 
less than 10% of patients (122). A recent study examined the microbiome of sputum from 
CF patients and found that although the patients were not being treated for fungal 
infections, many (18/19) did carry pathogenic fugal species of Aspergillus, Candida, 
Cryptococcus and Exophiala, among others (190). Fungal infections are in fact not 
uncommon in CF patients and can occur in association with other microorganisms (190-
193).  P. aeruginosa, however, remains the main pathogen associated with morbidity and 
mortality in CF patients and is more frequently found in adults (Figure 1.5) (122, 124, 
126, 194). 
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Figure 1.5. Pathogens found on the CF lungs by age. From an early age, CF patients are 
infected with a number of different organisms. By the time they reach adulthood, P. 
aeruginosa is the predominant pathogen (122).  
 
 An important feature of P. aeruginosa infections, is the tendency of this 
bacterium to convert to a mucoid phenotype in the lungs of CF patients, an event which 
signals the beginning of chronic stage of the infection leading to a progressive decline in 
lung function (195-197). This mucoid phenotype is characterized by the production of 
large quantities of alginate, a polysaccharide also known as mucoid exopolysaccharide, 
which plays a very important role in helping the bacterium evade the host immune system 
(123, 198, 199).  Alginate promotes a biofilm mode of growth, which in turn not only 
protects the bacteria from antimicrobial agents, but also helps the microorganisms escape 
phagocytosis by macrophages (200). Alginate overproduction exacerbates the already 
detrimental conditions of the CF lungs leading to further blocking of the airways and 
inexorable death. 
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1.2.6 Treatment 
 Treatment of P. aeruginosa infections varies greatly given severity of infection 
and resistance profile of the organism. Current strategies include treatment with a single 
drug, usually a β-lactam or an aminoglycoside, or combination therapy with at least two 
different antimicrobial agents (189, 201, 202). β-lactams, include a broad class of 
bactericidal agents, widely used in the clinical setting, and with minimal side effects to 
eukaryotes (Figure 1.6) (203-205). Several β-lactams have shown reliable results against 
P. aeruginosa, including the extended-spectrum penicillins ticarcillin and piperacillin that 
can be combined with the β-lactamase inhibitors clavulanic acid and tazobactam, 
respectively, to enhance the antibacterial action of the β-lactam (201, 202). The 
cephalosporin ceftazidime is stable to most β-lactamases and is the drug of choice if the 
isolate is determined to be susceptible (205, 206).  
 
 
 
 
 
Figure 1.6. Molecular structures of two β-lactams of the penicillin class.  
 
 The carbapenem β-lactams can be used if the organism is resistant to extended-
spectrum penicillins and cephalosporins (207, 208). Carbapenems have a wide spectrum 
of activity but can select for multidrug resistant (MDR) strains of P. aeruginosa, 
especially imipenem. The monobactam aztreonam, is the drug of choice if the patient is 
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Tobramycin Amikacin
allergic to penicillins and other β-lactams (209, 210). It can be helpful in treating isolates 
that produce metallo-β-lactamases as it is resistant to hydrolysis by class B enzymes. 
 Combination therapy is usually the first line of defense, particularly for MDR 
pseudomonal infections (189, 201).  The most commonly used combination includes the 
administration of a β-lactam with an aminoglycoside. The aminoglycosides are powerful 
antimicrobial agents that inhibit bacterial protein synthesis being predominantly active 
against aerobic, Gram-negative bacteria (211, 212). The discovery of gentamicin in 1963 
was a breakthrough in the treatment against P. aeruginosa infections, and subsequently 
other more powerful aminoglycosides, such as tobramycin and amikacin, were developed 
(213). Tobramycin has shown greater activity in vitro than most other aminoglycosides, 
and thus it is often the drug of choice to treat P. aeruginosa infections (211). Amikacin, 
however, is very effective against bacteria that are resistant to other aminoglycosides 
such as gentamicin and tobramycin. Its chemical structure makes it less susceptible to the 
inactivation by the enzymes that normally inactivate gentamicin and tobramycin (Figure 
1.7) (211).   
 
 
 
 
 
 
Figure 1.7. Molecular structures of amikacin and tobramycin. 
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 Aminoglycosides, however, can often have nephrotoxic and ototoxic side effects 
(214). Nephrotoxicity is usually reversible but ototoxicity, or the toxic effect on the inner 
ear, is generally irreversible and can lead to hearing loss (215). Thus, aminoglycosides 
should only be administered when no other antibiotic is deemed as effective, for instance 
in the treatment of MDR organisms and of critically ill patients, and should be replaced 
with less toxic agents as soon as the sensitivity profile of the organism is ascertained 
(211). Combination therapy with aminoglycosides often includes amikacin or tobramycin 
with either piperacillin, ticarcillin, ceftazidime, imipenem, meropenem or aztreonam 
(189, 201). 
 Another option when considering therapy for P. aeruginosa infections, is the 
combination of either an aminoglycoside or a β-lactam with ciprofloxacin (216, 217). 
Ciprofloxacin belongs to a class of antibiotics known as fluoroquinolones (218). 
Fluoroquinolones have a broad-spectrum of activity and act by preventing DNA 
replication through the inhibition of the enzyme DNA gyrase (218). Ciprofloxacin has 
great activity against P. aeruginosa and Gram-negatives and unlike the rest of above 
antibiotics, the majority of which are for parenteral use or aerosolized, it is available for 
oral administration (219, 220). It has been particularly good at treating respiratory 
infections in CF patients but prolonged monotherapy can lead to resistance (219, 221-
224). Additionally, serious side effects, such as damage of young cartilage, tendonitis and 
tendon rupture, hypoglycemia and arrhythmias, have been reported (225, 226).  It is often 
used in conjunction with inhaled antibiotics like the aminoglycoside tobramycin or the 
polymyxin colistin (123, 227). 
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 Colistin was one of the first drugs to show good in vitro activity against P. 
aeruginosa (228-230). It works by disrupting the structure of the outer membrane and 
increasing cell permeability leading to cell lysis (231). Earlier studies however, reported 
serious nephrotoxic and neurotoxic effects and thus its use was relegated to the external 
treatment of eye and skin infections (232, 233). The emergence of MDR strains, 
unresponsive to broad spectrum antibiotics but remaining susceptible to the drug, has 
brought colistin back into the antimicrobial limelight (234, 235). Despite its earlier 
reported toxicity, recent studies show its usefulness outweighs potential risks, which have 
also been shown to be lower than originally reported, perhaps as a result of better dosing 
strategies (236, 237). Although reported nephrotoxicity rates for intravenous use are up to 
14%, in many cases a lack of better alternatives has redefined colistin as the last line of 
treatment or salvage therapy (238, 239). For the treatment of respiratory infections, in 
both CF and non-CF patients, colistin can be administered as an aerosol, which has the 
advantage of a more direct higher dose delivery to the site of infection while limiting 
toxicity (240-242). Colistin has also been shown to be effective against the inner structure 
(core and stalk) of the P. aeruginosa biofilm suggesting this antimicrobial peptide can 
penetrate this complex structure (243).  
1.3 Mechanisms of intrinsic antibiotic resistance 
 P. aeruginosa can employ a number of mechanisms to evade, prevent or inhibit 
the actions of antibiotics, the most common of which include restricted membrane 
permeability, active efflux of antibiotics, alteration of drug targets, the formation of 
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biofilm, and the expression of β-lactamases (Figure 1.8) (244-247). The following 
sections will review some of these important mechanisms.  
 
 
 
 
 
 
 
 
 
 
Figure 1.8. Mechanisms of antibiotic resistance in P. aeruginosa. P. aeruginosa employs 
multiple mechanisms to inhibit the action of antibiotics including an intrinsically low 
membrane permeability, expression of efflux pumps, modification of antimicrobial 
targets and production of β-lactam-hydrolyzing enzymes. Reproduced from (248) with 
permission from Elsevier.  
 
1.3.1 Extrapermeability barrier 
 The cell wall of Gram-negative bacteria is composed of an inner membrane, a thin 
peptidoglycan layer and outer membrane (OM) that serves as a selective permeation 
barrier by restricting the passage of solutes across the membrane (Figure 1.9) (249, 250). 
The OM is generally an asymmetric lipid bilayer with an inner leaflet of phospholipids 
and a surface layer rich in lipopolysaccharide (LPS) (251, 252). 
22 
 
 
 
 
Figure 1.9. Cell wall of Gram-negative bacteria. An inner phospholipid bilayer 
containing mostly phosphatidylethanolamine (red lipids) with some phosphatidylglycerol 
(light brown lipids) surrounds the cytoplasm of the bacterial cell. The periplasm, or the 
space sandwiched between the inner and outer membranes, contains a thin peptidoglycan 
layer; membrane-derived oligosaccharides (MDO) can also be present. The outer layer of 
the OM is rich in LPS. Kdo, 3-deoxy-D-manno-octulosonic acid; (n) variable number of 
O-antigen repeats; (PPEtn), pyrophosphoethanolamine (253).  
(https://amit1b.wordpress.com/the-molecules-of-life/10-the-living-cell-gallery/) 
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 In order to reach their targets inside the cell, antibiotics must first cross the outer 
membrane. Permeability of the OM is largely governed by the low fluidity structure of 
the LPS layer and by the presence of channels or pores in the membrane known as porins 
(250, 254). Generally, small, hydrophilic compounds, like β-lactams, are taken up by 
porins, while lipid-mediated pathways are thought to be responsible for the uptake of 
hydrophobic antibiotics like aminoglycosides and polymyxin (255-257).   
 
1.3.1.1  LPS as a barrier and lipid-mediated uptake 
 
 LPS is one of the first barriers that solutes encounter when traversing the cell.  It 
is usually comprised of lipid A, the core sugars and the O antigen, and it is a very 
strongly negatively charged structure (258, 259). Divalent cations such as calcium (Ca
2+
) 
and magnesium (Mg
2+
) have a high affinity for LPS and help to neutralize some of these 
negative charges while at the same time bridging neighboring LPS molecules (260-265). 
Bridging of adjacent LPS molecules through divalent cations, as well as through 
hydrogen bonding, promotes strong lateral interactions, stabilizes the structure and 
creates a gel-like core of low fluidity in the lipid interior restricting the passage of solutes 
and antibiotics across the membrane (266-268).   
 The low fluidity of the LPS structure is thought to restrict partitioning by 
hydrophobic compounds and antibiotics (255, 269). Hydrophobic probes have been 
shown to be excluded from the membranes of P. aeruginosa and Escherichia coli (270, 
271). Similarly, P. aeruginosa and other Gram-negative bacteria intrinsically display 
high MICs (minimum inhibitory concentration) against hydrophobic antibiotics such as 
macrolides, novobicin, clindamycin and fusidic acid. (255, 272). Defects in efflux, 
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however, have been shown to reduce the MICs of hydrophobic antibiotics. The intrinsic 
resistance to hydrophobic antibiotics thus, is determined not only by the normal structure 
of LPS but also by the ability of some of these compounds to be effluxed. LPS is 
generally considered effective at slowing down the passage of hydrophobic antibiotics 
and permeation rates through the outer membrane have been found to be 50-100 times 
slower than through a simple lipid bilayer (273). 
 The structure of LPS, however, can be compromised by the presence of 
polycationic compounds (274-276). Polycations, having sometimes a higher affinity for 
LPS than divalent cations, can readily displace them from their regular binding sites in 
the LPS, leading to disruptions in the membrane barrier and increasing permeability of 
the outer membrane (271, 275). Specifically, the bulkiness of the polycations is thought 
to create transient cracks in the structure of the LPS, thus allowing uptake of other 
compounds such as hydrophobic antibiotics and of the polycations themselves in a 
process known as self-promoted uptake. Examples of antibiotics that promote their own 
entry into the cell by disrupting the normal structure of LPS via their cationic nature 
include aminoglycosides, polymyxins, cationic detergents and polycationic peptides, 
among others (256, 276-281). Permeabilization of the outer membrane with such 
compounds can additionally sensitize the cells to permeation by other compounds and 
antibiotics including lysozyme, β-lactams, and a number of hydrophobic antibiotics 
(erythromycin, clindamycin, novobiocin, fusidic acid and cloxacillin) (274, 282-284). 
Membrane permeabilizers, such as the metal chelator EDTA, have a similar effect and 
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can enhance the uptake of a number of compounds and antibiotics that are not themselves 
permeabilizers (285). 
1.3.1.2  Porin-mediated transport 
A major determinant of permeability is the presence of water-filled channels in 
the outer membrane called porins. OprF is the major general porin in P. aeruginosa (286, 
287). It is a non-specific channel for the passage of large substrates and has an exclusion 
limit of about 3000 daltons in contrast to 600 daltons for OmpF, the general porin in E. 
coli (287-289). Notwithstanding the large pore size and its abundance in the outer 
membrane, OprF is considered a slow porin because of its slow rate of diffusion and low 
permeability (289, 290). A study showed that the rate of arabinose influx was 50 times 
slower through the P. aeruginosa OprF than through the E. coli OmpF channel (291). In 
general, the rate of solute diffusion across the outer membrane of P. aeruginosa has been 
at least two orders of magnitude lower than that of E. coli (287, 292). 
The slow rate diffusion has been attributed to the conformation of the OprF 
channel in P. aeruginosa. Various studies suggest that OprF can exist in two different 
conformations, open or closed, and that only a minority of the channels are ever open, 
thus accounting for the decreased permeability as compared to E. coli (291, 293-295). 
While having the majority of channels closed may seem arbitrary, the periplasmic C-
terminus of the closed conformer is predicted to interact with the peptidoglycan layer as a 
way to stabilize the structure of the cell envelope (296-299). Thus, the closed conformer 
of OprF appears to play a major structural role in P. aeruginosa besides that of 
permeability, its absence leading to abnormal cell morphology and destabilization of the 
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outer membrane (300, 301). However, even with only about 5% of the channels open at 
any one time, OprF is still a major determinant of permeability in P. aeruginosa (293, 
302). 
Another porin affecting permeability and β-lactam resistance is the substrate-
specific porin OprD. OprD is specific for basic amino acids, dipeptides and carbapenems 
(imipenem, meropenem, doripenem) (20, 21, 23, 34). In the clinical setting, exposure to 
imipenem often leads to mutations, deletions or insertions in oprD and loss of the protein 
resulting in impermeability and clinical resistance to imipenem (29-33, 38). Although 
loss of OprD also increases the MIC against meropenem, it does not by itself usually lead 
to clinical resistance (303-305), presumably because meropenem can also get inside the 
cells via other routes (306-308). Additionally, both meropenem and doripenem are 
subject to efflux by the MexAB system while imipenem is not (309-312). Thus, clinical 
resistance to imipenem can happen with just the loss of OprD (313-315), while both 
absence of OprD and upregulation of the MexAB pump are needed for meropenem and 
doripenem resistance to occur (304, 309-311, 316). 
As previously mentioned, OprD also mediates the uptake of basic amino acids 
and peptides that structurally resemble carbapenems (Figure 1.10) (21, 23). The 
positively charged residues at C2 of imipenem closely resemble a number of basic amino 
acids such as histidine, lysine, arginine and ornithine that not surprisingly have been 
shown inhibit imipenem transport through OprD (317). Small peptides containing lysine 
have also been shown to inhibit transport, while addition of basic amino acids to different 
media increased the resistance of different P. aeruginosa strains against carbapenems 
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(22, 23, 36). Such finding could be of concern in the clinical setting as the empirically 
demonstrated MIC might not reflect the real MIC in the blood or serum where the 
presence of basic amino acids may reduce the efficacy of carbapenem treatment. 
 
 
Figure 1.10.  Molecular structures of the β-lactam imipenem and of the amino acids L-
lysine and L-arginine. 
 
Many other specific and gated porins, for uptake of a myriad of substrates 
including iron and carbohydrates, exist in the outer membrane of P. aeruginosa (318). As 
they have not been associated with resistance, they will not be further discussed here.  
The porins involved in efflux are examined below.  
 
1.3.2 Efflux pumps  
Efflux pumps are ubiquitous in nature and have been recognized in both 
prokaryotic and eukaryotic cells (319). They are membrane-bound pumps that transport a 
variety of solutes such as dyes, antibiotics and toxic compounds to the outside of the cell 
by using the energy of ATP hydrolysis or the energy derived from transmembrane 
electrochemical gradients, such as the proton motive force (320, 321).  Efflux pumps can 
be substrate specific or they can transport a variety of structurally different compounds, 
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including different classes of antibiotics (319).  Pumps that are able to export a wide 
range of antibiotics are often associated with multidrug resistance (319). Efflux-
determined resistance can be caused by an increase in expression of efflux proteins, often 
as a result of mutations in efflux regulatory genes, or by mutations that enhance the 
export capabilities of the pump itself (320).  
Five different classes of efflux pumps have been described in bacteria: the major 
facilitator superfamily (MFS), the small multidrug resistance (SMR) family, the 
multidrug and toxic compound extrusion (MATE) family, the ATP-binding cassette 
(ABC) family, and the resistance nodulation-division (RND) family (Figure 1.11). RND 
efflux pumps are of particular interest in Gram-negative bacteria where they play a 
crucial role in intrinsic and acquired resistance in synergy with the outer membrane 
barrier (246, 322, 323). They are responsible for the export of a variety of substrates such 
as toxic substances, dyes, detergents, antibiotics, as well as substances produced by the 
host such as bile, hormones and antimicrobial peptides (324-328). RND pumps typically 
have a tripartite arrangement comprised of an inner membrane transporter, a periplasmic 
adaptor protein and an outer membrane channel that driven by the proton motive force, 
work in concert to transport solutes across two membranes towards the extracellular 
space (329, 330). Capture of solutes from the periplasm has also been reported in both E. 
coli and P. aeruginosa (331-333). 
Twelve RND efflux pumps have now been described in P. aeruginosa: MexAB-
OprM (317, 334, 335), MexCD-OprJ (336, 337), MexEF-OprN (338), MexGHI-OpmD 
(339, 340), MexJK (341), MexMN (342), MexPQ-OpmE (342), MexVW (343), MexXY 
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(344, 345), TriABC-OpmH (346), MuxABC-OpmB (347) and CzrAB-OpmN (348). 
Together they form a family of multidrug efflux pumps with an extensive substrate range 
that includes aminoglycosides, fluoroquinolones, β-lactams, tetracycline, 
chloramphenicol and macrolides, among others (Table 1.1).  
Figure 1.11. Family of efflux pumps found in bacteria and their substrates. Reproduced 
from (319) with permission by the American Society for Microbiology. 
 
 RND efflux-encoding genes are organized into operons frequently in association 
with an immediately upstream located transcriptional regulatory gene (320, 322, 349). 
The first gene of the RND operon (mexA, mexC, mexE, and mexX) generally encodes a 
membrane fusion protein connected to the cytoplasmic membrane and expanding through 
the periplasm. The second gene (mexB, mexD, mexF, and mexY) encodes an inner 
membrane transporter that moves the substrate across the cytoplasmic membrane into the 
periplasm. An additional gene may be present in some operons (oprM, oprJ, and oprN). 
This third gene encodes an OM protein that allows passage of substrates across the outer 
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membrane into the extracellular space. Operons that do not code for the outer membrane 
protein themselves, may instead use the OM protein from another pump. For instance, the 
mexXY, mexJK, mexMN, and mexVW operons, lacking an OM-encoding gene, use the 
OprM protein of the MexAB system as an outer membrane channel, MexJK can 
additionally use OpmH (349).  
 
Table 1.1: Substrate profile of RND efflux pumps described in P. aeruginosa (312, 323). 
Efflux pump  Substrates 
MexAB-OprM  
Fluoroquinolones, tetracycline, chloramphenicol, β-lactams 
(except imipenem), β-lactamase inhibitors, novobiocin, 
macrolides, trimethoprim, tigecycline, triclosan, sulfonamides, 
ethidium bromide, SDS, aromatic hydrocarbons, 
thiolactomycin, cerulenin, acylated homoserine lactones 
MexCD-OprJ  
Fluoroquinolones, tetracycline, chloramphenicol, β-lactams 
(except imipenem), novobiocin, macrolides, trimethoprim, 
triclosan, ethidium bromide, SDS, aromatic hydrocarbons, 
crystal violet 
MexEF-OprN 
Fluoroquinolones, chloramphenicol, trimethoprim, aromatic 
hydrocarbons, triclosan 
MexGHI-OpmD  Norfloxacin, vanadium 
MexJK  Tetracycline, erythromycin, triclosan  
MexMN Chloramphenicol, thiamphenicol 
MexPQ-OpmE Fluoroquinolones, tetracycline, chloramphenicol, macrolides 
MexVW 
Fluoroquinolones, tetracycline, chloramphenicol, 
erythromycin, ethidium bromide, acriflavine 
MexXY 
Fluoroquinolones, aminoglycosides, tetracycline, 
erythromycin macrolides, chloramphenicol several β-lactams, 
not imipenem, 
TriABC-OpmH  Triclosan 
MuxABC-OpmB 
Aztreonam, macrolides, novobiocin, tetracycline 
CzrAB-OpmN 
Cadmium, zinc 
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 MexAB-OprM is the major contributor of efflux-mediated intrinsic resistance in 
P. aeruginosa (350). Although constitutively expressed, the MexAB-OprM pump 
mediates resistance to varied antimicrobial agents having the widest substrate range of all 
known RND P. aeruginosa pumps (317, 335). Recently, Yang et al. studied the promoter 
activity of all 12 RND pumps found in P. aeruginosa (351). In agreement with previous 
reports, mexAB-oprM had the highest activity in all conditions tested. mexJK, mexVW, 
mexXY and muxABC-opmB were also constitutively expressed, but at much lower levels 
than mexAB. Still lower, but detectable activity was observed for mexGHI-opmD, 
mexPQ-opmE and mexMN, with no activity detected for the rest of the pumps. 
 These promoter expression studies are in agreement with previous reports that 
show most pumps are either silent or constitutively expressed and that their contribution 
to innate resistance is null (322, 350). In particular, disruptions of mexCD-oprJ and 
mexEF-oprN were not previously shown to affect susceptibility, suggesting these two 
pumps do not contribute to intrinsic resistance (338, 352). The MexXY system, on the 
other hand, is thought to contribute to the intrinsic resistance of P. aeruginosa against 
tetracycline, erythromycin, and gentamicin, as deletion of mexXY increases susceptibility 
against these antibiotics (353). Not surprisingly, these compounds, but not other MexXY 
substrates, were shown to induce expression of mexXY.  
 Although most pumps are silent or only weakly expressed, and likely not playing 
a role in innate resistance, their contribution should not be discounted as it is often 
mutations in their regulatory genes or regions (known and unknown), that lead to 
overexpression and multidrug resistance. For instance, MexCD-OprJ is silent in wild-type 
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but hyperexpression and variable levels of resistance have been attributed to in vitro and 
in vivo mutations in its repressor-encoding gene, nfxB (336, 354). Such mutations have 
also been reported in the regulatory genes for mexEF-OprN and mexJK, as well as for the 
operons already providing intrinsic resistance, mexAB-oprM and mexXY (322, 349). Thus 
collectively, the RND efflux pumps are a major determinant of efflux-mediated resistance 
in P. aeruginosa. 
 
1.3.3 Alteration and modification of penicillin-binding proteins 
 The peptidoglycan layer of Gram-negative bacteria consists of alternating 
subunits of N-acetylglucosamine (GlcNAc) and N-acetylmuramic acid (MurNAc), where 
MurNAc bears a stem peptide often consisting of L-alanine, D-glutamic acid, L-lysine or  
meso-diaminopimelic acid (meso-DAP), and D-alanyl-D-alanine (Figure 1.12) (355-358). 
Cross-linking of the glycan chains, or transpeptidation, is carried out by essential proteins 
known as penicillin-binding proteins, PBPs, and generally occurs between the third 
amino acid (DAP) of a stem peptide and the fourth (D-Ala) of the next peptide chain 
(Figure 1.12) (359). PBPs additionally catalyze other reactions in the later stages of 
peptidoglycan synthesis and remodeling including polymerization of the nascent glycan 
strand (transglycosylation), removal of the last D-alanine of the stem peptide 
(carboxypeptidation), and hydrolysis of the peptide bond that connects the two strands 
(endopeptidation) (360).  
 PBPs are generally classified as high molecular mass (HMM) and low molecular 
mas (LMM) enzymes and are further subdivided into classes A and B (360-362). A class 
C also exists for LMM PBPs. HMM class A PBPs are bifunctional with an N-terminal 
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glycosyltransferase domain and a C-terminal transpeptidase domain, while class B 
enzymes are only transpeptidases (Table 1.2). LMM class A and B PBPs are 
carboxypeptidases, and class C can be carboxypeptidases and/or endopeptidases. 
  
Figure 1.12. Structure of peptidoglycan. In Gram-negative bacteria the peptidoglycan 
layer is made up of alternating subunits of MurNAc and GlcNAc. A 4-5 amino acid stem 
peptide is attached to the GlcNAc subunits. Direct cross-linking can occur between the 
fourth D-Ala of one PG molecule and the third meso-DAP residue of the next.  
 
 
 
 
 
  
 
 
 
            Adapted from references (362) and (363). 
Category Subclasses In vivo function 
High 
Molecular 
Mass 
A glycosyltransferase and transpeptidase 
B transpeptidase 
Low 
Molecular 
Mass 
A carboxypeptidase 
B carboxypeptidase 
C carboxypeptidase/endopeptidase 
N-acetylmuramic acid             
(MurNAc)
Direct cross-link
N-acetylglucosamine              
(GlcNAc)
L-Ala
D-Glu
meso-dap or L-Lys 
D-Ala
D-Ala
Table 1.2: Classification of penicillin-binding proteins  
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 HMM PBPs are essential for survival whilst LMM enzymes are not. All PBPs, 
however, have D-alanyl-D-alanine-peptidase (DD-peptidase) activity in their respective 
DD-transpeptidase, DD-carboxypeptidase or DD-endopeptidase domains (360, 364). Not 
surprisingly, this DD-peptidase domain is subject to inhibition by β-lactam antibiotics as 
β-lactams resemble the natural substrates of PBPs, namely D-alanyl-D-alanine (Figure 
1.13). This is in fact the role of β-lactam antibiotics, to target and inhibit PBPs.   
 β-lactams covalently bind the active site of PBPs and form long-lived acyl-
enzyme complexes effectively acting as suicide inhibitors of the enzymes (362, 365). 
Binding and inhibition of PBPs by β-lactams prevents the final crosslinking step of the 
new peptidoglycan layer, thus disrupting cell wall synthesis and leading to cell death.  To 
successfully inhibit the action of PBPs, β-lactams rely on the specific binding to their 
PBP target. PBP mutations that reduce the specific binding and lower the affinity with 
which the β-lactam and its target bind, can render the drug ineffective and lead to 
resistance. 
 
  
 
 Figure 1.13. Molecular structures of penicillin and D-alanyl-D-alanine (366). 
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 β-lactam resistance has been reported in P. aeruginosa following treatment of a 
CF patient with high dosage of tobramycin and piperacillin in association with loss of/or 
decreased binding to PBP3 (367). Similarly, β-lactam-resistant strains, selected in vitro 
following growth on cefsulodin, did not express β-lactamase but did show reduced 
affinity of PBP3 towards the two β-lactams tested, namely cefsulodin and carbenicillin 
(368). Recently, a new mechanism of PBP-mediated resistance has been elucidated. 
Specifically, in vitro and in vivo ampC overexpression and β-lactam resistance were 
correlated to inactivation of a nonessential PBP4 in an ampD-independent manner (369, 
370). It is not known how prevalent this mechanism of resistance is in the clinical setting, 
but the phenotype was found to be reproducible upon deletion of PBP4.  
 Although modification of PBPs has also been previously reported in other Gram-
negative bacteria, it is not currently considered a major cause of β-lactam resistance in 
the clinical setting (365, 371). PBP-mediated resistance however, is a prevalent 
mechanism in Gram-positive bacteria, particularly in Streptococcus pneumoniae, 
methicillin-resistant S. aureus and the enterococci (371, 372).  
 
1.3.4 Expression of β-lactamases 
 Expression of β-lactamases is one of the most efficient and common ways of 
neutralizing the action of the commonly used β-lactam antibiotics (discussed in section 
1.4) (373, 374). β-lactam-hydrolyzing enzymes can be chromosomal- or plasmid-encoded 
and expressed constitutively or induced upon β-lactam challenge. Constitutive β-
lactamases are present at basal levels under normal conditions while inducible β-
lactamases are derepressed in the presence of antibiotics but maintained at low levels in 
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their absence (375, 376). Synthesis of chromosomally encoded β-lactamases has been 
found to be inducible in bacterial species having a specific transcriptional regulatory 
system (375, 377, 378). In contrast, synthesis of chromosomally encoded β-lactamases is 
constitutive in bacterial species lacking such regulatory systems. Derepression of the 
chromosomally encoded β-lactamase AmpC is considered the most common mechanism 
of β-lactam resistance in P. aeruginosa (379-382). The classes, mode of action and 
genetics of β-lactamases will be discussed in section 1.5. 
 
1.4 β-lactams   
 β-lactams are the most widely used class of antibiotics (204, 245, 383). They 
contain a signature β-lactam ring composed of one nitrogen and three carbons that is 
highly susceptible to hydrolysis by β-lactamases (Figure 1.14) (206). The major classes 
of β-lactam antibiotics include penicillins, cephalosporins, carbapenems, monobactams, 
and β-lactamase inhibitors (Figure 1.15).  
 
Figure 1.14.  Action of β-lactamases on the β-lactam ring. β-lactamases inactivate β-
lactam antibiotics by hydrolyzing the C-N bond present in the signature β-lactam ring.   
 
β-lactamase
Penicillin Penicilloic acid 
β-lactam ring  
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Figure 1.15. β-lactam classes. The major classes of β-lactams, penicillins, 
cephalosporins, carbapenems, monobactams, and β-lactamase inhibitors, differ in the ring 
structure fused to the four-membered signature β-lactam ring. Derivatives of each class 
differ in the substituent at the R groups. Adapted from (248). 
 
 Penicillin has the distinction of being the first antibiotic discovered.  In 1928 the 
bacteriologist Alexander Fleming noticed that growth of the mold Penicillium notatum 
lysed nearby growing Staphylococcus cells (384). Growth of a number of other 
microorganisms including Pneumococcus, Gonococcus, Streptococcus pyogenes and 
Streptococcus viridans were also inhibited by what Fleming concluded was an 
antibacterial agent that was being produced by the fungus. He aptly named this 
compound penicillin. Subsequent attempts to purify it were relatively unsuccessful, but in 
1940 Chain et al. succeeded in purifying penicillin and in using it as a therapeutic agent 
to treat mice infected with streptococci and staphylococci (385). In 1941, results from the 
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6-aminopenicillanic acid 7-aminocephalosporanic acid
first small clinical trial showing low toxicity and high efficacy were published (386). The 
chemical structure of penicillin was finally elucidated by X-ray crystallography in 1945, 
although the work was not published until 1949 (387). 
 A naturally occurring penicillin-like compound, termed cephalosporin C, was 
later reported by Newton and Abraham (388-390). This compound was isolated from the 
fungus Cephalosporium, now named Acremonium, and also possessed antibacterial 
properties but contained a six-membered ring fused to the β-lactam structure, instead of 
the five-atom structure normally seen for penicillins (Figure 1.15).  The real breakthrough 
came, however, with the discovery and synthesis of compounds containing only the β-
lactam nucleus without a side chain, namely 6-aminopenicillanic acid (6-APA) and 7-
aminocephalosporanic acid (7-ACA) (Figure 1.16) (391-393). It was possible to 
chemically modify these compounds to produce new and improved antibiotics with 
unusual side chains (394-399). Chemical additions or modifications of the side chains 
allowed the development of a vast number of semi-synthetic penicillins and 
cephalosporins with broad and extended-spectrum activity (Tables 1.3 and 1.4) (400-
403).  
 
 
 
 
 
Figure 1.16. Molecular structures of 6-aminopenicillanic acid and 7-
aminocephalosporanic acid. The 6-APA and 7-ACA compounds are useful structures 
containing only the β-lactam nucleus without a side chain. The current semi-synthetic 
penicillins and cephalosporins are derivatives of 6-APA and 7-ACA, where side chains 
have been added and modified. 
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Table 1.3: β-lactam antibiotics. I. Penicillins  
 Subclasses Representatives Representative Structure 
Narrow 
Spectrum 
Natural Penicillins 
Penicillin G 
Penicillin V 
 
Penicillin G 
Penicillinase-
resistant penicillins 
Methicillin 
Isoxozolyl penicillins 
(oxacillin, cloxacillin, 
dicloxacillin) 
 
Oxacillin 
Extended 
Spectrum 
Aminopenicillins 
Ampicillin 
Amoxicillin 
 
Amoxicillin 
Carboxypenicillins 
Carbenicillin 
Ticarcillin 
 
Ticarcillin 
Ureidopenicillins 
Piperacillin 
Azlocillin 
Mezlocillin 
 
Piperacillin 
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  Table 1.4: β-lactam antibiotics. II. Cephalosporins  
Generations Representatives Representative Structure 
1
st
 
Cefazolin 
Cefadroxil 
Cefaloridine 
Cefalotin 
  
Cefalotin 
2
nd
 
Cefaclor 
Cephamycins 
(Cefoxitin 
Cefotetan)  
Cefoxitin 
3
rd
  
Cefotaxime 
Cefsulodin 
Ceftriaxone 
 Ceftazidime 
Cefoperazone 
 
Ceftazidime 
4
th
 
Cefepime 
Cefpirome 
Cefepime 
5
th
 
Ceftobiprole 
Ceftaroline 
 
Ceftobiprole 
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  A third class of β-lactams, termed carbapenems, were first discovered in species 
of the genus Streptomyces (404). This genus is the source of a plethora of other natural 
antibacterial compounds including tetracycline, chloramphenicol, aminoglycosides, and 
cephalosporin C derivatives, among others (405-409). Specifically, thienamycin, the first 
carbapenem, was discovered in the species Streptomyces cattleya which also produces 
cephamycin C and penicillin N (404). Thienamycin was shown to be a very potent, broad 
spectrum antimicrobial, generally resistant to degradation by β-lactamases. However, it 
was also very unstable. Semisynthetic, stable alternatives of thienamycin have been 
developed and include those approved for use in the US (imipenem, meropenem, 
ertapenem, doripenem) (Figure 1.17), and in Japan (panipenem, biapenem, and 
tebipenem) (207). 
 
Figure 1.17.  Structure of antipseudomonal carbapenems approved for used in the US.  
Although very similar in structure to penicillins, position 1 of carbapenems has a carbon 
atom instead of sulfur; the structure is also unsaturated at carbons 2 and 3.  
 
 Monobactam antibiotics are also known as monocyclic β-lactams since they do 
not possess a ring fused to the β-lactam nucleus as seen for penicillins, cephalosporins 
and carbapenems (Figure 1.15). The first monobactam discovered was nocardicin A, 
produced by the bacterium Nocardia uniformis subsp. tsuyamanensis (410). Several other 
natural monocyclic β-lactams have been identified in various other bacterial species 
Meropenem DoripenemImipenem
1
2
3
47
56
42 
 
including Pseudomonas acidophila, Agrobacterium radiobacter, Gluconobacter and 
Acetobacter (411-414), the simplest of structures being produced by Chromobacterium 
violaceum (413). Development of semi-synthetic alternatives was undertaken as naturally 
occurring monobactams were shown to be very poor antimicrobials (415, 416). Currently, 
aztreonam, a synthetic derivative based on the monobactam nucleus, is the only 
monocyclic β-lactam approved for clinical use (Figure 1.18) (209, 210).  
 
 
 
 
 
  
 Figure 1.18. Structure of aztreonam, a monocyclic monobactam. 
 
 Aztreonam can be used to treat patients with allergies to penicillins and 
cephalosporins and is considered a safer alternative to aminoglycosides as this β-lactam 
does not cause ototoxic or nephrotoxic side effects (210). It is active against aerobic 
Gram-negative bacteria including P. aeruginosa and most of the Enterobacteriaceae, but 
it does not possess activity against Gram-positives or anaerobic Gram-negatives (417, 
418). It is stable to most plasmid- and chromosomal-mediated β-lactamases of classes A 
and D, and to all class B enzymes. Aztreonam, however, can be hydrolyzed by the class 
A Klebsiella pneumoniae carbapenemases (KPCs) (419, 420). Additionally, it does not 
induce expression of the chromosomal cephalosporinases from Citrobacter freundii, 
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Enterobacter cloacae, Serratia spp. and P. aeruginosa but can serve as a powerful 
competitive inhibitor of these enzymes as it is only slowly hydrolyzed by them (421-
424). Not surprisingly, it has been shown to enhance the antibacterial action of the β-
lactam cefepime by protecting it from degradation by the P. aeruginosa cephalosporinase 
(425). 
 A final, important category of β-lactams are the β-lactamase inhibitors. Three are 
currently commercially available: clavulanic acid from Streptomyces clavuligerus; and 
sulbactam and tazobactam, semi-synthetic penicillin derivatives carrying sulfur dioxide at 
position 1 (Figure 1.15) (426-428). Structurally they are very similar to conventional β-
lactams, having also a five-membered ring fused to the core β-lactam nucleus. Unlike 
regular β-lactams, however, β-lactamase inhibitors have only weak antibacterial action 
(423, 428).  Nonetheless, they are good inhibitors of class A β-lactamases for which they 
display high affinity, but generally they are poor inhibitors of the class B, C or D 
enzymes (429-432).  
 Clavulanic acid, sulbactam and tazobactam are suicide inhibitors that irreversibly 
inactivate the β-lactamases (423, 428). Since their main role is inhibitory and not 
bactericidal, β-lactamase inhibitors must be co-administered with β-lactams to achieve 
the desired antibacterial effect. A good inhibitor thus is one that can competitively bind 
the enzyme, having a higher affinity for it than that of the co-administered β-lactam, so as 
to provide protection to the antibiotic against destruction by the β-lactamase. The 
currently approved β-lactam-inhibitor combinations are amoxicillin-clavulanic acid, 
ticarcillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam (428). Studies 
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have shown however, that none of these inhibitors adequately inhibit the chromosomal 
cephalosporinase of P. aeruginosa and are thus deemed ineffective in the treatment of 
AmpC-expressing isolates (433-435).  
 
1.4.1 Mechanism of action of β-lactams 
 As described in section 1.3.4, β-lactams act by inhibiting the synthesis of the 
peptidoglycan layer, a structure that is important for maintaining cell wall integrity and 
stability (245). Early studies showed that radio-labeled penicillin covalently binds 
enzymes that are involved in cell wall synthesis; hence these enzymes were named 
penicillin-binding proteins (PBPs) (371). PBPs are found in almost all bacteria, but they 
usually vary amongst species in their affinity for β-lactam antibiotics, number and size 
(361).   
 There are about two to four essential PBPs in any given organism and their 
inhibition can lead to cell lysis, death or growth arrest (361, 371). One of the most 
important enzymatic activities associated with PBPs is the final transpeptidation step in 
the synthesis of the peptidoglycan layer. The binding and inhibition of the PBPs by the β-
lactam antibiotics prevents the final crosslinking step of the new peptidoglycan layer, 
thus disrupting cell wall synthesis (361, 371). It has been proposed that the structural and 
conformational similarities between penicillins and the D-alanyl-D-alanine part of the 
peptidoglycan (Figure 1.13) facilitates the binding of the β-lactam antibiotics to the active 
site of the PBPs. Seven PBPs have been reported in the bacterium P. aeruginosa using 
the techniques of polyacrylamide gel electrophoresis, but the number could be higher as 
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evidenced by the sequencing of the parent strain, PA01, which yielded nine PBPs (361, 
436). 
1.5 β-lactamases  
 β-lactamases (EC 3.5.2.6), as defined by the Nomenclature Committee of the 
International Union of Biochemistry and Molecular Biology, are a diverse group of 
enzymes that specifically target and hydrolyze the C—N bond of the four-atom ring 
found in β-lactam antibiotics (Figures 1.14 and 1.15). The first enzyme with penicillinase 
activity was detected in E. coli by Abraham and Chain in 1940, before the actual 
introduction of penicillin in the clinical setting (437). The widespread use of penicillin in 
the 1940s saw the emergence of penicillin-resistant staphylococci and S. aureus strains 
carrying penicillinase (438-441). Staphylococcal penicillinase-mediated resistance 
became prevalent and of great concern through the 1950s (439, 442-445) until the advent 
of semi-synthetic and more effective β-lactams in the 1960s led to the emergence and 
spread of β-lactamases, especially of the plasmid-encoded types, in Gram-negatives (446-
449). Although β-lactamases can be found in a number of Gram-positive pathogens, 
namely the staphylococci and Bacillus spp., these enzymes are more prevalent and 
widespread in Gram-negative organisms where they remain a major determinant of β-
lactam resistance (373, 374, 450, 451). More than 850 β-lactamases have now been 
identified. A comprehensive list can be found at the Lahey Clinic 
(http://www.lahey.org/Studies/). Four main classes, A, B, C and D, are commonly 
recognized based on amino acid homology (452, 453).  
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1.5.1 Mechanism of action  
 Class A, C and D β-lactamases use a serine ester mechanism to disrupt the β-
lactam ring. Specifically, the β-lactam ring is attacked by the free hydroxyl of the serine 
at the active site of the β-lactamase (Figure 1.19) (454, 455). The attack opens up the ring 
producing a covalent acyl enzyme complex. Hydrolysis of the complex regenerates the 
free, active enzyme and produces a hydrolyzed and inactive β-lactam. Class B enzymes, 
on the other hand, usually have one or two zinc ions in the active site, which are 
absolutely required for enzyme activity, hence they are known as metallo-β-lactamases 
(MLBs) (456, 457). A zinc ion can recruit and activate a hydroxide to attack the carbonyl 
carbon of the β-lactam ring leading to cleavage of the C–N bond and sometimes 
protonation of the nitrogen (456). 
 
 
 
 
 
 
 
 
Figure 1.19. Mechanism of action of serine β-lactamases. The β-lactamase first 
associates with the β-lactam to form a non-covalent complex. A free hydroxyl from the 
side chain of the active serine residue then attacks the β-lactam ring forming a covalent 
acyl ester. The acyl-enzyme complex then undergoes hydrolysis to produce an inactive β-
lactam. Reproduced from (373) with permission by the American Society for 
Microbiology. 
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1.5.2 Classification  
 One of the first classification schemes for β-lactamases was proposed by Jack and 
Richmond in 1970 with further updating in 1973 by Richmond and Sykes (458, 459).  
This classification grouped β-lactamases according to the spectrum of activity, inhibitor 
susceptibility, and the location of the gene coding for the enzyme (459). A major revision 
was proposed by Bush in 1989 (460) that was later expanded by Bush and colleagues in 
1995 (461). This scheme was based on functional similarities and took into account 
inhibitor and substrate profiles (461).   
 The classification proposed by Bush recognized four major groups of β-
lactamases with multiple subgroups (460, 461).  Group 1 are the cephalosporinases that 
are poorly inhibited by clavulanic acid (462). Group 2 include the penicillinases, 
cephalosporinases and broad-spectrum β-lactamases that are generally inhibited by β-
lactamase inhibitors (462, 463). Group 3 comprises the MLBs that can hydrolyze 
carbapenems, penicillins and cephalosporins (463). Group 4 contains penicillinases not 
inhibited by clavulanic acid (463). 
 Phenotypic classifications such as the one proposed by Bush and colleagues can 
be faulty since point mutations can change the substrate and inhibitor profile for a given 
enzyme (464). A classification scheme was thus proposed by Ambler based on amino 
acid similarities rather than phenotypic characteristics (452). The Ambler scheme is 
widely used today and, as previously mentioned, distinguishes four main classes of β-
lactamases: A, B, C, and D. 
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1.5.2.1  Molecular class A 
 Class A enzymes are among the most common β-lactamases encountered in the 
clinical setting and in the Enterobacteriaceae (373, 465). They are known as 
penicillinases since they are mostly active against penicillin and penicillin-derived β-
lactams, but extended-spectrum class A β-lactamases with activity against cephalosporins 
and carbapenems have also been reported (449, 461, 466). Most are well inhibited by the 
commercially available β-lactamase inhibitors clavulanic acid, tazobactam, and 
sulbactam (461, 467). The Class A β-lactamase-encoding genes are widely distributed in 
bacteria and are generally plasmid-borne but have also been reported in the chromosomes 
and integrons of Gram-negative bacteria (448, 468-472).  
 Common representatives include the TEM, SHV, PER and the TEM-, SHV-, and 
PER-derived β-lactamases (Table 1.5). TEM-1, the first plasmid-encoded β-lactamase, 
was reported in Greece in 1965 (473). It was originally identified in an E. coli isolate 
from a patient named Temoneira (473). TEM-1 is currently one of the most commonly 
reported β-lactamases in Gram-negatives being predominantly found in E. coli and in K. 
pneumoniae but also identified in H. influenza and Neisseria gonorrhoeae (373, 446, 
474). TEM-2, a less frequently reported point variant of TEM-1, has a more active 
promoter than its progenitor, a different isoelectric point but the same hydrolytic profile 
(475, 476).  
 A common group of class A enzymes are the SHV-type β-lactamases, named 
after sulfhydryl variable, since it was thought that the inhibition of this enzyme by p-
chloromercuribenzoate varied according to the substrate used (477). The earliest 
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representative of this group, SHV-1 is predominately found in K. pneumonia but plasmid 
dissemination has occurred to other enterobacterial species including E. coli and Proteus 
mirabilis (477-480). SHV enzymes are very structurally and functionally similar to TEM 
enzymes, SHV-1 sharing as high as 68% of its amino acid sequence with TEM-1 (478, 
481). TEM and SHV enzymes provide resistance against penicillins such as amoxicillin, 
ampicillin, tircarcillin and carbenicillin and the narrow-spectrum cephalosporins (478). 
Most class A extended-spectrum β-lactamases (ESBLs) are TEM-1, TEM-2- and SHV-1-
derived enzymes that differ from their precursors in as few as 1-4 amino acids (466, 482, 
483). These point mutations increase the hydrolysis spectrum of the enzymes to include 
extended-spectrum cephalosporins and monobactams (478). 
 
 
 Another important group of class A β-lactamases are the CTX-M-types ESBLs. 
These enzymes were first identified as non-TEM and non-SHV type ESBLs, exhibiting 
only about 40% similarity with TEM- and SHV-types, and having distinct hydrolytic 
activity against cefotaxime (484-487). They can occur in association with other TEM, 
SHV and OXA enzymes and are frequently carried on transmissible plasmids that can 
also carry blaTEM-1 (488-491). CTX-M-type enzymes are widely distributed among 
Molecular class  Representatives  
A TEM, SHV, CTX-M,  KPC, IMI, SME, GES, PER, VEB 
B IMP, VIM, SPM, GIM, SIM, NDM 
C AmpC, CMY, MIR, MOX, LAT, FOX, DHA, CFE, ACT 
D OXAs (OXA-10, OXA-23, OXA-40, OXA-48, OXA-50) 
Table 1.5: β-lactamase Ambler classification    
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members of the Enterobacteriaceae family including E. coli, P. mirabilis, C. freundii, S. 
marcescens, Salmonella, Klebsiella and Enterobacter spp., but have also been reported in 
other non-enterobacterial species such as Vibrio spp. and Aeromonas hydrophila (485, 
492-503). 
 Unlike the TEM- and SHV-derived ESBLs that arose by point mutations of their 
precursors, the CTX-M enzymes appear to be the result of plasmid transfer from naturally 
occurring chromosomal enzymes in the Kluyvera genus (504-506). Many CTX-M 
enzymes have been reported to be identical or near identical to the CTX-M-like enzymes 
KLUA and KLUC of the Kluyvera spp. (504, 505, 507), with others like KLUG-1 sharing 
85-86% similarity with the CTX-M-1 enzymes (506). Additionally, the genetic regions 
surrounding the acquired CTX-M enzymes have been shown to be 80-100% identical to 
regions surrounding the corresponding β-lactamase-encoding gene in the Kluyvera 
chromosome (504, 507-509). ISEcp1 or ISEcp1-like insertion sequences have been 
detected upstream of many CTX-M-plasmid-encoded enzymes (490, 500, 504, 510, 511), 
while some CTX-M enzyme are encoded in the class I integrons InS21, In35 and In60 
(508-510, 512) further strengthening the case for horizontal gene transfer from the 
Kluyvera chromosome.  
 A fourth relevant group of class A β-lactamases are the non-metallo-
carbapenemases. The chromosomally encoded representatives of this group include the 
imipenem-hydrolyzing β-lactamase (IMI) and the non-metallo-carbapenemase (NMC-A) 
described in E. cloacae (513-515), as well as the SME-types isolated from S. marcescens 
(516-518). The spectrum of hydrolysis of these enzymes includes not only the 
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carbapenems, but also penicillins, narrow-spectrum cephalosporins and aztreonam (519, 
520). These chromosomally encoded non-metallo-carbapenemases however, do not 
generally pose as much a threat as the TEM, SHV and CTX-M ESBLs, as they are only 
infrequently reported.  
 Plasmid-borne representatives of class A non-metallo-carbapenemases include the 
Klebsiella pneumoniae carbapenemase (KPC) and the Guiana extended spectrum (GES) 
family of enzymes. The first KPC was detected in a K. pneumoniae isolate from North 
Carolina in 1996 (521). KPCs remained relatively rare until the early 2000s when they 
reemerged in the East Coast of the United States (522-525) causing multiple nosocomial 
outbreaks in the New York area, sometimes through clonal spread (526-529). 
Subsequently KPCs have been isolated in several European and South American 
countries (530-538) as well as in Israel, China and Taiwan (539-541).  The blaKPC genes 
are usually carried on the plasmid-borne transposon, Tn4401, which undoubtedly 
contributes to the ease of dissemination observed (521, 524, 532, 542, 543). Thus, 
although most frequently observed in K. pneumoniae (544, 545), KPCs have also been 
isolated from P. aeruginosa, E. coli, C. freundii, S. marcescens, as well as from 
Salmonella and Enterobacter spp. (520, 522, 546, 547).  
 Similar to the TEM, SHV and CTX-M ESBLs, the KPC enzymes can hydrolyze 
penicillins and cephalosporins (520). Unlike the ESBLs, however, KPCs can also 
hydrolyze carbapenems to varying degrees (548). As carbapenems are often the first line 
of defense against microorganisms that express ESBLs, the emergence of carbapenem-
resistant organisms, that are already resistant to penicillins and cephalosporins, severely 
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limits treatment options. The dissemination of KPCs is thus of great concern. Hydrolysis 
of carbapenems by KPCs, however, does not always lead to resistance, in some cases it 
can mean a decrease in susceptibility, with intermediate to high level resistance also 
being observed (523, 525). 
 GSE-1 was first reported in a K. pneumonia isolate from French Guiana (470). 
Currently 15 GSE enzymes are recognized, five of which display carbapenemase activity, 
albeit at low levels (520, 549). In every other sense they are typical ESBLs able to 
hydrolyze penicillins and extended-spectrum cephalosporins (519, 520). The GSE 
enzymes have been mostly identified in P. aeruginosa but have also been reported in 
some enterobacterial species (469, 550-552). Although GSE β-lactamases are relatively 
rare, nosocomial outbreaks have been reported in Korea, Portugal and South Africa (550, 
553, 554). 
 Most of the class A enzymes, including the extended-spectrum PER- and VEB-
types, have been reported in P. aeruginosa (482, 549). Class B and D enzymes (discussed 
below), however, are more prevalent in P. aeruginosa, whereas the class A enzymes are 
widely distributed in the Enterobacteriaceae (448, 477, 555, 556).  
1.5.2.2  Molecular class B 
 Class B or metallo-β-lactamases (MLBs) are often described as being a class apart 
since unlike their serine counterparts they require Zn
+2
 in their active site in order to 
hydrolyze β-lactams (456, 457).  They have a broad hydrolysis spectrum that includes the 
carbapenems and most often also penicillins and cephalosporins (456, 461, 463).  MLBs 
are resistant to inhibition by the commercially available serine β-lactamase inhibitors and 
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are unable to hydrolyze the monobactam aztreonam (456, 557).  The requirement for zinc 
means they are sensitive to inhibition by EDTA, a known metal chelator (457, 461).  
They are often carried on plasmid-borne transposons and integrons, but can also be 
chromosomally encoded.   
 Chromosomally encoded MLBs are mostly found on environmental and 
sometimes opportunistic pathogenic bacteria that are rarely a cause for concern, with the 
notable exceptions of Bacillus anthracis and Stenotrophomonas maltophilia (457).  
Chromosomal MLBs include CphA from A. hydrophila (558), BCII from B. cereus (559), 
Bla2 from B. anthracis (560), SFH-1 from Serratia fonticola (561), FEZ-1 from 
Legionella gormanii (562), TUS-1 and MUS-1 from Myroides spp. (563), and L1 from S. 
maltophilia (564), among others. Frequently the MLBs are coproduced with 
penicillinases and cephalosporinases and are induced upon β-lactam challenge. For 
example, A. hydrophila coordinately expresses two β-lactamases, CepH 
(cephalosporinase) and AmpH (oxacillinase) in addition to the MLB CphA, also named 
ImiH (565, 566).  Coproduction of various β-lactamases is also observed in several other 
Aeromonas species such as A. veronii, A. jandaei, A.  caviae, and A. salmonicida (566-
568).  Similarly, S. maltophilia produces two chromosomally encoded and inducible 
enzymes, L1, a metallo-β-lactamase, and L2, a class A cephalosporinase (569-572). 
 The first occurrence of transferable imipenem resistance was reported in a P. 
aeruginosa isolate from Japan (573). The identified enzyme, IMP-1, was encoded in a 
conjugative plasmid that could be mobilized into other Pseudomonas strains. IMP-1 was 
later identified in several S. marcescens strains from general hospitals in the nearby cities 
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of Anjyo and Okazaki from the Aichi prefecture in Japan (574-576). An IMP-type 
enzyme was also detected by DNA hybridization in fifteen P. aeruginosa clinical isolates 
from three different geographical areas in Japan (577). DNA fingerprinting showed that, 
for the most part, the strains were heterogeneous, while the blaIMP gene displayed little to 
no variation, thus illustrating a plasmid-mediated proliferation that was not clonal in 
nature (577). Further studies have shown that the IMP-1 enzyme and variants have 
proliferated in Japan in the Enterobacteriaceae, including S. marcescens, E. coli, C. 
freundii, K. pneumoniae, Enterobacter spp., as well as in non-enterobacterial species 
such as P. aeruginosa, Pseudomonas putida, Achromobacter xylosoxidans and 
Alcaligenes spp. (578-583).  
 PCR analysis of 42 strains carrying the blaIMP gene detected class 3 integron 
sequences in 79% of them (579). A larger Japanese study involving 357 blaIMP-1-positive 
strains that included P. aeruginosa, identified class I integron sequences in 99% of them 
(580). Association of blaIMP with mobile genetic elements has likely facilitated the 
dissemination of the enzyme in Japan. The IMP family of enzymes has also been reported 
worldwide in places like Portugal (584), Italy (585), Canada (586), China (587, 588), 
Australia (589, 590), England (591) and Korea (592, 593), among others. The current 
data however, suggest that these are local occurrences rather than dissemination from the 
alleles in Japan. Indeed, phylogenetic trees place IMP-1 in one of the later evolving 
branches of the dendrogram (457, 594). 
 A second and also prevalent class of MLBs is the integron-borne VIM-type.  The 
first reported representative of this group, VIM-1 (Verona integron-encoded metallo-β-
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lactamase) was detected in Italy in 1997 in a P. aeruginosa β-lactam-resistant isolate 
(595). Expression of the enzyme in a heterologous background conferred high level 
resistance against penicillins (ampicillin, carbenicillin, piperacillin and mezlocillin) and 
cephalosporins (cefoxitin, ceftazidime, cefoperazone and cefepime), while decreasing 
susceptibility to the carbapenems (595). VIM-1 was found to be only distantly related to 
other MLBs, sharing only 31% identity with IMP-1 (595). The blaVIM-1 gene was located 
in the chromosome and encoded as part of a gene cassette carried in a class 1 integron, 
which itself carried another gene cassette (aacA4) for aminoglycoside resistance (595). 
Not surprisingly, a blaVIM-1 gene was subsequently reported in a plasmid from an A. 
xylosoxidans isolate from the same hospital (596). A VIM-type enzyme, exhibiting a 90% 
amino acid similarity with VIM-1, was reported in France in a P. aeruginosa isolate in a 
nonconjugative plasmid (597). The variant, termed VIM-2, has since been found 
throughout Europe and the rest of the world, and is often reported as the most detected of 
acquired MLBs (598-604). A number of other VIM variants have also been reported 
throughout the world and in a number of bacterial species including E. coli, K. 
pneumoniae, E. cloacae, S. marcescens, C. freundii, Acinetobacter baumannii, P. putida 
and P. aeruginosa; the latter being the most common host for these enzymes (457, 549). 
 Other noteworthy MLBs include SPM-1 (for Sao Paulo MLB), GIM-1 (for 
German imipenemase) and SIM-1 (for Seoul imipenemase). SPM-1 was first detected in 
1997 in a P. aeruginosa clinical isolate from Brazil (605). It was encoded in a plasmid, 
but unlike the IMP and VIM enzymes that are regularly associated with class 1 integrons, 
SPM-1 was associated with a novel transposable-like element with probable recombinase 
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activity (606). Thereafter, P. aeruginosa SPM-1-producing strains have become prevalent 
in Brazil and isolated from both clinical and environmental sources (607-610). To date, 
SPM-1 has only been reported outside of Brazil in A. baumannii isolates from various 
hospitals in Iran (611), and in a P. aeruginosa isolate from a Swiss man who had been 
previously treated in a Brazilian hospital (612).  
 GIM-1 was first reported in five multidrug-resistant P. aeruginosa isolates from a 
hospital in Dusseldorf, Germany (613). Subsequent reports identified more GIM-1-
producing P. aeruginosa isolates in hospitals within a 40 km radius from the location of 
the original report (614). Although so far GIM-1 has not been reported outside of 
Germany, it has however, spread to a number of enterobacterial species including 
Acinetobacter pittii, E. cloacae, Klebsiella oxytoca, S. marcescens, E. coli, and C. 
freundii (615-618).    
 SIM-1 was first detected in the chromosome of Acinetobacter clinical isolates 
from Korea (619). Later, blaSIM-1 was also detected in two Acinetobacter (genomospecies 
10) isolates that additionally carried blaIMP-1 or blaVIM-2 (620). To date, SIM-1 has not 
been detected outside of Korea, except for an Acinetobacter baylyi clinical isolate 
reported in China that additionally harbored OXA-23 in a large 360-kb plasmid (621).  
Similar to the IMP and VIM enzymes, both GIM-1 and SIM-1, are carried in class I 
integrons (613, 619). Although both SPM-1 and GIM-1 have been detected in P. 
aeruginosa, the IMP- and VIM-types are the most commonly detected MLBs in this 
pathogen and in the Acinetobacter spp. (549, 622).  
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1.5.2.3  Molecular class C  
 Class C enzymes or AmpC β-lactamases are generally chromosomally encoded 
but have also been reported in plasmids (623, 624). They can hydrolyze penicillins and 
cephalosporins including the cephamycins (cefoxitin and cefotetan) and the oxyimino-
cephalosporins (cefotaxime, ceftriaxone, and ceftazidime), as well as the monobactam 
aztreonam (625, 626). The increased rate of hydrolysis observed against some 
cephalosporins as compared to penicillins, particularly the first generation cephalosporins 
cefazolin, cephaloridine, cephalothin and cephalexin, has given rise to their common 
designation of cephalosporinases (625). Although able to slowly hydrolyze some of the 
later generation cephalosporins, such as cefotaxime and cefoxitin, these enzymes often 
display high affinity for these substrates as evidenced by low Km values (625, 627). The 
penicillins cloxacillin, oxacillin and carbenicillin act as transient inhibitors able to 
efficiently form acyl-enzyme complexes but usually being very poorly hydrolyzed by the 
class C enzymes (626). Additionally, the class A inhibitors are generally not good 
inhibitors of the cephalosporinases, although tazobactam and sulbactam have been shown 
to inhibit some class C enzymes (429, 430, 432).  
 Chromosomal class C enzymes are ubiquitous in Gram-negative bacteria and very 
frequently encountered in the Proteobacteria including the Aeromonadales (Aeromonas 
spp.) and the Pseudomonadales (A. baumannii, P. fluorescens and P. aeruginosa) (623). 
They are particularly well represented in members of the Enterobacteriales, including 
some commonly encountered species and pathogens such as C. freundii, E. aerogenes, E. 
cloacae, E. coli, Morganella morganii, Providencia stuartii, S. marcescens, Shigella spp. 
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and Yersinia enterocolitica, among others (555, 623). Some well-known members of the 
Enterobacteria group such as K. pneumoniae, K. oxytoca, P. mirabilis, Salmonella spp. 
and Yersinia pestis (623), however, do not carry a chromosomal class C enzyme, 
although this does not preclude the possibility of carrying plasmid-borne AmpC. 
 In many of the species carrying a chromosomal ampC, including P. aeruginosa, 
C. freundii and E. cloacae, ampC expression is constitutively low but induced upon β-
lactam challenge (377, 628). Induction is tightly controlled by the transcriptional 
regulator AmpR and intricately linked to the recycling of the peptidoglycan layer (375). 
On the other hand, in E. coli and Shigella spp. ampC does not respond to induction by β-
lactams and is only produced at very low levels (629, 630). Consequently the natural 
AmpC expression in such backgrounds does not lead to resistance. The marginal levels of 
AmpC β-lactamase observed in such species stem from the genetic environment 
surrounding the structural β-lactamase gene. In species with an inducible system (e.g., 
AmpC of P. aeruginosa), ampR is frequently located upstream of ampC and divergently 
transcribed; while species with a non-inducible system lack ampR and have a very weak 
promoter (378, 631, 632). Additionally, an attenuator is located between the promoter 
and the β-lactamase-encoding gene leading to the premature termination of the majority 
of transcripts (633). Derepression and hyperproduction in species having a non-inducible 
system, i.e., lacking ampR, can occur but often require mutations in the promoter and 
attenuator regions and/or the combined effect of different mutation types in order to 
provide any meaningful β-lactam resistance (634-638). Although such mutations have 
been reported in both E. coli and in Shigella spp. (634, 639, 640), they are rarer than 
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those leading to constitutive hyperexpression in species with an inducible system (376, 
630). Mutational derepression or stable derepression of ampC, as it is also known, 
however, has been reported as one of the most common mechanisms of β-lactam 
resistance in species that have an inducible AmpC system such as P. aeruginosa, C. 
freundii, E. cloacae, M. morganii, P. stuartii, Enterobacter and Serratia spp. (380, 446, 
465, 641-645). The genetics of inducible class C β-lactamases will be covered in section 
1.5.3.   
  Although chromosomal ampC-types are the predominant class C enzymes in 
Gram-negative bacteria, dissemination into plasmids began to emerge in the late 1980s 
and continued to spread worldwide (646-649). They are predominantly found in species 
not usually known to possess chromosomal ampC, such as K. pneumoniae, K. oxytoca 
and Salmonella spp., but have also been reported in E. coli (624, 649). Representatives 
include MIR-1, MOX-1, LAT-1, FOX-1, ACT-1 and the CMY-types first reported in K. 
pneumonia, as well as CFE-1 and DHA-1 first identified in E. coli and Salmonella 
enteritidis, respectively (Table 1.5) (624, 649, 650). The original chromosomal enzymes 
of Proteobacteria described above are the likely progenitors of these plasmid-borne 
enzymes (649). For instance, CMY-2 and the closely related types LAT-1 and CFE-1, 
appeared to have originated from the AmpC of C. freundii sharing 96, 95 and 99% amino 
acid sequence with that enzyme, respectively (647, 651, 652). CMY-1-types, including 
MOX-1, were originally thought to have descended from P. aeruginosa, but have since 
been shown to be more closely related to the chromosomal enzymes of the Aeromonas 
(646, 650, 653). The genetic support is usually an integron-based plasmid that often 
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carries other resistance genes such as those coding for aminoglycoside and quinolone 
resistance, or even other β-lactamase-encoding genes such as blaTEM-1, blaCTX-M-3 and 
blaVIM-1 (649, 654-658). The hydrolysis spectrum remains the same as that of their 
chromosomal-encoded counterparts (623, 649). 
 Although plasmid-encoded AmpC enzymes have been reported worldwide, they 
are not as prevalent in the clinical setting as the ESBLs. They are most commonly 
reported in K. pneumoniae isolates from patients that have had long hospital stays or 
prolonged care at the ICU, where urinary indwelling catheters and an 
immunocompromised system are predisposing factors (650, 659-662).  Plasmid-encoded 
AmpC enzymes have not so far been described in P. aeruginosa (549).  
1.5.2.4  Molecular class D 
 Transferable drug resistance among Gram-negative bacteria started being reported 
and characterized in the early 1960s (663-665). The agents mediating resistance were 
dubbed resistance or R factors and later shown to be extrachromosomal pieces of DNA, 
termed plasmids (666). Datta and Kontomichalou recognized two distinct penicillinase-
encoding R-factors, RTEM and R1818, on the basis of substrate profile (473). The enzyme 
from R1818, later renamed R46 (667), was able to hydrolyze methicillin and cloxacillin 
more efficiently than the penicillinase from RTEM, which displayed only slight activity 
against these substrates (473). Additionally the R1818 penicillinase was able to hydrolyze 
cloxacillin almost as fast as it could hydrolyze penicillin (473). Later work showed that 
the penicillinase from R1818 also hydrolyzed oxacillin faster than benzylpenicillin (668-
672). Other studies characterized several more R factors mediating expression of β-
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lactamases that resemble that of R1818 in the rapid hydrolysis of oxacillin and cloxacillin 
(670, 671, 673).  
 Two different classes of oxacillin-hydrolyzing enzymes were then distinguished 
on the basis of molecular weight and substrate profile (674). One group was characterized 
by having low molecular weight (∼24,000) and high hydrolysis rate against methicillin, 
while the other had high molecular weight (∼40,000) but relatively low hydrolysis of the 
same compound. The lowest rate of hydrolysis, however, was around 40-fold higher than 
that previously observed for the original TEM enzyme against methicillin (473). 
Isoelectric focusing further divided the oxacillinases into three main subclasses that were 
designated as OXA-1, OXA-2 and OXA-3 to reflect their preference for the isoxazolyl 
penicillins such as oxacillin and cloxacillin (475).  
 The first oxacillinases described, particularly OXA-1 (675, 676), OXA-2 (447, 
669, 677) and OXA-3 (671, 678, 679) from plasmids RGN238, R46, and R57b, 
respectively, were characterized by their ability to degrade isoxazolyl penicillins and by 
their sensitivity to inhibition by NaCl (674). As more OXAs were reported and 
characterized, it became apparent that these were a diverse group of enzymes with a 
heterogeneous substrate profile that in some instances did not include the oxacillin-type 
β-lactams (680). More than 350 oxacillinases are now recognized 
(http://www.lahey.org/studies/webt.asp) and they can be broadly divided into the narrow-
spectrum, extended-spectrum and the carbapenem-hydrolyzing types (680). 
 The plasmid-mediated narrow-spectrum OXA enzymes include the originally 
characterized oxacillinases in E. coli (OXA-1), S. typhimurium (OXA-2), and K. 
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pneumoniae (OXA-3),  as well as a few others also first described in E. coli (OXA-4, 
OXA-7), K. pneumoniae (OXA-9, OXA-47), A. baumannii (OXA-37) and P. aeruginosa 
(OXA-5, OXA-6, OXA-10, OXA-20, LCR-1) (680). Generally they can hydrolyze 
penicillins and sometimes early generation cephalosporins but not extended-spectrum 
cephalosporins. The hydrolysis spectrum however, can vary greatly from enzyme to 
enzyme. For instance, OXA-1 can generally hydrolyze amino- and ureidopenicillins, 
narrow-spectrum cephalosporins (681), as well as the broad-spectrum cephalosporins 
(675, 681), albeit weakly; whereas the P. aeruginosa OXA-5 can only hydrolyze 
penicillins and cephalothin (682). Similarly the P. aeruginosa OXA-10, originally 
categorized as a P. aeruginosa specific enzyme (PSE-2), hydrolyses carbenicillin and 
oxacillin, as well as aztreonam and some of later generation cephalosporins like 
cefotaxime and ceftriaxone, albeit slowly (683). The P. aeruginosa LCR-1 only 
hydrolyzes penicillins including oxacillin (684).   
 The extended-spectrum class D enzymes are mostly point mutation variants of the 
narrow-spectrum OXA-2 and OXA-10 enzymes (680, 685). These mutations extend the 
hydrolysis spectrum to include the extended-spectrum cephalosporins. OXA-11, the first 
reported OXA-10 variant, was identified in a P. aeruginosa isolate taken from the 
bloodstream of a Turkish patient (686).  It was carried on a plasmid and had two amino 
acid substitutions (Asn146Ser and Gly167Asp). Several other OXA-10 variants, 
including OXA-14 (687), OXA-16 (688), OXA-17 (689), and OXA-19 (690) were also 
identified in P. aeruginosa isolates from both Turkey and France. Up to nine 
substitutions were observed per variant (OXA-19, OXA-28, OXA-145, OXA-147), with 
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OXA-14 having only one point mutation (http://www.lahey.org/Studies/). The 
Gly167Asp substitution appears to be the common thread among the variants that are 
very resistant to ceftazidime.  
 Unlike the OXA-10 ESBLs, the majority of which have more than one point 
mutation, the seven currently known OXA-2 variants have each only one substitution. 
OXA-15 (691) and OXA-36 have both a substitution at aspartate 149, to glycine and 
tyrosine respectively (685, 691). Both OXA-10 and OXA-2 ESBLs are carried in 
plasmid-borne class 1 integrons in association with aminoglycoside resistance cassettes 
(680). ES-OXAs are not widely distributed and have been mostly reported in P. 
aeruginosa (549). 
  A very important class of oxacillinases is comprised of the carbapenem-
hydrolyzing β-lactamases (CHDLs). The majority has been identified in plasmids from 
the nosocomial and opportunistic pathogen A. baumannii, not usually in association with 
integrons (622, 692). CHDLs can significantly hydrolyze carbapenems often leading to 
decreased susceptibility or resistance towards meropenem and imipenem (685, 693).  
They are also able to hydrolyze most penicillins and provide high-level resistance to the 
aminopenicillins (ampicillin, amoxicillin) and the carboxypenicillins (ticarcillin) with 
variable hydrolysis against the ureidopenicillins (piperacillin). CHDLs, however, do not 
generally significantly hydrolyze cephalosporins or provide any meaningful resistance 
against these compounds (519, 693). The notable exception is OXA-146 which 
hydrolyses ceftazidime (694).  
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 OXA-23, the first OXA carbapenem-hydrolyzing β-lactamase identified, was 
recovered from an A. baumannii isolate taken from a patient in Scotland (695). It was a 
plasmid-borne enzyme that showed very weak relation to other β-lactamases. Nineteen 
different variants have so far been reported for the OXA-23 group, the OXA-23 allele, 
however, remains the most common of this group with a widespread prevalence (685, 
693).  The OXA-51 group, currently consisting of 95 variants, is naturally present in the 
chromosome of A. baumannii (696, 697). These enzymes are not thought to play a major 
role in the intrinsic resistance as their expression is unregulated and uninducible. The 
blaOXA-51 gene however, has sometimes been reported in association with the upstream-
located ISAba1 or ISAb9 (698-700). The promoters carried within these insertion 
sequences have been shown to drive expression of blaOXA-51 in carbapenem-resistant 
isolates (698-700).  
 Other important CHDLs include the OXA-40, OXA-48, OXA-58 and OXA-143 
groups (701-703). Although most display low level of carbapenem hydrolysis, they have 
often been reported in carbapenem- or multidrug-resistant strains, whereby their 
transformation into E. coli or susceptible A. baumannii confers decreased susceptibility 
or carbapenem resistance (703-707). CHDLs are predominant and widespread in A. 
baumannii but relatively rare in P. aeruginosa (549, 685, 692, 693, 708, 709). 
 
1.5.3 Genetics of inducible class C β-lactamases  
 
 The inducible expression of AmpC β-lactamase in the Enterobacteriaceae and in 
P. aeruginosa is regulated by AmpR, a LysR-type transcriptional regulator (710-712). 
The induction of ampC, however, also involves the interplay of several other amp genes 
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and is coordinately linked to the recycling of the peptidoglycan layer (375, 713, 714).  In 
the Enterobacteriaceae model, ampG encodes a transmembrane protein that serves as a 
permease for passage of the inducer (1,6-anhydromurapeptides) that results from 
remodeling of the peptidoglycan layer during normal cell growth (715, 716). AmpG 
transports 1,6-anhydromurapeptides into the cytoplasm where the amidase AmpD 
hydrolyses them for murein recycling (717). It has been proposed that during normal 
physiological growth, the muramyl peptides processed by AmpD maintain AmpR in an 
inactive conformation that is unable to induce the expression of ampC (716, 718, 719). 
 In the presence of β-lactams, however, there is an excessive breakdown of murein 
leading to an accumulation of 1,6-anhydromurapeptides in the periplasm and in the 
cytoplasm (718, 720).  Under these conditions, AmpD cannot keep up with the increased 
concentration of 1,6-anhydromurapeptides in the cytoplasm. The high number of 
muramyl peptides can then induce a conformational change in AmpR to promote the high 
level expression of ampC (716, 721).  AmpD can thus function as a negative regulator of 
ampC expression in the absence of β-lactams.  In fact, mutational inactivation of ampD, 
in both Enterobacteriaceae and P. aeruginosa, leads to constitutive over-expression of 
AmpC and consequently increased β-lactam resistance (722, 723).  Recent work by Juan 
and colleagues reveals that three ampD homologs in P. aeruginosa are responsible for a 
stepwise ampC up-regulation mechanism that ultimately leads to constitutive 
hyperexpression of this β-lactamase (643). Details of this intricate mechanism are further 
discussed in Chapter 4. 
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1.5.4 Genetics of class D β-lactamases   
 Oxacillinase-encoding genes have been reported in a multitude of bacterial 
species including P. aeruginosa. Most of these and other β-lactamase-encoding genes 
appear to be unregulated, with insertion sequences often providing strong promoters for 
high-level expression of such genes (471, 698, 700, 724-728). To date, the only known 
regulatory systems of chromosomal-encoded class D β-lactamases are that of Ralstonia 
pickettii and Aeromonas spp. (567, 729, 730).  
 R. pickettii carries two inducible chromosomally encoded β-lactamases, OXA-22 
and OXA-60, exhibiting a narrow-spectrum of hydrolysis that includes the penicillins 
(731, 732). Induction requires the presence of the divergently transcribed ORF rp3 found 
190 bp upstream of the OXA-60-encoding gene (730, 733). Imipenem was found to 
increase the mRNA levels of blaOXA-22 and blaOXA-60 as well as that of rp3, suggesting 
regulation by Rp3 occurs at the transcriptional level (733). Rp3 is thought to function as 
an activator as a recombinant Rp3 was shown to bind tandem repeats upstream of both 
OXA-encoding genes and to protect regions of ∼30 bps there (733). RP3 was not similar 
to any known regulatory proteins. No significant similarities were found with P. 
aeruginosa proteins either. 
 Aeromonas spp. can produce two–three inducible and unlinked β-lactamases (552, 
696-698).  For instance, Aeromonas jandaei AER 14, formerly known as Aeromonas 
sobria AER 14, produces three chromosomally encoded β-lactamases, AsbA1 a class C 
cephalosporinase, AsbB1 (OXA-12) an oxacillinase, and AsbM1, a metallo-β-lactamase 
(734-736). Aeromonas veronii bv. sobria similarly produces a penicillinase (AmpS), a 
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cephalosporinase (CepS) and metallo-β-lactamase (ImiS) (737, 738), with the homologs, 
AmpH, CepH, and ImiH, also identified in A. hydrophila (565, 739).  
 The expression of all β-lactamases in A. hydrophila is coordinately regulated by a 
two-component system (TCS), encoded by blrA and blrB, and located immediately 
upstream of ampH, the oxacillinase-encoding gene (729). PCR analysis confirmed the 
presence of the blrAB operon in other species of the Aeromonas genera, including A. 
jandaei and A. veronii bv. sobria, where the TCS-encoding genes are also linked to the 
blaOXA gene (729). Regulation by a TCS thus appears to be a common and effective 
mechanism of coordinate β-lactamase expression in Aeromonas spp. 
 
1.5.5 The pox operon  
 Previous work showed that ampC mutations do not completely abolish β-
lactamase activity in the P. aeruginosa PA01 strain (740). Furthermore, the susceptibility 
profile of an ampC-deficient strain did not show an increase in sensitivity towards the 
three β-lactam representatives tested, benzyl-penicillin, meropenem and cefotaxime, as 
compared to the wild-type PA01 (740). In view of these results, the presence of a second 
chromosomally encoded β-lactamase in P. aeruginosa was postulated. In silico analysis 
revealed that ORF PA5514 encoded a putative β-lactamase with a signal peptide 
sequence at the N-terminus. The presence of a signal peptide is consistent with what is 
known about β-lactamases since they are localized to the periplasm and require a signal 
peptide for translocation.  
 Analysis of the sequences around PA5514, termed poxB, revealed the presence of 
an upstream ORF annotated PA5513, named poxA, 49 bp upstream.  In the absence of 
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promoter-like sequences in the intergenic region between PA5513 and PA5514, it was 
proposed that poxA and poxB form a two-gene operon (Figure 1.20). PoxA displayed 
high sequence similarity to hypothetical hydrolases and acyltransferases of yet unknown 
function. The presence of transmembrane spanning domains, as suggested by its 
hydrophobicity plot, and the absence of any signal sequence, indicate PoxA likely 
localizes to the inner membrane. 
 
 
 
 
       Figure 1.20. Restriction map of the pox operon. 
 
 PoxB, on the other hand, shows high sequence identity to class D β-lactamases 
from A. baumannii and Fusobacterium nucleatum (740). Alignment of the PoxB 
sequence with 26 conserved residues in class D β-lactamases revealed that 21 of the 26 
amino acids were identical.  Differences in four of the remaining five amino acids place 
PoxB in a new branch of a dendogram (740). PoxB, thus appears to be a new kind of 
oxacillinase, markedly different from other OXA enzymes (740).  
 Expression studies conducted in E. coli, where there is a naturally low basal level 
of β-lactamase expression, confirmed the role of PoxB as a β-lactamase. Specifically, 
Girlich et al. showed that introduction of poxB in an E. coli background yields β-
lactamase activity (741). Previous work in our lab also showed that both the poxB gene 
and the poxAB operon are capable of producing high basal levels of β-lactamase activity 
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in E. coli (740). The goal of this dissertation was to characterize PoxB and the poxAB 
operon and determine their contribution to β-lactam resistance in the nosocomial and 
intractable pathogen P. aeruginosa. 
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Chapter 2 
 
 
 
 
 
 
Characterization of a carbapenem-hydrolyzing enzyme, PoxB, in 
Pseudomonas aeruginosa 
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2.1 Abstract 
 
 Pseudomonas aeruginosa is an opportunistic pathogen often associated with 
severe and life-threatening infections that are highly impervious to treatment. This 
microbe readily exhibits intrinsic and acquired resistance to varied antimicrobial drugs. 
Resistance to penicillin-like compounds is commonplace and provided by the 
chromosomal AmpC β-lactamase. In the present work the contribution of a second, 
recently discovered, chromosomally-encoded β-lactamase, PoxB, and its relation to 
AmpC, were investigated. A single deletion of ampC surprisingly did not alter 
susceptibility against most of the penicillins or cephalosporins tested, however its 
overexpression provided resistance and/or decreased susceptibility against these β-
lactams. Carbapenem susceptibilities, as evidenced by minimum inhibitory 
concentrations (MICs), were mostly unaffected by the lack of AmpC. PoxB expression 
decreased susceptibility against the carbapenems but did not affect susceptibility against 
the penicillins or cephalosporins. Additionally, PoxB was only poorly inhibited by class 
A inhibitors, but a novel non-β-lactam inhibitor, termed avibactam, was a slightly better 
inhibitor of PoxB activity. Clinical concentrations of avibactam, however, failed to 
produce a change in MIC against the carbapenems by E-test. In addition, poxB was found 
to be cotranscribed with the upstream open reading frame, poxA, which itself was shown 
to encode a 32-kDalton protein of yet unknown function. 
 
Key Words: PoxB, OXA-50, AmpC, Oxacillinase, Class D β-lactamase 
 
Abbreviations: Congo red, CR; Coomassie brilliant blue, CB; Isopropyl β-D-1-
thiogalactopyranoside, IPTG; Minimum inhibitory concentration, MIC; Open reading 
frame, ORF; Sodium dodecyl sulfate-polyacrylamide gel electrophoresis, SDS-PAGE 
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2.2. Introduction 
 
 Pseudomonas aeruginosa is a ubiquitous and versatile opportunistic pathogen 
commonly affecting immunocompromised individuals such as those with severe burns, 
AIDS and cancer (89, 92, 96, 99, 109, 202). In addition, it is a significant source of 
nosocomial infections and the second most common cause of ventilator-associated 
pneumonia in the hospital setting (72, 73). Most notably, P. aeruginosa is the primary 
pathogen associated with lung deterioration and mortality in patients with cystic fibrosis 
(CF), a deadly, autosomal, recessive genetic disorder affecting about 70,000 individuals 
worldwide (122, 742). Treatment often proves challenging and ineffective as the 
bacterium exhibits innate and acquired resistance to a broad range of antibiotics (246, 
349, 743). In particular, resistance to the frequently used β-lactam-type antibiotics is 
common and mediated by the expression and derepression of the chromosomally encoded 
AmpC β-lactamase (379-381, 722). 
 The Ambler classification scheme distinguishes four different classes of β-
lactamases (classes A, B, C and D) on the basis of amino acid sequences (452).  All four 
classes have been reported in P. aeruginosa and are often transposon or plasmid-borne 
(601, 744-747). In addition to the acquired β-lactamases, P. aeruginosa strains frequently 
carry the chromosomal class C β-lactamase AmpC (711, 748). Derepression of ampC has 
been identified as a common cause of moderate to high-level β-lactam resistance in P. 
aeruginosa clinical isolates (379, 380, 643-645, 749). 
 A second chromosomally-encoded β-lactamase, termed PoxB (PA5514) or OXA-
50, has been reported in P. aeruginosa (740, 741). PoxB belongs to the class D β-
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lactamases, also termed oxacillinases, for the ability of some members of this class, 
particularly, the earlier reported ones, to degrade isoxazolyl penicillins such as oxacillin, 
methicillin, and cloxacillin (671, 674, 682, 750-752). The DBL numbering system is used 
to correlate homologous residues and signature sequences across class D β-lactamases 
that may otherwise be located at different amino acid positions (753). Differences in 
these amino acid signature sequences place PoxB in a new branch of the oxacillinase 
phylogenetic tree, suggesting it is only weakly related to other oxacillinases (740, 741).  
For instance, class A and D enzymes commonly have a serine-threonine-phenylalanine-
lysine (STFK) motif at position 70 in the DBL numbering system, where serine, the 
active site residue, and lysine are conserved in serine β-lactamases and in penicillin-
binding proteins (753, 754). To our knowledge, however, PoxB is only one of two 
oxacillinases where the traditional STFK motif of class D β-lactamases is replaced by 
STYK (serine-threonine-tyrosine-lysine) (740, 741), the other being OXA-62 from 
Pandoraea pnomenusa (755-757). Thus, PoxB appears to be a new kind of oxacillinase, 
markedly different from other known OXA enzymes. In addition, previous in silico 
analysis suggested poxB may form a two-gene operon with the upstream open reading 
frame (ORF), PA5513, termed poxA (740), which is predicted to encode a putative 
hydrolase or acyltransferase of yet unknown function. The role of poxA and its relation to 
poxB is yet to be determined. 
 In the present work we examine the role of PoxB and its contribution to β-lactam 
resistance by generating single in-frame deletions of both chromosomal β-lactamase-
encoding genes, namely ampC and poxB. We also study the efficacy of class A enzyme 
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inhibitors and of a novel non-β-lactam inhibitor termed avibactam, against PoxB. 
Additionally, the hypothesis that poxA and poxB form an operon and the role of PoxA 
were investigated.  
 
2.3 Materials and Methods 
 
2.3.1 Bacterial strains, plasmids and media.  Bacterial strains, plasmids and primers 
used in this study are shown in Table 2.1.  Escherichia coli and P. aeruginosa were 
cultured routinely in Luria-Bertani medium (LB; 10 g tryptone, 5 g yeast extract, and 5 g 
NaCl, per liter). Cation-adjusted Mueller Hinton broth (CAMHB) and agar (BBL, BD) 
were used for susceptibility testing using the broth microdilution method and E-test, 
respectively. T-broth (10 g Bacto tryptone and 5 g NaCl, per liter) was used for pellicle 
formation and Congo red (CR) binding assays. Antibiotics were used at the following 
concentrations: ampicillin (Ap) at 100 µg/ml, and gentamycin (Gm) at 15 µg/ml for E. 
coli; Gm at 75 µg/ml for P. aeruginosa.  
 
2.3.2 Construction of poxA, poxB, and oprD deletion mutants. A single in-frame 
deletion of poxA (PA5513) was constructed using overlap extension PCR and 
homologous recombination as previously described (758). Briefly, sequences upstream 
(816 bp) and downstream (773 bp) of the target deletion were amplified using primer 
pairs CApoxAUF1-CApoxAUR1 and CApoxADF2-CApoxADR2, respectively (Table 
2.1). The PCR products were then ligated through another round of PCR, cloned into the 
suicide vector pEXG2 (759) and moved into P. aeruginosa PA01 for homologous 
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recombination with the genome.  Double-cross-over recombinants were selected for by 
screening for Gm sensitivity and sucrose resistance. The deletion was confirmed by PCR 
amplification of deletion product from the genome and sequencing.  The strain is referred 
to as PA0∆poxA henceforth. In-frame deletions of poxB (PA5514) and oprD (PA0958) 
were generated in a similar manner using primer pairs DBpoxBUF1-DBpoxBUR1 and 
DBpoxBDF2-DBpoxBDR2; and DZoprDUF1-DZoprDUR1 and DZoprDDF2-
DZoprDDR2, respectively (Table 2.1). The poxB and oprD deletions were also 
introduced into a previously generated ampC deletion strain (PA0∆ampC) (760) to create 
PA0∆ampC∆poxB, PA0∆ampC∆oprD and PA0∆ampC∆poxB∆oprD. 
 
Table 2.1: Bacterial strains and plasmids used in this study 
Strains/Plasmids Relevant phenotype and genotype 
Reference/ 
Source 
Escherichia coli   
DH5α F- Φ80lacZΔM15 Δ(lacZYA-argF)U169 deoR 
recA1 endA1 hsdR17 (rk
-
 mk
+
) phoA supE44 λ
- -
thi-1 gyrA96 relA1 
New England 
Biolabs 
TOP10 F
- 
mcrA Δ(mrr-hsdRMS-mcrBC)Φ80lacZΔM15 
ΔlacΧ74 recA1 araD139 Δ(ara-leu)7697 galU 
galK rpsL (Str
R
) endA1 nupG 
Life 
Technologies 
BL21(DE3) F
- 
ompT hsdSB (rB-mB-) gal dcm (DE3) (761) 
Pseudomonas aeruginosa  
PA01 Wild-type  (762) 
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PKM119 PA0∆poxA, PA01 containing in-frame deletion 
of poxA   
This study 
PKM120 PA0∆poxB, PA01 containing in-frame deletion 
of poxB 
This study 
PKM201 PA0∆ampC, PA01 containing in-frame deletion 
of ampC 
(760) 
PKM202 PA0∆ampC∆poxB, PA01 containing in-frame 
deletions of ampC and poxB 
This study 
PKM121 PA0∆oprD, PA01 containing in-frame deletion 
of oprD 
This study 
PKM203 PA0∆ampC∆oprD, PA01 containing in-frame 
deletions of ampC and oprD 
This study 
PKM204 PA0∆ampC∆poxB∆oprD, PA01 containing in-
frame deletions of ampC, poxB and oprD  
This study 
Plasmids   
pEXG2 GmR; pMB1ori sacB (759) 
pGEM-T Easy  Ap
R
; TA cloning vector for PCR amplicons, 
pUC origin, f1 ori  
Promega 
pCR2.1-TOPO ApR, KmR; TA cloning vector for PCR 
amplicons, pUC origin, f1 ori lacZα 
Life 
Technologies 
pET15bVP ApR; pBR322 origin, oriV, expression vector, 
T7 promoter, His tag coding sequence  
(756) 
pMMB67EH-Gm  GmR; IncQ, RSF1010, lacIq Ptac expression 
vector  with ampR::aacC1 insertion at DraI  
(763) 
pDZ427 GmR; pET15bVP carrying an 891-bp XhoI and 
BamHI poxA fragment  
This study 
77 
 
pAmpC GmR; pMMB67EH-Gm carrying a 1297-bp 
fragment containing the ampC ORF 
This study 
pPoxA GmR; pMMB67EH-Gm carrying a 946-bp 
fragment containing the poxA ORF 
This study 
pPoxB GmR; pMMB67EH-Gm carrying an 835-bp 
fragment containing the poxB ORF 
This study 
Primers   
DZampCF 5’-GGAATTCAACGACAAAGGACGCCAA- 
TCCTC-3’ 
This study 
DZampCR 5’-CGGGATCCATGGCACCATCATAGCCA- 
GGACCGG-3’ 
This study 
DZpoxAF 5’-GGAATTCTTACACTGCGCGCCGTACG-
AGGA-3’ 
This study 
DZpoxAR 5’-CGGGATCCGATTCCCCACGGAAGGAG-
CGTT-3’ 
This study 
RTpoxARev1 5’-AGGAGAAGGGCACTGAAGAGGAGA-3’ This study 
RTpoxAFord2 5’-GACTTTCTCCTGCCCAATCCATGA-3’ This study 
RTpoxARev2 5’-CACCAACCAGAAGTTATCCACA-3’ This study 
DZpoxAFord4  5’-CTCGAGATGTCGCTATCCCCCTGGTT-
CC-3’ 
This study 
DZpoxARev4 5’GGATCCTCATGGATTGGGCAGGAGAA-
AGTC-3’ 
This study 
DZpoxBF  5’-GGAATTCAGGATGACCCCACAGGACC-
GAGCCAT-3’ 
This study 
DZpoxBR 5’-CGGGATCCCAGAGCGTCAGGGCAGT-
ATCC-3’ 
This study 
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CApoxAUF1 5’-GGAATTCGATCGTATTGCCGGGTCTC-
3’ 
This study 
CApoxAUR1 5’-GAGCATTCTAGCTAGCTAGAACCAGG-
GGATAGCGACAT-3’ 
This study 
CApoxADF2 5’-CTAGCTAGCTAGAATGCTCCCAATCC-
ATGAACGCTCCTT-3’ 
This study 
CApoxADR2 5’-CGGGATCCAAGCCGTAGAGCCGCTCG-
TT-3’ 
This study 
DBpoxBUF1 5’-GAATTCGGATTTCGACCTCTGGCTGT-
G-3’ 
This study 
DBpoxBUR1 5’-GAGCATTCTAGCTAGCTAGCAGGAGA-
AGGGCACTGAAGAG-3’ 
This study 
DBpoxBDF2 5’-CTAGCTAGCTAGAATGCTCTCAAGGC-
TCTC-GGGATACTG-3’ 
This study 
DBpoxBDR2 5’-CGGGATCCACTGGGTGTGGTTGGAGA-
AT-3’ 
This study 
DZoprDUF1 5’-GGAATTCCAAAGCGAACATACTGACC-
TCTC-3’ 
This study 
DZoprDUR1 5’-GAGCATTCTAGCTAGCTAGACTTATA-
GCACGCAGTGTTTCTTG-3’ 
This study 
DZoprDDF2 5’-CTAGCTAGCTAGAATGCTCCCTATAA-
AGGAAGGGCGTAGGTA-3’ 
This study 
DZoprDDR2 5’-CGGGATCCCGGTGGAAAGCAGATACT-
GACTGGTA-3’ 
This study 
 
 
2.3.3 PCR amplification and cloning of poxA, poxB and ampC. The P. aeruginosa 
PA01 genome was used as the template for PCR amplification of the poxA (PA5513), 
poxB (PA5514) and ampC (PA4110) ORFs with primer pairs DZpoxAF-DZpoxAR, 
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DZpoxBF-DZpoxBR, and DZampCF-DZampCR, respectively (Table 2.1). The amplicons 
were independently cloned into pCR2.1-TOPO and sequenced. Each insert was then 
moved into the EcoRI-BamHI sites of the broad-host range expression vector 
pMMB67EH-Gm (763) and propagated in E. coli TOP10 or DH5α. The plasmid carrying 
ampC, (pAmpC), was subsequently introduced by electroporation into PA0∆ampC∆poxB 
while pPoxA was introduced into PA0∆ampC, PA0∆poxA, and PA0∆poxB. The pPoxB 
plasmid was introduced into PA0∆poxA, PA0∆poxB, PA0∆ampC, PA0∆ampC∆poxB and 
PA0∆ampC∆poxB∆oprD. 
 For protein expression in E. coli BL21(DE3), the poxA ORF was amplified using 
primers DZpoxAFord4 and DZpoxARev4, cloned into the pGEM-T Easy vector 
(Promega, Madison, WI) and sequenced. The 891-bp fragment was then subcloned into 
the XhoI and BamHI sites of the broad host range shuttle vector pET15bVP (756) and 
propagated in E. coli TOP10 (Life Technologies, Grand Island, NY). The resultant 
plasmid was then introduced into E. coli BL21(DE3) (761) for expression studies.  
 
2.3.4 Protein expression and one-dimensional gel electrophoresis. To determine if 
poxA is translated, the ORF was cloned into the expression vector pET15bVP and 
introduced into E. coli BL21(DE3) as described in section 2.3.3. Stationary-phase 
cultures were diluted to an OD600 of 0.02 in 25 ml of LB broth and incubated with 
shaking at 37°C until the culture density reached an OD600 of 0.5.  Cells were then 
induced with 1 mM of isopropyl β-D-1-thiogalactopyranoside (IPTG) and reincubated at 
37°C. One-ml samples were taken at the time of induction and every hour for a total of 
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four hours for both IPTG-induced and non-induced samples. The cells were recovered by 
centrifugation, resuspended in 100 µl of 4X SDS protein sample buffer and boiled for 10 
minutes.  Proteins were separated on a 12% SDS-PAGE gel and stained with Coomassie 
brilliant blue (CB). 
 
2.3.5 Analysis of PA01 mRNA. To determine if poxA and poxB are cotranscribed, RNA 
was extracted from wild-type P. aeruginosa PA01, using the RNeasy mini kit (Qiagen).  
cDNA was synthesized with Superscript III (Invitrogen) and an (NS)5 random primer 
using standard methods (764).  Two sets of primers were used to amplify the intergenic 
between poxA and poxB plus 24 bp corresponding to the 3’ end of poxA and 53 or 486 bp 
from the 5’ end of poxB. RTpoxAFord2 and RTpoxARev1 were designed to amplify 126-
bp product, while amplification with RTpoxAFord2 and with RTpoxARev2 would yield 
a 559-bp product. RNA samples not treated with Superscript were also tested to ensure 
no carryover DNA contamination resulted from the RNA isolation procedure.  
 
2.3.6 β-lactamase assay. The β-lactamase assay was modified from a previously 
published protocol (765).  Briefly, stationary-phase cultures were diluted in 25 ml of LB 
broth to an OD600 of 0.02 and incubated with shaking at 37°C.  At an OD600 of 0.6, cells 
were induced with 50 µg/ml of benzylpenicillin, while cells containing the expression 
plasmid (pPoxB) were induced with 1 mM IPTG.  In both cases induction was carried out 
for an hour. Ten milliliter of cells were harvested by centrifugation and resuspended in 
1000 µl of 1x BugBuster solution (Novagen, EMD Millipore, Billerica, MA) containing 1 
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μl of benzonase (Novagen) and 1 KU of rLysozyme (Novagen). Lysate was rotated for 20 
min at room temperature before centrifuging at 4°C for 15 minutes to collect the β-
lactamase-containing supernatant.  A 2-µl aliquot of cell lysate was added to nitrocefin 
(final concentration, 100 µM) in 250 µl of assay buffer.  The reaction was incubated at 
37°C for 20 minutes and the hydrolysis of nitrocefin was measured 
spectrophotometrically at 482 nm. Total protein concentration was determined with 
Bradford on the same supernatant. The activity was expressed as nmol of nitrocefin 
degraded per minute per microgram of total protein. 
 
2.3.7 Minimum inhibitory concentration (MIC). MICs were determined by the E-test 
system according to the manufacturer’s instructions (bioMérieux, Marcy l’Etoile) or by 
the broth microdilution method according to standard protocols (766, 767).  E-test values 
were often reported as a range or as two independent values to illustrate variation seen in 
biological and technical replicates.  
 
2.3.8 Colony morphology on Tryptone Agar containing Congo red. Plates containing 
1% agar, 1% tryptone, 40 µg/ml of CR and 20 µg/ml of CB were spotted with 10 µl of 
0.025 OD600 cells. Plates were also supplemented with 1 mM IPTG and 10 or 20 mM 
NaNO3, when appropriate.  Plates were incubated at room temperature or in an anoxic 
chamber for 5-7 days and pictures were taken with the Epson Perfection V550 scanner 
(Long Beach, CA).  
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2.3.9 Pellicle formation and cell-surface interactions.  For pellicle formation, the 
strains were grown in 6 ml of T-broth at room temperature without shaking for 7 days as 
previously described (768). The tubes were inspected visually for formation of mats at 
the liquid-air interphase. To assess cell-cell and cell-surface interactions, cells were 
grown in borosilicate glass tubes overnight (O/N) with shaking at 37°C in T-broth in the 
presence and absence of 1 mM IPTG and inspected visually the next day for aggregates 
on the walls of the tubes (769). 
 
2.3.10 Congo red binding assay. The CR-binding assay was performed as previously 
described with minor modifications (770). Briefly, strains were grown in 2 ml of T-broth 
at 37°C without shaking for 48 hours. Cells were harvested by centrifugation, and washed 
with T-broth. The pellet was resuspended in 1 ml of T-broth containing 40 µg/ml of CR 
and incubated with shaking at 37°C.  After 90 minutes, the cells and the bound CR were 
pelleted by centrifugation. The optical density of the supernatant was determined at 495 
nm and the percentage of CR left in the supernatant was calculated.  
 
2.4 Results and Discussion 
 
 P. aeruginosa infections are commonly treated with a combination of β-lactams 
and aminoglycosides. Resistance to the β-lactam antibiotics is frequently observed in the 
clinical setting and is commonly due to the expression of enzymes that can hydrolyze 
these compounds, namely β-lactamases (645, 743, 771-773). P. aeruginosa clinical 
isolates often harbor acquired β-lactamases particularly of the oxacillinase- (class D) and 
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metallo-β-lactamase IMP- and VIM-types (class B) (549, 608, 610, 614, 747, 748, 774, 
775). Additionally, P. aeruginosa expresses a chromosomal cephalosporinase, AmpC, 
that provides intrinsic resistance and that can be expressed at high levels in the presence 
of β-lactams (711, 712, 776). A second chromosomally encoded oxacillinase-type β-
lactamase, PoxB, has also been reported (740, 741). The aim of this study was to examine 
the role of the class D β-lactamase PoxB in P. aeruginosa PA01. 
 
2.4.1 poxA and poxB form an operon.  Previous in silico analysis revealed the 
oxacillinase-encoding gene (PA5514) to be located 49-bp downstream of a putative ORF 
annotated PA5513 (Figure 2.1A). Given the close proximity between PA5513 and 
PA5514, the absence of promoter like sequences in the intergenic region, and the 
presence of a potential ρ-independent terminator downstream of PA5514, we previously 
hypothesized that poxA and poxB form a two-gene operon (740). To determine if in fact 
these two genes are cotranscribed, RNA was extracted from the prototypic P. aeruginosa 
PA01, cDNA was synthesized and two sets of primers (RTpoxAFord2-RTpoxARev1 and 
RTpoxAFord2-RTpoxARev2) were used to amplify the intergenic region plus small 
portions of the 3’ of poxA and the 5’ of poxB (Figure 2.1A). As expected, the first set of 
primers yielded a 126-bp amplicon in both genomic DNA and cDNA templates (Figure 
2.1B, lanes 1 and 2), with the second set yielding a 559-bp product in the same templates 
(Lanes 5 and 6). In the absence of template DNA or reverse transcriptase, no 
amplification was detected for both primer sets (Lanes 3, 4, 7 and 8).  This work confirms 
that these two genes are cotranscribed and that they form an operon.   
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Figure 2.1. The poxAB operon. (A) The pox genes and the approximate location of 
primers used to show PA5513 and PA5514 form an operon. Two sets of primers were 
used to amplify the intergenic region as well as the 3’ end of poxA and the 5’ start of 
poxB from wild-type cDNA. Primer pair RTpoxAFord2 and RTpoxARev1, denoted as F2 
and R1 respectively, were used for amplification of a 126-bp product, while 
RTpoxAFord2 and RTpoxARev2, denoted F2 and R2, were used to amplify a 559-bp 
region. (B) A 126-bp amplicon was detected in wild-type genomic and cDNA samples 
(Lanes 1 and 2) upon amplification with F2 and R1. Similarly, a 559-bp product was 
observed upon amplification with F2 and R2 in wild-type genomic and cDNA samples 
(Lanes 5 and 6). No amplification could be detected with either primer set in the absence 
of reverse transcriptase or template DNA (Lanes 3, 4, 7 and 8).  
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2.4.2 poxA is translated into a 32.4-kDalton protein. Since our present work indicates 
poxA and poxB are cotranscribed, it is also expected that poxA mRNA is translated into a 
protein with a function potentially related to that of PoxB.  To confirm our prediction, the 
poxA ORF was amplified and cloned into the expression vector pET15bVP (756) and 
expressed in E. coli BL21(DE3) (761). Whole cell extracts were obtained from cells 
carrying the poxA-overexpressing plasmid in the presence and absence of IPTG. Proteins 
were visualized in an SDS-PAGE gel. A protein band corresponding to PoxA was 
detected at around 32 kDalton an hour after induction with IPTG and thereafter (Figure 
2.2, Lanes 3-6). The same band was also  present but reduced in whole cell extracts  from 
uninduced  cells  that  had  been grown for 4 hours after induction (Lane 7).  PoxA was 
absent from the uninduced and induced conditions at the 0 time point (Lanes 1 and 2), as 
well as from cells containing only empty vector (Figure 2.2, lanes 8-9).  Thus the poxA 
ORF codes for a protein.  
 Since both poxA and poxB are part of a single operon, they could potentially have 
related functions. In silico analysis reveals that the nucleotide sequences composing this 
operon are not found anywhere else but in P. aeruginosa. Sequences showing high 
similarity to both the poxA ORF (73-82%) and the PoxA protein (66-78%) were also 
identified in other Pseudomonas species such as P. denitrificans, P. entomophila, P. 
monteilii, and P. putida, but were unlinked to any β-lactamase-encoding gene. Similar to 
PoxA, these hypothetical proteins are classified as putative hydrolases or acyltransferases 
of the α/β hydrolase superfamily. The α/β hydrolase fold is present in a varied number of 
proteins that share little in terms of function or  sequence  homology  but show structural 
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similarity (777, 778). Proteins carrying the canonical α/β fold include lipases, esterases, 
proteases, peroxidases as well as transporters and hormone precursors. The role of PoxA 
and its relation to PoxB are yet to be determined. 
 
2.4.3 poxA and poxB deletions do not alter β-lactamase activity or β-lactam 
susceptibility.  To investigate the role of poxA and poxB in P. aeruginosa, single in-
frame deletions of each of the genes were generated. The β-lactamase and β-lactam 
susceptibility profiles were compared with that of the parent strain PA01. An in-frame 
deletion of poxB was also introduced into a previously generated PA0∆ampC strain 
(760). Single deletions of poxA or poxB did not alter the β-lactamase or susceptibility 
profiles of the strains as compared to the wild-type PA01 (Table 2.2 and Figure 2.3).  
Since the AmpC β-lactamase was present in these backgrounds and potentially obscuring 
the role of PoxB, the susceptibility and β-lactamase activity were also examined in strains 
lacking ampC.   
 Little to no β-lactamase was detected in both PA0∆ampC and PA0∆ampC∆poxB 
suggesting AmpC is responsible for the activity observed in wild-type and in deletion 
poxA and poxB strains (Figure 2.3).  Interestingly, a deletion of ampC alone significantly 
increased susceptibility against the aminopenicillins (ampicillin and amoxicillin), but 
produced only minor changes against the carbapenems (imipenem and doripenem), with 
no effect observed against the cephalosporins and the rest of the penicillins (Table 2.2).  
When overexpressed, however, AmpC was capable of restoring the phenotype and/or 
increasing resistance against all penicillins and cephalosporins tested (Table 2.3), in most 
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cases past clinical breakpoints, while having little to no effect on the carbapenems. These 
results are in agreement with the known hydrolysis spectrum of AmpC that includes 
penicillins and cephalosporins but rarely carbapenems (625, 626, 779, 780). Resistance 
against penicillins and cephalosporins has been observed in the clinical setting and 
correlates with different levels of AmpC derepression (379-381, 722, 781-783). Lastly, 
deleting poxB from an already ampC-deficient background did not further alter 
susceptibility suggesting either that PoxB plays no role in β-lactam resistance or that it is 
not expressed under the tested experimental conditions  (Table 2.2).   
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 β-lactam 
Minimum Inhibitory Concentration (µg/ml) 
PA01 ∆poxA ∆poxB ∆ampC ∆ampC∆poxB 
Ampicillin >256 >256 >256 16-24 24 
Ampicillin/sulbactam >256 >256 >256 16-32 16-32 
Amoxicillin >256 >256 >256 8-12 16-24 
Amoxicillin/clavulanate  >256 >256 >256 8 8 
Ticarcillin/clavulanate 8-12 12 8-12 8 12 
Piperacillin/tazobactam 3-4 3 3 3 3-4 
Piperacillin 4-6 4 4 
4 
4-6 
Aztreonam 1.5-3 2 2  1.5-3 2-3 
Cefepime 1-1.5 1-1.5 1 0.75-2 1 
Cefotaxime 4-6 6 6 4-6 4 
Ceftazidime 1-1.5 1.5 1.5 1.5  1 
Imipenem 1-1.5 1.5 1.5 0.25- 0.5 0.38-0.5 
Meropenem 0.25-0.5 0.38-0.50 0.38 0.25-0.75 0.25- 0.38 
Doripenem 0.125-0.38 0.38 0.38 0.094 0.094-0.125 
 
Table 2.2: Susceptibility profiles of poxA, poxB and ampC deletion mutants 
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Figure 2.3.  β-lactamase activity profile of pox and ampC deletion mutants. The β-
lactamase activities of PA0∆poxA, PA0∆poxB, PA0∆ampC and PA0∆ampC∆poxB were 
quantified in the presence (blue bars) and absence (white bars) of the inducer 
(benzylpenicillin at 50 µg/ml for 1h). Assays were carried out on cell lysate with 100 µM 
of nitrocefin as chromogenic substrate. One milliunit of β-lactamase was defined as 1 
nanomole of nitrocefin hydrolyzed per minute per microgram of protein. * p-value< 
0.005 for  β-lactamase activity in PA01 induced versus activity in PA01 uninduced; ** p-
value< 0.05 for  β-lactamase activity in PA0∆poxA induced versus activity in PA0∆poxA 
uninduced; *** p-value< 0.005 for β-lactamase activity in PA0∆poxB induced versus 
activity in PA0∆poxB uninduced, as determined by paired t-test.   
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2.4.4 PoxB is a carbapenemase.  To determine the role of PoxB in P. aeruginosa, we 
overexpressed poxB in a low-copy plasmid under the control of an IPTG-inducible 
promoter in both PA0∆ampC and PA0∆ampC∆poxB.  Overexpression of PoxB provided 
little to no resistance against the penicillins and the cephalosporins (Table 2.3). There 
was, however, a significant decrease in susceptibility (increase in MIC) against the 
carbapenems, meropenem and doripenem, as determined by E-test (Table 2.3). A four-
fold increase in MIC was also observed against meropenem (not tested against 
doripenem) using the broth microdilution method (Figure 2.4). PoxB, however, did not 
appear to alter susceptibility against imipenem in an ampC- or ampCpoxB-deficient 
background suggesting PoxB may not be able to hydrolyze this carbapenem.  
 In carbapenems, the signature β-lactam ring, composed of one nitrogen and three 
carbons, is fused to an unsaturated five-atom ring that binds sulfur at position C2 (Figure 
2.5).  The basic structural differences between the carbapenems (imipenem, doripenem, 
and meropenem) are imparted by the varying side chains extending from the sulfur at C2.  
Meropenem and doripenem have bulkier side groups than imipenem. Additionally, there 
is a methyl group at C1, absent from imipenem that could be the basis for the lack of 
activity of PoxB against this compound. However, beyond structural differences, 
resistance/susceptibility to imipenem in P. aeruginosa must also take into account the 
role of the outer membrane porin OprD. 
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Figure 2.4. Determination of meropenem MIC in a PoxB-overexpressing background. 
The MIC of meropenem was determined by the microbroth dilution method in 
PA0∆ampC∆poxB (pPoxB) (blue square), PA0∆ampC∆poxB (vector) (grey triangles) 
and in PA01 (vector) (light blue diamond). Cells were grown O/N in the presence of 1 
mM IPTG with increasing concentrations of meropenem (0-3 µg/ml).  The final cell 
density measured at OD600 after 18 hours of growth is reported. * p-value< 0.0001 for 
OD600 of PA0∆ampC∆poxB (pPoxB) versus optical density for PA0∆ampC∆poxB 
(vector) with 0.25 µg/ml meropenem; ** p-value= 0.0005 for OD600 of 
PA0∆ampC∆poxB (pPoxB) versus optical density for PA0∆ampC∆poxB (vector) with 1 
µg/ml meropenem, as determined by unpaired t-test.   
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Figure 2.5. Chemical structures of carbapenems: meropenem, imipenem and doripenem. 
The positions of atoms in the core β-lactam ring and the carbapenem nucleus structure are 
numbered and depicted in meropenem. 
 
 OprD is a substrate-specific porin that mediates the diffusion of basic amino acids 
and imipenem into the cell (757, 784, 785).  Imipenem remains a viable and powerful 
treatment option against P. aeruginosa, however, mutations in or loss of oprD and 
subsequent resistance to this β-lactam, often arise after imipenem treatment (313, 315, 
786). In the absence of oprD, the MIC for imipenem increases to ∼8-16 µg/ml as the 
antibiotic cannot penetrate the cell as fast as it could in the wild-type (305, 314, 315). 
Imipenem will still enter the cell, most likely through other pores and porins, albeit at a 
much lower rate (L. Silver, Personal communication). This slower rate of diffusion 
makes imipenem a better substrate for the AmpC β-lactamase, which is active in the 
periplasm of the cell. Thus, in an oprD-deficient background, the activity of imipenem is 
determined by the expression of ampC and potentially poxB, but not by the mex efflux 
system, as imipenem, unlike meropenem and doripenem, is not subject to efflux (312, 
787, 788).  If ampC is also removed from the equation, the activity of imipenem should 
be determined by PoxB.  Previous studies have shown PoxB has some affinity against 
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imipenem (741), however, PoxB activity against imipenem has not been examined in an 
oprD-deficient background. We thus set out to test the ability of PoxB to provide 
resistance against imipenem in the absence of oprD.  
 As expected, deletion of oprD alone significantly decreased susceptibility of the 
strains against the carbapenems, with the greatest increase in MIC observed for 
meropenem followed by imipenem (Table 2.4).  In such a background, the MIC is 
presumably dictated by the action of AmpC and PoxB, along with efflux for meropenem 
and doripenem. AmpC plays a major role in providing resistance here, since in its 
absence, the strain becomes very susceptible to imipenem, but less so to meropenem and 
doripenem (Table 2.4). This work corroborates previous studies where imipenem 
resistance was found to be dependent upon both the loss of oprD and the expression of 
AmpC β-lactamase (305). Similarly, in our study AmpC afforded greater protection 
against imipenem in a less permeable background, e.g., loss of oprD (Table 2.4). 
Specifically the loss of oprD raised the MIC from 1 to 8 µg/ml, with a further deletion of 
ampC restoring susceptibility to that of wild-type levels (MIC = 1 µg/ml). Resistance 
against meropenem and doripenem in our study, was found to be affected mainly by the 
loss of oprD, with only minor changes observed upon deletion of ampC, suggesting these 
two carbapenems are not good substrates for AmpC and/or they are efficiently effluxed. 
In agreement with these results, our single ampC deletion mutant also showed a slight 
increase in susceptibility against imipenem but no change against meropenem (Table 
2.2).  
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 A further deletion of poxB from an ampCoprD-deletion mutant did not alter 
susceptibility (Table 2.4). However, overexpression of PoxB in an oprDampCpoxB-
deficient background significantly increased the MICs of all the carbapenems, including 
imipenem (Table 2.4), showing that in fact PoxB can hydrolyze all of these β-lactams. In 
particular, the increase in MIC observed for meropenem reached the CLSI clinical 
resistant breakpoint for this carbapenem (≥ 8 µg/ml) (767). Determination of MIC by the 
microbroth dilution method corroborated the E-test results (Figure 2.6 A-D).  
 Previous biochemical studies showed that the supposed preferred substrates of 
oxacillinases, namely oxacillin and cloxacillin, were hydrolyzed very poorly, if at all by 
PoxB (741). Additionally, PoxB exhibited very low affinity towards most of the 
substrates tested, which included benzylpenicillin, ampicillin, piperacillin and 
cephalothin. PoxB, however, did exhibit the highest affinity towards imipenem, although 
its ability to hydrolyze it was low (741).  Against meropenem, PoxB exhibited low 
affinity and weak hydrolysis, while overexpression in trans did afford the cells a 
decreased in susceptibility (increase in MIC) against meropenem but not imipenem (741).  
Similarly, our work shows that PoxB does not significantly hydrolyze penicillin and 
cephalosporin β-lactams. In contrast to previous work, however, we show PoxB is 
capable of hydrolyzing not only meropenem but also imipenem and doripenem producing 
a decrease in susceptibility (higher MIC) towards these β-lactams when overexpressed.  
Although PoxB biochemically may not have the greatest affinity towards some of these 
carbapenems, its expression does afford the cell greater protection against these β-
lactams.  PoxB thus is a carbapenemase with a narrow spectrum of hydrolysis.   
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Figure 2.6.  Determination of carbapenem MICs in P. aeruginosa oprD-deficient strains 
by the microbroth dilution method. (A) MIC of imipenem in the presence of 1 mM IPTG. 
(B) Optical density of cells grown O/N with increasing concentrations of imipenem (0-3 
µg/ml) in the presence and absence of IPTG (1 mM). (C) MIC of meropenem in the 
presence of 1 mM IPTG. (D) Optical density of cells grown O/N with increasing 
concentrations of meropenem (0-3 µg/ml) in the presence and absence of IPTG (1 mM).  
D 
C 
D 
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2.4.5 Expression of PoxB does not alter efflux.  It is expected that the significant 
decrease in susceptibility against carbapenems observed above is caused by the 
expression of PoxB and not by an increase in the activity of efflux pumps, especially as 
imipenem is not the subject of efflux. Nonetheless, the activity of efflux pumps was 
checked by examining the susceptibility of PoxB-overexpressing strains against known 
efflux substrates. As expected, the MIC values did not significantly differ between wild-
type and PoxB-overexpressing strains (Table 2.5), suggesting efflux systems were neither 
enhanced nor compromised by the increased expression of PoxB. Thus, these results 
clearly argue that the increase in carbapenem MIC (Tables 2.3 and 2.4) is provided by the 
expression of PoxB.   
 
 
 
 
 
 
 
 
 
2.4.6 Inhibitors of PoxB.  β-lactam antibiotics are often co-administered with β-
lactamase inhibitors to improve the efficacy of treatment against β-lactamase-expressing 
pathogens (423, 428, 557). β-lactamase inhibitors are β-lactams themselves with only 
Antibiotic 
Range (µg/ml) 
PA01 vector 
PA0∆ampC∆poxB 
(vector) 
PA0∆ampC∆poxB 
(pPoxB) 
Chloramphenicol 32 32 32 
Trimethoprim 150 150 100 
Novobiocin 512 512 512 
Tetracycline 8 8 8 
Ofloxacin 1 1.5 1 
Norfloxacin 0.75 0.75 0.75 
Ciprofloxacin 0.19 0.19 0.19 
Levofloxacin 0.38 0.38 0.38 
 
Table 2.5: MIC in the presence of efflux substrates 
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minor antibacterial activity (789-792) that can either reversibly or irreversibly inhibit the 
β-lactamase thus preventing it from hydrolyzing the co-administered antibiotic (423, 793-
796). Currently, three irreversible β-lactamase inhibitors, clavulanic acid (797, 798), 
sulbactam (426, 799, 800) and tazobactam (801, 802) are approved for clinical use.  Their 
activity is limited to most class A enzymes, being generally ineffective against classes B, 
C and D β-lactamases (428, 467).  PoxB has been shown to be only poorly inhibited by 
these (741). A new β-lactamase inhibitor, termed avibactam, with a broader spectrum of 
activity has been developed and is currently undergoing phase III clinical trials in 
combination with ceftazidime (803-805). Unlike the aforementioned compounds, 
avibactam is not a β-lactam, although its structure closely resembles one (804).  The 
ability of avibactam to inhibit PoxB activity was examined and compared to that of weak 
inhibitors of oxacillinases, namely tazobactam, sulbactam and clavulanic acid. 
 Subinhibitory concentrations of imipenem (0.5 µg/ml) and meropenem (1 µg/ml) 
that only allowed PA0∆ampCΔpoxBΔoprD to grow when PoxB was overexpressed 
(Figure 2.6A and 2.6C) were used to examine the inhibitory action of tazobactam, 
sulbactam and clavulanic acid against PoxB. A slight inhibition of growth was apparent 
with tazobactam in the presence of imipenem, and to a smaller extent with sulbactam 
(Figure 2.7). In the presence of clavulanic acid, growth either remained unaltered or was 
slightly enhanced. Overall, as expected, the ability of PoxB-overexpressing strains to 
grow on imipenem or meropenem was not significantly affected by the presence of these 
inhibitors at the tested clinical concentrations, indicating these compounds did not inhibit 
PoxB activity (Figure 2.7). 
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Figure  2.7. Effect of tazobactam, sulbactam and clavulanic acid on PoxB activity. The 
ability of PA0∆ampCΔpoxBΔoprD (pPoxB) to grow in the presence of subinhibitory 
concentrations of imipenem (0.5 µg/ml) or meropenem (1 µg/ml) was examined in the 
presence of the class A enzyme inhibitors tazobactam (A), sulbactam (B) and clavulanic 
acid (C). OD600 readings after O/N growth with aeration at 37°C are reported. 
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 Similarly, the ability of avibactam to inhibit PoxB activity was tested by growing 
PoxB-expressing strains in CAMH agar with IPTG in the presence and absence of 
avibactam at a clinically used concentration (4 µg/ml). The presence of PoxB increases 
the MIC against imipenem, meropenem and doripenem (as detailed in Section 2.4.4, 
Table 2.4) since PoxB can hydrolyze these carbapenems. Inhibition of PoxB by 
avibactam, should then produce a decrease in MIC against the carbapenems. Our results 
show, however, that the MIC of PoxB-expressing cells was not altered in the presence of 
this inhibitor (Table 2.6), suggesting avibactam does not significantly inhibit PoxB 
activity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Minimum Inhibitory Concentration (µg/ml) 
Carbapenems CAMH 
PA0∆ampC∆poxB 
∆oprD (vector) 
PA0∆ampC∆poxB 
∆oprD(pPoxB) 
Imipenem 
Alone 0.25 0.75 
IPTG 1.5 6 
IPTG + AV 1.5 4, 6 
    
Meropenem 
Alone 6 4 
IPTG 4, 6 32 
IPTG + AV 6, 4 32 
    
Doripenem 
Alone 0.75-1 0.75-1 
IPTG 0.75-1  8 
IPTG + AV 1-1.5 8 
AV- Avibactam at 4 µg/ml 
Table 2.6: Effect of avibactam on carbapenem MIC  
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 The inhibitory action of these compounds was also tested directly on cell lysate 
from PoxB-overexpressing cells by quantification of the β-lactamase activity. 
Concentrations as high as 700 µM of tazobactam failed to reduce the β-lactamase activity 
in cell lysates from PA0∆ampCΔpoxB (pPoxB) cells, while only a minor reduction was 
observed with 4000 µM of sulbactam (Figure 2.8A and 2.8B). A general downward trend 
of inhibition was observed with clavulanic acid starting at 50 µM, but a 50% inhibition 
was not reached even at high levels of the inhibitor (4000 µM). Avibactam decreased 
PoxB activity by more than half (Figure 2.8C) at a concentration of 2000 µM (530.488 
µg/ml), which is 75-fold higher than that of the highest concentration of avibactam used 
in clinical studies (0.5-7 µg/ml) (806-808). Notwithstanding that avibactam produced 
greater inhibition than the other tested inhibitors, the large quantities of the compound 
needed to inhibit PoxB activity, makes avibactam a weak inhibitor.  
 Avibactam at a concentration of 4 µg/ml has proven sufficient and efficient at 
increasing susceptibility and/or eliminating resistance against a number of β-lactams in a 
large number of clinical isolates (809-811). For instance, in a study of 1466 Gram-
negative isolates collected from patients hospitalized with pneumonia, bloodstream, intra-
abdominal and urinary tract infections, avibactam in combination with ceftazidime 
effectively reduced MICs from 16 or 32 to 0.25 µg/ml in 90% of Enterobacterial isolates 
(809). About 99.8% of such isolates exhibited an MIC of ≤4 µg/ml, the CLSI clinical 
susceptible breakpoint for ceftazidime (809). Similarly, avibactam reduced the MIC 
anywhere  from 16 or 32  to  4-8 in 90%  of  P. aeruginosa isolates,  with an average of  
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Figure 2.8. PoxB β-lactamase activity in the presence of tazobactam, sulbactam, 
clavulanic acid and avibactam. The β-lactamase assay was performed on lysate from 
IPTG-induced (1 mM) PA0∆ampCΔpoxB (pPoxB) cells. Lysate was incubated for 20 min 
with increasing concentrations of tazobactam (A), sulbactam (B), clavulanic acid (C), and 
avibactam (D). Chromacef was used as a chromogenic substrate. One milliunit of β-
lactamase was defined as 1 nanomole of chromacef hydrolyzed per minute per 
microgram of protein.  
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96.8% of all isolates showing a ceftazidime/avibactam MIC of ≤8 µg/ml, the CLSI 
susceptible breakpoint for ceftazidime in this organism (809).  
  Although avibactam has shown variable activity against class D enzymes, it 
remains a more potent and effective inhibitor of class A (805-808, 812) and C (805, 807, 
812, 813) enzymes, including the problematic class A Klebsiella pneumoniae 
carbapenemases or KPCs (814, 815). A study found that avibactam potentiated the 
activity of both ceftazidime and aztreonam against meropenem-nonsusceptible Gram-
negative bacilli expressing multiple β-lactamases of the class A and C types (811). 
Avibactam, however, was less successful at reducing the MIC of Acinetobacter 
baumannii isolates carrying OXA-23-like genes (MIC90 fold reduction of 2-4 vs fold 
reduction of 32-256 against class A, B and C enzymes in that particular study) (811).  
Similarly, avibactam did not significantly improve the activity of cefepime, ceftazidime 
or imipenem in A. baumannii isolates carrying PER-1, OXA-51 and OXA-58, with only a 
minor increase in susceptibility (∽2-fold decrease in resistance) observed (816). The 
efficacy of ceftazidime against an OXA-5-expressing P. aeruginosa clinical isolate was 
also not improved by the presence of avibactam (817).  
 OXA-48 appears to be just one of a few class D enzymes against which avibactam 
is active. A study showed that K. pneumoniae and E. coli isolates harboring the 
carbapenemase OXA-48 exhibited significant reduction in the MIC of imipenem, 
cefepime and ceftazidime when combined with avibactam, leading to susceptibility in 
90% of isolates (816). In another study, the number of K. pneumoniae OXA-48-
producers showing resistance was eliminated and/or susceptibility was enhanced by the 
106 
 
addition of avibactam (818). However, a kinetics study also found the rates of reaction of 
avibactam with OXA-48 and OXA-10 to be much slower than that of the other tested 
class A and C enzymes (804). The P. aeruginosa OXA-10 was actually found to be 
poorly inhibited by avibactam (804). Although avibactam has not been tested against 
very many OXA enzymes and while the structure and hydrolytic activities of 
oxacillinases is wide and varied, the emerging trend suggests that avibactam is not a very 
good inhibitor of class D enzymes.  It is thus not surprising avibactam is only a weak 
inhibitor of PoxB (OXA-50). 
 
2.4.7 Inhibition by NaCl.  Oxacillinases are known to be inhibited by NaCl in vitro 
(669, 674, 682). This characteristic is commonly attributed to the presence of a Tyr 
residue at position 144, with replacement by Phe leading to resistance to inhibition (703, 
819). Inhibition is often showed directly by measuring enzyme activity (β-lactamase 
assay), or indirectly by determining MIC changes (820). Previous work showed 
inhibition of purified PoxB by NaCl (IC50, 50 mM), which not surprisingly carries Tyr at 
position 144 (741). We here further test if the previously reported NaCl inhibition of 
PoxB can translate into quantifiable changes that can affect the ability of PoxB to provide 
resistance. To that end, PA0∆ampCΔpoxBΔoprD (pPoxB) was grown in the presence of 
subinhibitory concentrations of imipenem (0.5 µg/ml) or meropenem (1 µg/ml) that only 
allowed growth if PoxB was expressed. Growth was monitored O/N and inhibition of 
growth was used as an indirect indicator of PoxB activity.  
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 NaCl produced a small, but steady increase in growth up to a concentration of 50 
and 100 mM in the presence of meropenem or imipenem, respectively (Figure 2.9). A 
slight growth decrease was detected in the presence of meropenem at NaCl 
concentrations of 100 mM or higher. Concentrations of ≥200 mM decreased growth 
below the level of untreated cells, suggesting NaCl was compromising PoxB-dependent 
growth (Figure 2.9). In the presence of imipenem, growth never fell below that of 
untreated cells, but the enhancement of growth seen with up to 100 mM was lost at NaCl 
concentrations of 200 mM or higher, also suggesting that this higher range of solute was 
affecting the ability of PoxB to hydrolyze the β-lactam.  
 
 
 
 
 
 
 
 
 
 
Figure 2.9. PoxB activity in the presence of NaCl. Inhibition of PoxB by NaCl was 
examined by growing PA0∆ampCΔpoxBΔoprD (pPoxB) O/N in the presence of 
subinhibitory concentrations of meropenem or imipenem with IPTG (1 mM) and with 
increasing concentrations of NaCl. The subinhibitory concentrations of meropenem and 
imipenem selected were those previously shown to allow growth of only PoxB-
overexpressing cells.  
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 Although small inhibition of growth is detected with NaCl, particularly at higher 
concentrations, NaCl did not completely abolish growth of PA0∆ampCΔpoxBΔoprD 
(pPoxB) in LB or CAMH broth containing meropenem or imipenem (Figure 2.9). In 
short, PoxB activity did not appear to be inhibited by NaCl to levels significant enough to 
prevent hydrolysis of the carbapenems and subsequently growth in media containing 
these β-lactams. The slight decrease in growth observed, however, was determined to be 
mostly unrelated to osmolarity, since cells grown in the presence of NaCl only lysed at a 
concentration of 800 mM of solute (Figure 2.10). A concentration of 400 mM does 
appear to slightly affect osmolarity leading to a <2-fold reduction in absorbance as 
compared to growth in 200 mM of NaCl. 
Figure 2.10. Determination of MIC for NaCl.  The concentration of NaCl needed to lyse 
cells was determined by growing PA01 (vector) and PA0∆ampCΔpoxBΔoprD (pPoxB) 
O/N with increasing concentrations of NaCl in CAMHB media.   
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 Inhibition by NaCl, however, was apparent on cell lysate from PA0∆ampCΔpoxB 
(pPoxB) cells (Figure 2.11). Specifically, β-lactamase activity decreased with increasing 
concentrations of NaCl. The phenotype was readily observed in the absence of IPTG.  
However, in the presence of IPTG, where the levels of PoxB are significantly higher, 
NaCl inhibition could not be appreciated (Data not shown).    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.11. Inhibition of PoxB by NaCl. PoxB inhibition was measured in vitro as a 
function of β-lactamase activity. The β-lactamase assay was performed on lysate from 
IPTG-induced and uninduced (1 mM) PA0∆ampCΔpoxB (pPoxB) cells. Lysate was 
incubated for 20 min with increasing concentrations of NaCl (0-800 mM). Only data for 
uninduced lysate is shown. Nitrocefin was used as a chromogenic substrate. One milliunit 
of β-lactamase was defined as 1 nanomole of nitrocefin hydrolyzed per minute per 
microgram of protein. 
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 The CF lung is notoriously susceptible to bacterial infections and in particular to 
colonization by P. aeruginosa (122, 123). The most widely accepted hypothesis of CF 
pathobiology, the low volume hypothesis, states that mutations in the CFTR gene cause 
an excessive intake of NaCl in the lung epithelium leading to surface airway dehydration 
and impaction of mucus thus setting up the stage for the chronic and persistent bacterial 
infections that are the hallmarks of CF lung disease (155, 177, 189). The CF lung, with its 
imbalance of Na
+
 and Cl
-
 ions transport, may confer an advantage to OXA-producing 
organisms susceptible to inhibition by NaCl than otherwise provided by healthy lung. By 
the same token, OXA-enzymes susceptible to NaCl inhibition may exhibit decreased 
activity in the normal lung. However, it has been difficult to measure the salt content on 
surface airway epithelium. Mice and epithelial culture studies, although substantiating the 
low volume hypothesis, have not shown a difference in ion content between healthy and 
CF models (174, 176, 821-823). Thus, it is difficult to ascertain the ramification of the 
imbalance of Na
+
 and Cl
-
 transport caused by CFTR mutations on the activity of OXA-
type β-lactamases, if at all.  
 
2.4.8 PoxA and Congo red binding phenotype.  A Biolog microarray phenotypic assay 
pointed to a growth defect for the PA0ΔpoxA mutant in the presence of 10 mM NaNO3. 
Since P. aeruginosa is a facultative anaerobe capable of using NO3 as a terminal electron 
acceptor (824), we investigated the colony morphology of poxA mutants on CR and CB 
plates with NaNO3 in aerobic and anaerobic conditions. Interestingly, a phenotype was 
observed in the presence of oxygen and in the absence of NaNO3 (Figure 2.12). 
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Specifically, overexpression of PoxA produced colonies with an outer dark ring and a 
darker inner ring, while the center of the colony remained white (Figure 2.12). The 
observed red phenotype here is indicative of hyperbinding to CR and suggests enhanced 
production of extracellular polysaccharides such as Pel or Psl (768, 770).  
 
Figure 2.12. Colony morphology on CR. Fresh cultures were diluted to an OD600 of 0.05 
and 10 μl of each were spotted on agar plates containing 1% tryptone and 1% agar 
supplemented with 40 μg/ml CR and 20 μg/ml CB in the presence of gentamycin (75 
μg/ml ) and  IPTG (1 mM).  Plates were incubated at 25°C in the dark for five days.  The 
colonies were imaged every 24 hours using an Epson scanner. Fifth-day colonies are 
shown.   
 
 Non-mucoid P. aeruginosa strains can secrete two extracellular polymeric 
substances, Pel (768, 825, 826) and Psl (769, 827) polysaccharides, that are known to 
contribute to biofilm formation. Although the P. aeruginosa strain PA01 has all the genes 
necessary for production of both Pel and Psl, the latter has been shown to play a bigger 
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role in biofilm formation and maturation in this background (768, 769, 826, 827).  The 
PA14 strain, on the other hand, can only produce Pel due to a three-gene deletion in the 
psl locus (768, 825, 826). Nonetheless, a recent study showed that both Pel and Psl 
polysaccharides were involved in micro- and macrocolony formation and in 
subpopulation interactions in the PA01 biofilms (828), while a PA01 psl mutant was able 
to form biofilm after acquiring mutations that allowed it to overexpress Pel (829). 
 CR is known to bind polysaccharides containing β-1,3- or β-1,4-glycosidic 
linkages (830), and thus has been used to detect the carbohydrates-rich components in the 
extracellular matrices of a number of  bacteria (831-833). CR is in fact routinely used to 
detect the presence of the Pel and Psl polysaccharides in P. aeruginosa (768-770, 825). In 
order to determine if hyperbinding to CR observed upon expression of PoxA (Figure 
2.12), is the result of increased production of either Pel or Psl polysaccharides, pellicle 
formation, autoaggregative properties and binding to CR were examined in liquid media. 
All strains were able to form pellicle at the liquid-air interphase and there was no 
difference by visual inspection in the amount of pellicle being formed (Figure 2.13). 
Similarly, not much difference was observed in the ability of the pellicles to bind CR 
(Figure 2.14) or in the ability of the strains to form aggregates on the walls of the tubes 
(Data not shown).   
 Expression of PoxA thus, does not appear to contribute to an increased production 
of Pel or Psl in liquid media. Thus, at first glance, the CR-binding phenotype observed in 
Figure 2.12, does not appear to be the result of an increased production of Pel or Psl 
polysaccharides. Clearly the surface attached biofilm growing on plates are able to bind 
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CR there, but the basis for binding remains unknown. Given that CR is known to bind 
polysaccharides, it is likely that the CR phenotype observed here is due to increased 
production of a carbohydrate or polysaccharide. Alternatively, the surface attached 
biofilms that grow on plates may be conducive to the production of Pel or Psl in plates 
but not in liquid media. CR, however, has also been shown to bind non-cellulose material 
of the extracellular matrix, such as the proteinaceous thin aggregative fimbriae and curli 
polymers produced by Salmonella spp. and E. coli isolates, respectively (834-836). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.13. Pellicle formation in PoxA-expressing cells.  Stationary phase cultures were 
diluted to an OD600 of 0.025 in T-broth and pellicle formation was monitored at room 
temperature without shaking for seven days. Seventh-day cultures are shown.  
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Figure 2.14.  CR-binding assay.  Two-day old cells were pelleted, resuspended in T-
broth containing CR (40 µg/ml) and grown with aeration at 37°C for 90 minutes. The 
cells along with bound CR were pelleted by centrifugation and the OD495 of the 
supernatant was used to calculate the percentage of bound CR. 
 
2.5 Concluding Remarks 
 
 P. aeruginosa carries two chromosomal β-lactamases, AmpC, a penicillinase and 
cephalosporinase; and PoxB, a carbapenemase.  The role of AmpC and its contribution to 
β-lactam resistance are well-established and evident here. In our study, AmpC expression 
readily afforded protection against the cephalosporins and penicillins but not against the 
carbapenems.  PoxB, on the other hand, had a narrow spectrum of hydrolysis that mostly 
included the carbapenems. Similar to other class D enzymes, PoxB was only poorly 
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inhibited by the currently available inhibitors: clavulanic acid, tazobactam and sulbactam. 
A novel inhibitor, avibactam, was slightly more effective at reducing PoxB activity but 
clinical concentrations failed to decrease MIC of carbapenems by E-test. Additionally, 
poxB was shown to form an operon with an upstream ORF of yet unknown function, 
termed poxA. Expression of PoxA in trans enhanced CR-binding abilities suggesting the 
production of a CR-binding substance likely rich in carbohydrates. 
 PoxB appears to be constitutively expressed, but its relevance in the clinical 
setting is still unknown.  Mutational derepression of AmpC is a common mechanism of 
resistance. Thus, it is plausible that mutations in poxB regulatory genes may lead to 
increased expression and carbapenem resistance in the clinical setting. Expression and 
regulation of poxB are examined in Chapter 3.               
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Chapter 3 
 
 
 
Regulation of the poxAB operon encoding a class D β–lactamase in 
Pseudomonas aeruginosa 
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3.1 Abstract 
 
 Regulation of AmpC β-lactamase in Pseudomonas aeruginosa is a tightly 
controlled process that involves the global transcriptional regulator AmpR and the 
recycling of muramyl peptides of the peptidoglycan layer. AmpC is normally produced at 
low basal levels, but β-lactams such as benzylpenicillin, cefoxitin and imipenem, can 
induce its high level expression. A second chromosomally encoded carbapenemase, 
PoxB, has been characterized in P. aeruginosa, but its regulation has not yet been 
examined. Although expression of poxB appears to be constitutive, studies in a 
heterologous host suggest AmpR could also be involved in its regulation. In the present 
work regulation of poxB by AmpR was detected at the transcriptional level by RT-PCR. 
Quantification of β-lactamase activity, however, did not show regulation at the protein 
level.  Further, AmpR failed to bind the pox promoter suggesting indirect regulation. A 
global genetic screen for transposon insertions into pox regulators identified a possible 
link between polyamine transport and pox promoter activity. 
 
Key Words: PoxB,  AmpR, β-lactamase regulation 
 
Abbreviations: Electrophoretic mobility shift assay, EMSA; Open reading frame, ORF; 
pox promoter, Ppox; RT-PCR, Real-time polymerase chain reaction; Transposon, Tn 
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3.2 Introduction  
 
 Pseudomonas aeruginosa PoxB is a class D β-lactamase with a narrow spectrum 
of hydrolysis that mostly includes the carbapenems (741, 837). It is poorly inhibited by 
the clinically used class A enzyme inhibitors and by avibactam, a new non-β-lactam 
inhibitor that is currently undergoing clinical trials (Chapter 2) (741). Additionally, PoxB 
forms a two-gene operon with the upstream open reading frame (ORF), poxA, whose 
function is still unknown. The pox operon appears to be constitutively expressed but its 
regulation has not been investigated.  
 It is not uncommon for regulatory proteins to be encoded in the general vicinity of 
the genes they regulate (730, 739). For instance, the transcriptional regulator AmpR is 
encoded immediately upstream of, and divergently transcribed from, the ampC structural 
gene that it regulates (711, 776). It was our previous hypothesis that a two-component 
regulatory system encoded by mifSR, located immediately upstream of the pox operon 
and divergently transcribed, could be involved in its regulation. The response regulator 
MifR has recently been implicated in the formation of biofilm (838). Deletion of either or 
both mifS and mifR, however, did not affect β-lactam and carbapenem susceptibility or 
poxB expression (G. Tatke, Personal communication).   
 Previous work from our lab, however, seems to implicate AmpR as possible 
regulator of pox expression (710). Specifically, expression of ampR in an Escherichia 
coli heterologous host resulted in decreased PoxB β-lactamase activity (710). AmpR is an 
interesting candidate for regulator of pox expression. As a LysR-type transcriptional 
regulator, AmpR regulates ampC expression by binding to the promoter region in the 
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presence and absence of β-lactam inducers in both the Enterobateriaceae and P. 
aeruginosa (839, 840). In this manner, AmpR can accomplish either repression or 
induction given the presence/absence of activating inducer.  Recently, AmpR has been 
redefined as a global regulator, differentially controlling expression of various other 
genes involved in virulence, quorum sensing, biofilm formation as well as various 
transcriptional regulators (841-844). The AmpR regulon is quite extensive and possibly 
includes both direct and indirect interactions. It would thus not be surprising if AmpR 
also regulates expression of the pox operon.  
 In the present work we analyze the role of AmpR as potential regulator of poxB 
expression. Our findings suggest AmpR regulates poxB but does not directly interact with 
the pox promoter (Ppox) which indicates indirect regulation. A P. aeruginosa transposon 
library was constructed and screened for insertions into regulators of pox expression. 
Two transposon mutants exhibiting increased Ppox activity carried insertions in genes 
involved in the transport and uptake of polyamines, essential molecules implicated in a 
wide range of cellular functions (845-847). Polyamines reduced the susceptibility of P. 
aeruginosa towards various β-lactams but provided resistance only against the 
carbapenems. The mechanism by which polyamines are able to induce carbapenem 
resistance is not well understood but could be related to a decrease in cell permeability or 
to the increased expression of the carbapenem-hydrolyzing β-lactamase PoxB. 
Polyamines have, in fact, been shown to modulate gene expression through binding of 
both DNA and RNA (848-851). Thus, polyamine-dependent regulation, although 
unprecedented for β-lactamases, is plausible. 
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3.3 Materials and Methods 
 
3.3.1 Bacterial strains, plasmids and growth media.  Bacterial strains and plasmids 
used in this study are listed in Table 3.1.  E. coli and P. aeruginosa were cultured 
regularly in Luria-Bertani medium (10 g tryptone, 5 g yeast extract, and 5 g NaCl, per 
liter) at 37°C. Antibiotics were used at the following concentrations: ampicillin (Ap) at 
100, gentamicin (Gm) at 15 and tetracycline (Tc) at 20 µg/ml for E. coli; Gm at 75 and 
Tc at 60 µg/ml for P. aeruginosa. For construction of PA0ΔampRΔpoxB, a previously 
generated in-frame deletion of poxB was introduced into PA0ΔampR (843) using overlap 
extension PCR and homologous recombination as previously described (758). The 
presence of the deletion was checked by gene-specific PCR. 
 
Table 3.1: Bacterial strains and plasmids used in this study 
Strains/Plasmids Relevant phenotype and genotype 
Reference/ 
Source 
Escherichia coli   
DH5α F- Φ80lacZΔM15 Δ(lacZYA-argF)U169 deoR 
recA1 endA1 hsdR17 (rk
-
 mk
+
) phoA supE44 λ
- -
thi-1 gyrA96 relA1 
New England 
Biolabs 
TOP10 F
- 
mcrA Δ(mrr-hsdRMS-mcrBC)Φ80lacZΔM15 
ΔlacΧ74 recA1 araD139 Δ(ara-leu)7697 galU 
galK rpsL (Str
R
) endA1 nupG 
Life 
Technologies 
SM10λpir KmR, thi-1, thr, leu, tonA, lacY, supE, 
recA::RP4-2-Tc::Mu, pir 
Stephen Lory 
122 
 
Pseudomonas aeruginosa  
PA01 Wild-type  (762) 
PKM201 PA0ΔampC, PA01 containing in-frame deletion 
of ampC 
(760) 
PKM315 PA0ΔampR, PA01 containing in-frame deletion 
of ampR  
(843) 
PKM332 PA0∆ampR∆poxB, PA01 containing in-frame 
deletions of ampR and poxB 
This study 
PKM106 PA0attB::mini-CTX-lacZ; Tc
R
 (852) 
PKM117 PA0attB::PampC-lacZ; Tc
R 
 This study 
PKM118 PA0attB::Ppox-lacZ; Tc
R
 This study 
PKM319 PA0ΔampRattB::mini-CTX-lacZ; TcR This study 
PKM335 PA0ΔampRattB::Ppox-lacZ; Tc
R
 This study 
Plasmids   
mini-CTX-lacZ Tc
R
; Integration-proficient vector for single-
copy chromosomal lacZ fusion at the attB site 
(853) 
pMMB67EH-Gm GmR; IncQ, RSF1010, lacIq Ptac expression 
vector  with ampR::aacC1 insertion at DraI 
(763) 
pBTK24 ApR, GmR; transposon delivery vector, ori R6K Stephen Lory 
pPoxA GmR; pMMB67EH-Gm carrying a 946-bp 
fragment containing poxA ORF  
Chapter 2 
pOC19 Gm
R
; pMMB67EH-Gm containing His-tagged 
AmpR at C-terminus  
(852) 
pDZ29 ApR; pCR2.1-TOPO derivative containing a 
217-bp EcoRI-BamHI pox promoter fragment 
This study 
pDZ197 Tc
R
; Ppox fused to the lacZ of mini-CTX-lacZ This study 
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3.3.2 Construction of promoter fusions.  A ΦCTX-based system was used to construct 
single-copy promoter fusions, where the expression of the promoterless reporter gene 
lacZ is under the control of Ppox. Briefly, Ppox was amplified using primers 
KM_PpoxAFov (5’-GAATTCTCACAGGCCGCCGAGCAGCGGCAG-3’) and 
KM_PpoxARev (5’-GGATCCCTCACCAGCCGCGCAGGGTGAAACC-3’). The 
amplicon was cloned into the TA cloning vector pCR2.1-TOPO, sequenced and 
subcloned into the EcoRI-BamHI sites of the integrative vector mini-CTX-lacZ and 
resequenced for fidelity. The transcriptional fusion was subsequently introduced into P. 
aeruginosa PA01 and the isogenic mutant PA0∆ampR as a single copy at the attB site. A 
previously generated PA0::PampC-lacZ was used as positive control for promoter-driven 
expression of lacZ (710). 
 
3.3.3 Quantification of poxB mRNA expression. Total RNA was extracted from P. 
aeruginosa PA01 and a previously generated PA0∆ampR (843) in the presence and 
absence imipenem (0.15 µg/ml) using the RNeasy mini kit (Qiagen).  cDNA synthesis 
was performed with Superscript III (Invitrogen) and the (NS)5 random primer as 
previously described (764).  qPCR was performed with the ABI 7500 cycler (Applied 
Biosystems) using the Power SYBR Green PCR Master Mix with ROX (Applied 
Biosystems). clpX (PA1802) was used as endogenous control and amplified with 
DBS_qRT_clpXF (5'-TGCGATTACGATGTGGAGA-3') and DBS_qRT_clpXR (5'-CC- 
CTCGATGAGCTTCAGCA-3') (843). DZRTpoxBFord1 (5’-AATCGGCCAGGTTGT-
GGATAA-3’) and DZRTpoxBRev1 (5’-GGAGCAGAAAGCGGGTCTGT-3’) were 
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used for the real time amplification of poxB. Gene expression was normalized to that of 
the PA01 uninduced value. 
 
3.3.4 β-lactamase assay.  The β-lactamase assay was performed as previously described 
with some modifications (765). Briefly, stationary-phase cultures of PA01, PA0∆ampR 
and PA0∆ampR∆poxB were diluted in 25 ml of LB broth to an OD600 of 0.01 and 
incubated with shaking at 37°C.  At OD600 of 0.6-0.8, cells were induced with 0.15 µg/ml 
of imipenem and reincubated for 1 hour at 37°C. Ten milliliters of cells were harvested 
by centrifugation and resuspended in 800 µl of 1x BugBuster solution (Novagen).  
Benzonase (1 μl/ml of BugBuster used) (Novagen) and rLysozyme (1 KU (Novagen) 
were then added and the mixture was rotated for 20 min at room temperature. The lysate 
was centrifuged at 4°C for 15 minutes to collect the β-lactamase-containing supernatant. 
A 2-µl aliquot of cell lysate was added to nitrocefin (final concentration, 100 µM) in 250 
µl of 50 mM sodium phosphate buffer. The reaction mixture was incubated at 37°C for 
20 minutes and the hydrolysis of nitrocefin was measured spectrophotometrically at 482 
nm. The Bradford assay was used to determine total protein concentration of each 
sample. β-lactamase activity was expressed as nmol of nitrocefin degraded per minute per 
microgram of total protein. 
 
3.3.5 β-galactosidase assay.  The β-galactosidase activity was quantified as a measure of 
Ppox activity as previously described (854). Briefly, fresh cultures of PA01 and 
PA0∆ampR harboring Ppox-lacZ were grown at 37°C and induced with benzylpenicillin 
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(50 μg/ml) at an OD600 of 0.5 for 1 hour. The assay was performed on 1-ml cell lysate 
using ortho-nitrophenyl-β-galactoside (ONPG) as a chromogenic substrate and the 
activity was expressed in Miller units. Assays performed as part of transposon screening 
were routinely done in the absence of induction.  
 
3.3.6 Electrophoretic mobility shift assay (EMSA).  The pox promoter region was 
amplified using P. aeruginosa PA01 genome as template with primers EM-PpoxAFor 
(5'-CGATCAGGGTCTGCAGCGAGC-3') and EM-PpoxARev (5'-GGCTTGCCGCTC-
GGTTCGC-3') and the 335-bp amplicon was used to perform EMSA. Briefly, the 
promoter fragment was radiolabelled at the 5’ end by incubation with T4 polynucleotide 
kinase (NEB) and [γ-32P]ATP (3,000 Ci mmol-1; Perkin Elmer). The labeled fragment 
was diluted to a final concentration 100 nM and unincorporated nucleotides were 
removed by sephadex G-25 (Biorad, Hercules, CA) spin chromatography.  DNA binding 
reactions containing 50 fmol of 
32
P-labeled DNA probe and varying amounts of total 
protein membrane fractions were incubated for 20 minutes and loaded thereafter in a non-
denaturating 5% PAGE. Protein membrane fractions were used as AmpR was shown to 
be membrane-associated (852). Radioactive signals were detected by scanning a 
phosphostorage cassette with the GE Healthcare Typhoon 9400 scanner.   
 
3.3.7 Pilot experiment to construct transposon library.  Before attempting to generate 
a transposon library it was necessary to determine the conditions needed to obtain good 
coverage over the PA01 genome. About 20,000 to 40,000 mutagenized colonies, which is 
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roughly 5-7 times the number of genes (~5500) in PA01, are necessary. A pilot study was 
thus conducted by setting matings between the donor E. coli SM10λpir (pBTK24) and the 
recipient PA0ΔampR::Ppox-lacZ. PA0ΔampR::Ppox-lacZ was grown overnight (O/N) at 
both 37°C and 42°C, while E. coli SM10λpir (pBTK24) was grown O/N only at 37°C. 
The donor and recipient were then diluted (1/5) and grown at 37°C in LB for about 4 
hours. The recipient strain that was grown O/N at 42°C was also diluted and incubated in 
a dry bath at 42°C for 4 hours. When the cultures reached an OD600 of 2.5 or higher, after 
approximately 4½ hours, 6 mls of both the donor and recipient were centrifuged at 
13,000 rpm for a minute. After discarding the supernatant, the cells were washed in 1 ml 
of LB broth, repelleted and resuspended again in 1 ml of LB broth. One set of matings 
was set up using the recipient that was grown at 42°C (Matings A-C), while the others 
were done with the recipient that had grown at 37°C (Matings D-E) (Table 3.2).    
 
Table 3.2: Mating volumes used in pilot study  
  
 
Strains 
Pilot Matings (µl) Controls (µl) 
A B C D E 
Recipient 
(37°C) 
Recipient 
(42°C) 
Donor 
PA0ΔampR::Ppox-
lacZ at 37°C 
- - - 200 400 400 - - 
PA0ΔampR::Ppox-
lacZ at 42°C 
200 600 400 - - - 600 - 
E. coli SM10 λpir 
(pBTK24) 
1000 600 800 1000 800 - - 1000 
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 All mating mixtures were centrifuged, the supernatant discarded and the pellet 
resuspended in 30 µl of LB. The suspensions were then spotted on LB plates and 
incubated at 37°C for 4 hours. All spots were resuspended in 200 µl of LB. Fifty and 150 
μl of each were plated on selective media (LB-PIA-Gm75). For the controls, only 100 µl 
of each strain were plated (Table 3.3). The most efficient matings had the recipient grown 
at 42°C at a 1:1 ratio of donor to recipient (Table 3.2 and 3.3). 
 
3.3.8 Transposon mutagenesis and screening for regulators of the pox operon. The 
reporter strains, PA0::Ppox-lacZ and PA0∆ampR::Ppox-lacZ, displaying distinctly different 
levels of pox promoter activity, were each mutagenized on four different occasions. 
Twenty matings were set-up each time with the objective of obtaining enough 
transposon-mutagenized colonies to cover the entire PA01 genome. Matings were set-up 
as described in the pilot study. Briefly, O/N cultures of recipients and donor grown at 42 
and 37°C, respectively, were freshly diluted 1/5 in LB broth and grown for four hours at 
42 and 37°C, respectively. At the four-hour time point, enough culture of both donor and 
recipient strains were centrifuged at 13,000 rpm for one minute (1 ml culture/eppendorf 
tube). The suppernatants were discarded and the pellets resuspended in 1 ml of LB. 
Matings were set up in donor to recipient ratios of 5:1, 2:1, and 1:1 (Table 3.4). All 
mating mixtures were centrifuged, the supernatant discarded and the pellet resuspended 
in 30 µl of LB, which were then spotted on LB plates and incubated at 37°C for an 
additional four hours. All spots were individually resuspended in 200 µl of LB and 50 
and 100 µl were plated on selective media (LB-PIA-Gm
75 
or LB-PIA-Gm
75
-X-gal
100
). 
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Table 3.4: Mating ratios used for generation of P. aeruginosa library 
   
 For the PA0::Ppox-lacZ library, colonies obtained with the 1
st
 and 2
nd
 mating 
events, were all pooled and frozen into five 96-well plates since selection was done only 
in LB-PIA-Gm
75
. Screening of these pools for dark blue colonies remains to be done on 
LB-PIA-Gm
75
-X-gal
100 
(Figure 3.1). Colonies for the 3
rd
 and 4
th
 mating events were 
directly selected on LB-PIA-Gm
75
-X-gal
100
. The blue colonies resulting from this 
screening were individually frozen in 4 x 96-well plates and further analyzed as described 
in later sections.   
 For the PA0ΔampR::Ppox-lacZ  library, all colonies obtained were pooled and 
frozen with 10% skim milk in 57 x 2-ml-vials (mating events 1-3) and in two 96-well 
plates (4
th
 mating event) (Figure 3.2). Screening for white colonies has so far been done 
on 34 wells (A1-C10, Plate #1, mating event 4). The screening was done by inoculating a 
scraping from a well into 10 ml of LB broth and growing at 37°C for 45 minutes. Each 
culture was then serially diluted and the 10
-5 
and 10
-6 
dilutions were plated onto LB-PIA-
Gm
75
-X-gal
100
. White to light blue colonies were selected for further analysis and 
individually frozen on 10% skim milk. 
 
Strains 
Matings Controls 
1-7 8-14 15-20 Recipient  Donor 
PA01::Ppox-lacZ  or 
PA0ΔampR::Ppox-lacZ   (µl) 
200 600 400 600 - 
E. coli SM10 λpir (pBTK24) (µl) 1000 600 800 - 1000 
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Figure 3.2. Selection and screening of the PA0ΔampR library 
 
 
 
Figure 3.1. Selection and screening of the PA01 library 
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3.3.9 Mapping of the transposon (Tn) insertion site.  Insertion sites were mapped by a 
two-round semi-random PCR (825) using either pure colony or purified DNA as 
template. The first round of PCR was performed using the Tn-specific primer Round1-
BTK24 (5’-GTCGTAAATCACTGCATAATTCG-3’) and the random primer Round1-
Pa(1) (5’-GGCCACGCGTCGACTAGTACNNNNNNNNNNGATAT-3’) (855), that can 
anneal anywhere on the genome and has a nonrandom tail. One microliter of purified 
product from the first round of PCR was used as template for a nested PCR with primers 
Round2-BTK24 (5’-GCACTCCCGTTCTGGATAAT-3’) and Round2-Pa (5’-GGCCAC- 
GCGTCGACTAGTAC-3’) (855). The products were gel-purified and sequenced with 
another nested Tn-specific, outward-facing primer BTK24-seq (5’-GCGGATAACAAT- 
ATAATGTGTGGA-3), that will read through the junction and into the genome. Mapped 
insertions were subsequently confirmed by gene-specific PCR. 
 
3.4 Results and Discussion  
 
 
3.4.1 AmpR downregulates poxB expression.  Previous work in an E. coli heterologous 
background showed increased PoxB activity in the absence of AmpR suggesting the 
transcriptional regulator normally acts to downregulate poxB expression (710). 
Regulation of the pox operon, however, has not yet been examined in P. aeruginosa. The 
expression of poxB was thus quantified in the presence and absence of β-lactams in an 
ampR deletion strain (PA0ΔampR) by RT-PCR.  In the absence of the inducer, equivalent 
amounts of poxB mRNA were observed in both wild-type and PA0ΔampR (Figure 3.3).  
In the presence of the inducer, however, significantly higher amount of poxB mRNA was 
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detected in an ampR-deficient background. This finding confirms previous work done in 
a heterologous host (710) and suggests AmpR negatively regulates pox expression in the 
presence of β-lactams. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3. Expression of poxB in the absence of AmpR. RNA was isolated from PA01 
and PA0ΔampR in the presence and absence of imipenem (0.15 µg/ml), reversed 
transcribed to cDNA and tested by qPCR with poxB specific primers, as described in the 
Materials and Methods. Values were normalized to the expression of the wild-type 
uninduced sample and represent the mean (±SD) of two experiments conducted in 
triplicates. * p-value< 0.01 for poxB expression in PA0ΔampR induced as compared to 
PA01 induced, as determined by unpaired t-test.   
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3.4.2 PoxB β-lactamase activity. To determine if the differential RNA expression 
observed in the absence of ampR actually translates into quantifiable changes at the 
protein level, the β-lactamase activity of PA0ΔampR and PA0ΔampRΔpoxB strains was 
measured in the presence and absence of the inducer. As expected, in the wild-type β-
lactamase levels are detectable and induced upon β-lactam challenge (Figure 3.4). This 
activity could be due to either AmpC alone or AmpC and PoxB combined.  
 The β-lactamase activity did not significantly increase in the absence of induction 
in PA0∆ampR, the levels being equivalent to that of wild-type uninduced. In the presence 
of the inducer, however, deletion of ampR resulted in the loss of induction, suggesting the 
activity observed is likely due to the constitutive expression of ampC, which requires 
AmpR for induction. A further deletion of poxB from an already ampR-deficient strain 
yielded β-lactamase levels similar to that of PA0∆ampR, with no inducibility being 
detected upon exposure to β-lactams. A PA0ΔampCΔampR strain behaved similarly to an 
ampC deletion strain characterized in Chapter 2, in that it produced negligible amounts of 
β-lactamase. The activity of PoxB thus, appears to be very low and masked by the 
expression of ampC. The inducibility of poxB observed at the mRNA level (Figure 3.3) 
does not translate into a detectable difference in terms of β-lactamase activity in the 
conditions tested.  
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Figure 3.4.  β-lactamase expression of PA01 and its isogenic mutants. The β-lactamase 
activity was quantified for the wild-type strain PA01 and the isogenic mutants 
PA0∆ampR, PA0∆ampR∆poxB, PA0∆ampC and PA0∆ampC∆ampR, in the presence and 
absence of the inducer. Logarithmic-phase cultures were induced with 0.15 µg/ml of 
imipenem for 1 hour before harvesting. Assays were performed in triplicates on 
BugBuster and rLysozyme-treated lysate using nitrocefin as chromogenic substrate. One 
milliunit of enzyme is defined as 1 nmol of nitrocefin hydrolyzed per minute per 
microgram of total protein. * p-value= 0.0001 for β-lactamase activity in PA0ΔampR 
induced versus activity in PA01 induced, as determined by unpaired t-test.  
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3.4.3 AmpR does not bind Ppox. As a LysR-type transcriptional regulator, AmpR 
regulates gene expression by binding to DNA with its canonical N-terminal HTH motif 
(856). Binding to the ampC promoter has been found to occur in both the presence and 
absence of β-lactams (839, 840, 852). An EMSA was thus performed to determine if 
AmpR directly binds the pox promoter. A [γ-32P] ATP radiolabeled Ppox fragment was 
incubated with increasing concentrations of total membrane fractions extracted from cells 
overexpressing a C-terminal His-tagged AmpR that was previously shown to be 
functional (852). Cell extracts were recovered in the presence and absence of 
benzylpenicillin. A 193-bp fragment corresponding to the ampC promoter region was 
used as positive control as it was been previously shown to bind AmpR (852). 
 As expected and previously shown, AmpR was able to shift PampC in the presence 
and absence of the inducer (Figure 3.5, Lanes 16 and 18), indicating EMSA conditions 
were working properly. AmpR, however, did not shift a 335-bp Ppox fragment in the 
presence (Lanes 8-12) or absence (Lanes 2-6) of benzylpenicillin, indicating AmpR does 
not bind the pox promoter. If AmpR is in fact regulating expression of poxB, as suggested 
by previous work and by qPCR here, then this regulation is indirect. This hypothesis is 
further substantiated by the absence of an AmpR-binding site in the pox promoter region. 
 Previous work from our lab has shown AmpR is global regulator controlling 
expression of not just ampC, but also of various other genes including a number of 
putative and characterized transcriptional regulators and sigma factors such as creB, 
pprB, algB, algT/U and rpoS (710, 842, 843). Thus it is possible that AmpR regulates 
poxB through these or other, as of yet, unidentified regulators.  
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3.4.4 PoxA autoregulates its own promoter. Autogenous regulation is a common 
regulatory mechanism in which a gene product regulates expression of the very gene that 
encodes it (857).  Autoregulation, especially negative autoregulation, is a common theme 
among transcriptional factors and regulators, with over 40% of E. coli transcriptional 
factors regulating their own synthesis (857-859). Autoregulation however, also occurs in 
non-regulatory structural genes including those coding for enzymes involved in a myriad 
of metabolic processes, often with the first gene regulating the expression of the rest of 
the genes in that operon (857, 860).  
 Since the role of PoxA was unclear, we postulated that PoxA may autoregulate 
the pox operon. In order to determine if this was the case, poxA was expressed in a low-
copy plasmid under an IPTG inducible promoter and introduced into PA01 carrying a 
chromosomal Ppox-lacZ fusion.  In the absence of induction, the pox promoter exhibited 
high basal, constitutive levels in both the presence and absence of poxA in trans (Figure 
3.6).  After one hour induction with IPTG, a small but significant decrease in Ppox activity 
was observed in the presence of poxA, suggesting PoxA at high levels can negatively 
regulate its own transcription. The trend, although no longer statistically significant, was 
also observed 2 hours after IPTG induction. In wild-type, PoxA may contribute to 
maintaining low levels of PoxB. Indeed poxB mRNA levels are relatively low and appear 
for the most part to be uninducible in PA01 (Figure 3.3). PoxA is a putative hydrolase of 
yet uncharacterized function.   
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Figure 3.6.  Activity of the pox promoter in the presence of pPoxA.  The activity of the 
pox promoter activity was quantified in PA01 carrying a chromosomal lacZ fusion in the 
presence and absence of PoxA in trans.  Exponentially growing cultures were induced 
with 1 mM IPTG for 1 or 2 hours before harvesting for quantification of β-galactosidase 
activity. * p-value <0.05 for promoter activity of PA0::Ppox-lacZ (pPoxA) in the presence 
of IPTG vs Ppox activity in the same strain in the absence of IPTG, as determined by 
paired t-test. 
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3.4.5 Approach to identifying regulators of the pox operon. To identify other possible 
regulators of the pox operon we have taken a global approach that involves construction 
of a P. aeruginosa mutant library with potential transposon insertions into regulators of 
pox expression. In order to screen for desired insertions, two reporter strains, PA0::Ppox-
lacZ and PA0∆ampR::Ppox-lacZ, were constructed and the conditions needed for a 
successful genetic screening were investigated by examining promoter activity in the 
presence of X-gal or ONPG. 
 As expected from previous work, the pox promoter was found to be more active 
in the absence of ampR as evidenced by the distinctly dark blue phenotype displayed by 
PA0∆ampR::Ppox-lacZ on plates containing X-gal (Figure 3.7 B and D). PA0::Ppox-lacZ, 
on the other hand, having an intact AmpR that can repress Ppox, displayed a greenish to 
light blue colony phenotype (Figure 3.7 A and C). For subsequent selection and screening 
of the mutant library, 100 µg/ml of X-gal was used, however, lower concentrations of 40 
and 60 µg/ml of X-gal were also effective at showing color differences.  
 The promoter activity was also investigated by the β-galactosidase assay. In the 
positive control PampC activity was detected in the absence of induction and induced 3-
fold upon β-lactam challenge (Figure 3.8).  On the other hand, Ppox activity was detected 
in both PA0::Ppox-lacZ and PA0∆ampR::Ppox-lacZ, with higher activity observed in the 
absence of ampR upon induction with β-lactams (Figure 3.8). These findings are in 
agreement with the mRNA study (Figure 3.3) and the visual analysis of Ppox activity 
(Figure 3.7). 
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Figure 3.7. Activity of the P. aeruginosa pox promoter. The 10
-5
 and 10
-6
 dilutions of 
freshly grown PA01 (Panels A and C) and PA0∆ampR (Panels B and D) cells carrying 
Ppox-lacZ were plated on LB agar plates containing 40 (data not shown), 60 or 100 µg/ml 
of X-gal. The promoter activity was ascertained by visually inspecting colony color 
phenotype after an O/N incubation at 37°C.  
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Figure 3.8. Ppox activity in the presence and absence of ampR. PA01 and PA0∆ampR 
cells carrying Ppox-lacZ were grown at 37°C and induced with benzylpenicillin at an 
OD600 of 0.5 for 1 hour. The assay was performed on cell lysate using ONPG as a 
chromogenic substrate. β-galactosidase activity was quantified in Miller units in the 
presence and absence of β-lactams. * p-value<0.05 versus uninduced PA0::PampC-lacZ; ** 
p-value<0.02 versus uninduced PA0∆ampR::Ppox-lacZ as determined by paired t-test. 
 
 3.4.5.1 Identifying negative regulators.  Having an intact ampR, PA0::Ppox-lacZ 
displays a light blue phenotype on X-gal (Figure 3.8). Thus we postulate that the dark 
blue colonies resulting from the transposon mutagenesis of this strain are likely to have 
insertions into negative regulators of pox expression (Figure 3.9).  Alternatively, a false-
negative dark blue colony could result from insertions immediately upstream of lacZ such 
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Ppox lacZ
Ppox lacZ
that transcription from the Tn drives expression of the β-galactosidase gene. Only 
mapping can determine the exact Tn insertion site.  
 
Strain 
Colony 
color on    
X-gal 
Transposon insertion 
Resulting 
phenotype 
Regulator 
PA0:: 
Ppox-lacZ 
 White -
light blue 
 
Dark Blue 
Negative 
False Negative 
ΔampR:: 
Ppox-lacZ 
Dark Blue 
 White-light 
blue 
 
Positive 
False Negative 
False Negative 
 
Figure 3.9. Predicted color phenotype before and after Tn insertion into putative 
regulators of the pox operon.  Blue triangles indicate transposon insertion sites; yellow 
arrows denote any positive or negative regulator-encoding genes. 
 
 3.4.5.2 Identifying positive regulators. PA0∆ampR::Ppox-lacZ displays a 
distinctly dark blue phenotype on X-gal (Figure 3.8). Upon Tn mutagenesis of this strain, 
colonies that display a white to light blue color, indicative of a decrease in Ppox activity, 
potentially have insertions in genes encoding positive regulators of pox expression 
(Figure 3.9). There are, however, two other possible Tn insertions that can lead to 
repression of lacZ resulting in a white phenotype: (a) Tn insertion into Ppox that controls 
the transcription of lacZ, or (b) Tn insertion into lacZ itself.  To determine where in the 
genome the insertion occurred, Tn-specific primers will be used to sequence through the 
transposon junctions and into the genome. 
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3.4.6 Construction of mariner Tn library.  A P. aeruginosa PA01 mutant library was 
constructed by mutagenesis of PA0::Ppox-lacZ and PA0∆ampR::Ppox-lacZ with the Tn 
delivery vector pBTK24 (Figure 3.10). This vector is derived from the pBT20 
minitransposon (861) and like its predecessor, carries the Himar1 mariner transposase 
element isolated from the horn fly Haematobia irritans (855, 862, 863).  
 
 
 
 
 
 
 
 
 
Figure 3.10. Plasmid map and features of the mariner transposon vector, pBTK24. 
pBTK24 has an ori R6K origin for replication in E. coli and an ampicillin marker for 
plasmid propagation. The transposase-encoding gene, mariner C9, is responsible for 
excision and recombination of the transposable element. Inverted repeats depicted in blue 
flank the transposon, which carries a gentamicin cassette for selection and an outward-
facing Ptac promoter for transcription of downstream genes. 
 
 The pBTK24 vector also carries an oriT origin for transfer into Pseudomonas, but 
having only an E. coli origin of replication (ori R6K), is a suicide delivery vector that 
cannot be propagated in a P. aeruginosa background. The mariner C9 transposase is 
encoded on the plasmid backbone to promote transposition and to prevent transposase 
integration into the genome. The transposable element itself is flanked by 29-bp inverted 
IR
IR
Transposable 
Element 
Ptac
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terminal repeats (ITRs), which are recognized by the transposase for transposition by a 
cut-and-paste mechanism (861). Additionally, the transposable element contains a 
gentamicin cassette for selection and an outward-facing Ptac promoter for transcription of 
downstream genes to prevent polarity. 
 
 3.4.6.1 Generation of the transposon library.  Transposon libraries of 
PA0::Ppox-lacZ and PA0ΔampR::Ppox-lacZ were obtained by mutagenesis with E. coli 
SM10 λpir (pBTK24). Each recipient strain was mutagenized on four different occasions 
(mating events), with a total of 20 matings per event, in order to generate a library with 
coverage over the entire PA01 genome. A total of 163,266 colonies were obtained for the 
PA0ΔampR::Ppox-lacZ library and more than 503,988 colonies were obtained for 
PA0::Ppox-lacZ (Table 3.5). 
    
          Table 3.5. Approximate colony count after Tn mutagenesis  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
          ND-Not determined 
Strains Mating Events  Colony Count 
PA0::Ppox-lacZ   
1 387,625 
2 86,427 
3 299,36 
4 ND 
Total > 503, 988 
PA0ΔampR::Ppox-lacZ    
1 973 
2 3,329 
3 19,766 
4 139,198 
Total 163,266 
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3.4.7 Mapping insertion sites and identification of regulators 
 
 3.4.7.1 PA0::Ppox-lacZ library.  Mapping was first attempted on 44 blue colonies 
obtained from the PA0::Ppox-lacZ library (3
rd
 and 4
th
 mating events, Plate # 8, Figure 3. 
1). Out of these, 15 insertions could be confirmed by gene-specific PCR and were 
selected for further analysis. The majority of the Tn insertions were mapped to genes and 
operons involved in the biosynthesis of lipopolysaccharide (LPS) (Table 3.6). Often 
insertions occurred twice in the same gene but at different positions within the ORF (e.g., 
wbpJ, wzt, wbpY, and rmlA).  Two clones had a Tn insertion that mapped to the same 
location within wzt, suggesting these two clones were siblings. Three different insertions 
were found within the PA3488 ORF, coding for a hypothetical, unclassified protein. 
 Although these 15 colonies displayed a dark-blue phenotype on X-gal indicative 
of increased lacZ expression, the promoter activity as determined by β-galactosidase 
assay was equivalent to that of wild-type (Figure 3. 11  A and B). Thus, determination of 
promoter activity by blue/white screening alone was deemed to be insufficient for 
identification of regulators.  
 It is likely that disturbances in LPS created by Tn insertions in such genes, led to 
porosity of the membrane and leakage of the enzyme where it could readily cleave X-gal.  
Subsequently, all blue PA01 colonies frozen in the 4 x 96-well plates (Plates 8-11) from 
the 3
rd
 and 4
th
 mating events (Figure 3.1) were further screened by assaying the level of 
β-galactosidase activity before selecting for mapping. Colonies producing significantly 
different levels of enzyme as compared to the control strain were selected for mapping.  
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Table 3.6. Mapped insertions from PA01 library, Plate # 8 
 
  
  
 
 
 Screening did not reveal any noteworthy colonies in Plates 9 and 11, however, in 
Plate 8, two colonies were identified, B6 and G7, as having 8-fold higher promoter 
activity than the control (Figure 3. 12). These, however, turned out to be false negative as 
mapping  revealed the Tn inserted  immediately  upstream of the lacZ  ORF and mapping  
Well 
ID 
Insertion 
Site 
Insertion 
Coordinate 
Gene Function 
A4 PA3147 3530530 wbpJ Glycosyltransferase 
B4 PA3147 3530649 wbpJ Glycosyltransferase 
E1 PA5450 6140010 wzt 
ABC subunit of A-band LPS 
efflux transporter 
F1 PA5450 6140164 wzt 
ABC subunit of A-band LPS 
efflux transporter 
E9 PA5450 6140164 wzt 
ABC subunit of A-band LPS 
efflux transporter 
E11 PA5448 6137971 wbpY Glycosyltransferase 
H1 PA5448 6137221 wbpY Glycosyltransferase 
C1 PA5451 6141320 wzm 
Membrane subunit of A-
band LPS efflux transporter 
A1 PA5163 5812349 rmlA 
dTDP-glucose 
pyrophosphorylase 
E6 PA5163 5812475 rmlA 
dTDP-glucose 
pyrophosphorylase 
D3 PA4999 5616945 waal O-antigen ligase 
F7 PA0795 874014 prpC Citrate synthase 
B5 PA3488 3906941 - Hypothetical protein 
E4 PA3488 3906772 - Hypothetical protein 
F5 PA3488 3907035 - Hypothetical protein   
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Figure 3.11. β-galactosidase activity of Tn mutants. The β-galactosidase activities of 15 
Tn mutants showing a dark-blue phenotype on X-gal were quantified in the absence of 
induction as described in Materials and Methods. The pox promoter activity of the 
mutants (panel A and B) was found to be similar to the unmutagenized parent strain 
PA0::Ppox-lacZ (Control).  
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revealed the Tn inserted immediately upstream of the lacZ ORF and downstream of the 
cloned pox promoter, with the -35 and -10 sequences of the Tn inserted in the direction of 
lacZ. Thus, the outward-facing promoter of the transposable element appears to be 
driving the high level expression of lacZ observed in these clones. 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Figure 3.12. β-galactosidase activity of Tn mutants. The β-galactosidase activities of 96 
blue colonies from the PA01 library (Plate 8) were quantified in the absence of induction 
as described in Materials and Methods.  Only two colonies from plate 8, B6 and G7, 
were identified as having significantly higher lacZ expression than the unmutagenized 
control, PA01::Ppox-lacZ.  
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 Screening of Plate 10 revealed that colonies A3, A4, A5, A6, B8 and B11 had 
both a darker blue and higher β-galactosidase activity than the control (Figure 3.13 K and 
L).  Similar to clones B6 and G7 above, colonies A3, A4 hat the Tn inserted immediately 
upstream of the lacZ ORF and downstream of the cloned pox promoter. Colonies A6 and 
A12 had insertions in the LPS genes wbpY and wbpL. As these two colonies only had 
slightly higher β-galactosidase activity than control, they were not pursued further. 
Clones A5 (DZ478) and B8 (DZ481) had insertions in PA0322 and in PA0301 (spuE), 
respectively (Figure 3.14). The role of these two genes will be explored in a later section.  
 Although the data from Plate 8 failed to identify any regulators, these data serve 
to validate the study and screening methods. In general, colonies displaying high lacZ 
activity were also dark in color. On the other hand, having a dark blue phenotype does 
not always correlate with increased lacZ expression. Specifically, disturbances in the LPS 
layer can allow for the color phenotype to be enhanced as a leakier, more porous 
membrane presumably allows escape of LacZ or uptake of X-gal (J. Goldberg, personal 
communication). Lastly, the outward-facing promoter of the transposable element was 
found to be very efficient at transcribing downstream genes, with expression of lacZ 
increasing up to 8-fold when such promoter was located upstream (Figure 3.12). Thus 
evaluation of potential clones must take into account not only the contribution of the Tn-
disrupted gene but also the transposon-driven expression of nearby genes. 
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Figure 3.13. Qualitative and quantitative screening of PA0::Ppox-lacZ transposon 
mutants. Twenty-four dark blue colonies from Plate 10, wells A1 through B12, were 
patched onto an LB plate containing imipenem (0.15 µg/ml), Gm (75 µg/ml) and X-gal 
(100 µg/ml) and incubated O/N at 37°C for qualitative determination of promoter activity 
(Panel K). The β-galactosidase activities were also quantified in triplicates in the absence 
of induction as described in Materials and Methods (Panel L). Rows D-E and G-H are 
technical replicates of rows A-B. Wells C1-C3 and F1-F6 represent activity of the control 
unmutagenized strain PA0::Ppox-lacZ. The promoter activity, as measured by β-
galactosidase assay (Panel L), is consistent with the activity observed in X-gal plates 
(Panel K). Colonies A3, A4, A5, A6, B8 and B11 have both a dark blue phenotype and 
increased hydrolysis of ONPG as evidenced by the darker yellow color. Although 
colonies A1 and A12 appear to have slightly more β-gal activity than then control (Panel 
L), only data from A3, A4, A5, A6, B8 and B11 could be subsequently reproduced.  
A
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Figure 3.14.  Genomic localization of PA0322 and spuE.  PA0322 and SpuE were 
identified as possible regulators of the pox operon using genome-wide genetic screen.  
spuE encodes a polyamine transport protein and is part of a transcriptional unit 
containing two operons involved in the biosynthesis and transport of polyamines (Pannel 
A).  PA0322, is a probable amino acid transporter with homology to the E. coli amine 
transport protein YcjJ, also implicated in a polyamine-utilizing pathway (Pannel B). 
These two genes are about 25, 000 bp and 21 ORFs away from each other (Pannel C) and 
localized in a clusters of genes mostly involved with polyamine transport, utilization and 
metabolism. 
 
 3.4.7.2 PA0ΔampR::Ppox-lacZ library. Screening of PA0ΔampR::Ppox-lacZ 
library has thus far identified 77 white to light blue colonies (Figure 3.15A), 14 of which 
showed varying degrees of mucoidy.  Additionally, 21 colonies displaying a dark blue 
phenotype were selected for further analysis as they appeared to be darker than the 
unmutagenized parent strain, PA0ΔampR::Ppox-lacZ (Figure 3.15B). 
Figure 3.15.  Screening of PA0ΔampR::Ppox-lacZ library. Colonies obtained after Tn 
mutagenesis of PA0∆ampR were all pooled and frozen in 10% skim milk in vials and 96-
well plates.  Screening was performed on a number of wells (A1-C10) from Plate #1 by 
growing scrapings in LB at 37°C for 45 minutes. The 10
-5 
and 10
-6 
dilutions were plated 
on LB-PIA-Gm
75
-X-gal
100
. Seventy-seven white (Panel A) and 21 darker blue (Panel B) 
colonies were selected for further analysis.  
A B
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 The 77 white to light blue colonies were further screened by patching them onto 
LB-Gm
75
-X-gal
100 
plates. Ten of these colonies displayed a clear white phenotype, and 
not surprisingly carried insertions within various positions of lacZ. The rest of the 77 
colonies, ranging in color from light blue to the typical light green of P. aeruginosa, were 
further analyzed by assaying β-galactosidase activity. Only two colonies, CR88 and 90, 
were found to produce low β-galactosidase activity but similarly carried insertions in 
lacZ. 
 The 21 dark blue colonies showing a darker phenotype than that of the 
unmutagenized parental strain, were suspected of having the insertion immediately 
upstream of lacZ, with the promoter from Tn likely responsible for intense blue color 
observed.  Alternatively, the intense blue color could be due to increased leakage from 
the cell, as previously hypothesized. A region immediately upstream of lacZ was thus 
PCR amplified to check for transposon insertion.  All but six of these colonies had 
insertions in the MCS of mini-ctx-lacZ, thus explaining the intense dark color observed.  
The remaining six colonies were assayed for promoter activity, however all colonies 
produced β-gal similar to that of the isogenic strain. Thus far, the PA0ΔampR library has 
not yielded any potential leads, however, screening has not yet been completed for this 
library. 
 
3.4.8 Role of PA0301 and PA0322. Since colonies B8 and A5 (plate 8, PA01 library) 
had increased lacZ activity, a darker blue phenotype and carried Tn insertions in spuE 
and PA0322, respectively, we decided to further explore the role of these two genes and 
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their possible link to β-lactam resistance. SpuE (PA0301) forms part of the 
spuABCDEFGH gene cluster (Figure 3.14A) involved in the utilization and transport of 
polyamines (putrescine, cadaverine, spermidine, spermine) (864). Polyamines are small 
polycationic organic compounds having more than one primary amine (  ̶ NH2 group) and 
ubiquitously found in prokaryotes and eukaryotes (Figure 3.16) (845, 865). They are 
essential for growth and due to their cationic nature they are able to interact with 
polyanionic molecules such as nucleic acids (848, 866-868). They have also been shown 
to stabilize and condense DNA (869-871). Their ability to bind DNA and RNA translates 
into a range of pleiotropic effects such as modulation of protein-DNA interaction, 
transcription and translation among many others (846, 849-851, 872-874). They have also 
been reported to affect the activity of a number of ion channels such as the inwardly 
rectifying potassium channel and to decrease outer membrane permeability in E. coli 
(875-877).  
  
 
 
 
 
 
 
Figure 3.16.  Structures of some commonly encountered polyamines 
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 Besides their synthesis and catabolism, bacteria are able take up polyamines from 
the environment (847, 878). P. aeruginosa can use polyamines as sole source of carbon 
and nitrogen (864, 879). Two main ABC-transporter-type polyamine uptake systems have 
been reported in E. coli: the PotA/B/C/D or the spermidine-preferential pathway, and the 
PotF/G/H/I or the putrescine-specific system (880-882).  A homologous system has been 
found in P. aeruginosa encoded by the spuABCDEFGH gene cluster, where spuD and 
spuE encode the periplasmic polyamine binding proteins for putrescine-preferential and 
spermidine-specific binding, respectively (864, 883). SpuG and SpuH are the pore-
forming permeases in the inner membrane and SpuF is the ATPase for energy-driven 
transport. SpuA, B and C encode putative enzymes for the utilization of polyamines.   
 Previous work showed that polyamines decreased expression of T3SS secretions 
and virulence genes in PA01 (884). Polyamines were also shown to increase resistance in 
P. aeruginosa against aminoglycosides, with resistance against quinolones and cationic 
peptides being mediated by the expression of the oprH-phoPQ operon (885). In contrast, 
polyamines significantly increased susceptibility of P. aeruginosa against a number of β-
lactams including the penicillins ampicillin, carbenicillin, piperacillin and ticarcillin, and 
the third generations cephalosporins ceftazidime, cefoperazone and ceftriaxone (886).  
This reduction in resistance was not linked to a decrease in expression of ampC or to 
disruption of the outer membrane as expected of polycationic ions which are known to be 
outer membrane disorganizers (886).  Similarly, A. baumannii clinical and lab strains 
were shown to be more susceptible to the β-lactams aztreonam, carbenicillin, piperacillin 
156 
 
and ticarcillin when treated with spermine and spermidine, but only a slight to moderate 
effect was observed against ceftazidime or meropenem (887). 
 PA0322 also encodes a probable amino acid transporter sharing 61% homology 
with the E. coli YcjJ (PuuP) enzyme, which coincidently is a putrescine importer (888-
890). The Puu system is one of several putrescine utilization pathways reported in E. coli 
besides the Pot system. Not much is yet known about the role of PA0322 as it still 
remains uncharacterized. PA0322 does appear to form a putative operon with the 
upstream ORF PA0321, which displays 67% similarity to an acetylpolyamine 
aminohydrolase from Mycoplana ramosa involved in putrescine catabolism (891).  
 While identifying two targets that involve polyamine transport/utilization is 
promising, the range of pleiotropic effects these molecules have can obscure the real 
connection to the pox promoter. The observed phenotype may simple be an indirect effect 
with no actual connection to Ppox. Additionally, membrane perturbations cannot be ruled 
out as the main cause of the observed phenotype. 
 Increased poxB expression has been shown to decrease susceptibility against the 
carbapenems (Chapter 2). In order to see if carbapenem susceptibility was altered in these 
clones and if polyamines can affect susceptibility towards these β-lactams, the MIC 
against carbapenems was determined in the presence and absence of the polyamine 
spermidine. Addition of 1 mM of spermidine produced little to no change in 
susceptibility across strains and β-lactams, while a concentration of 20 mM spermidine 
was bactericidal to all strains tested (Table 3.7).  
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  Table 3.7. β-lactam MIC in the presence of spermidine   
β-lactam 
 
Polyamine 
(mM) 
PA0::Ppox-
lacZ 
PA0::Ppox-lacZ 
PA0322::Tn 
PA0::Ppox-lacZ 
spuE::Tn 
     
Meropenem 
0 1.5 1.5 1 
1 1.5 2 1.5 
5 >32 >32 >32 
10 >32 >32 >32 
     
Doripenem 
0 0.19 0.19 0.19 
1 0.25 0.25 0.50 
5 0.75 1 1 
10 2 2 2 
     
Imipenem 
0 0.75 1 1 
1 1.5 1.5 1.5 
5 6 8 12 
10 >32 >32 >32 
     
Ceftazidime 
0 1.5 1.5 1.5-2 
1 1.5 1.5 1.5 
5 2 1.5 2 
10 8 8 8 
     
Piperacillin 
0 4 3 4 
1 4 3 3 
5 4 4 4 
10 12 12 12 
     
Ticarcillin/ 
Clavulanate 
0 12 12 12 
1 12 12 8 
5 6 8 8 
10 8 8 8 
     
Aztreonam 
0 2 2 1.5 
1 2 1.5 1.5 
5 1 1 1 
10 1.5 1.5 1.5 
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 The presence of 5 or 10 mM of spermidine rendered all strains very resistant 
towards meropenem (MIC >32 µg/ml). This change however, occurred in both the 
unmutagenized and mutagenized strains and thus is likely unrelated to altered Ppox 
activity in Tn mutants. Similarly, spermidine at 5 mM produced a significant increase in 
MIC against imipenem, with 10 mM leading to resistance against this β-lactam in a 
strain-independent manner (MIC >32 µg/ml). A smaller but significant decrease in 
susceptibility was also produced against doripenem that, although not leading to 
resistance, raised MIC values 4-5-fold and 10-fold in the presence of 5 and 10 mM of 
spermidine, respectively. Spermidine also produced a 2-3-fold increase in MIC against 
ceftazidime and piperacillin, while having no effect on aztreonam. Overall, although 
spermidine was able to alter the MIC values against various β-lactams tested, the most 
dramatic increase in MICs were produced against the carbapenems, leading to resistance 
against meropenem and imipenem. This experiment does not reveal if poxB expression is 
altered or enhanced by the presence of polyamines, merely that polyamines significantly 
raise the MIC values against the carbapenems and other β-lactams. 
 The mechanism by which carbapenem MIC is raised is not clear but it could be 
related to a decrease in cell permeability. Previous studies in E. coli have shown that 
polyamines decrease outer membrane permeability to the β-lactam cephaloridine by 
inhibiting permeation through the porin channels OmpF and OmpC (875, 877).  
Similarly, the polyamine cadaverine induced closing of liposome-reconstituted porins in 
E. coli and was proposed to be a modulator of porin activity in vivo (876). Under 
conditions of oxidative stress, polyamines also increased resistance in E. coli against 
159 
 
fluoroquinolones, antibiotics that are known to traverse the cell via porins (892). Thus a 
decrease in outer membrane permeability could account for the decrease in susceptibility 
to carbapenems that is observed in the presence of polyamines in the current study. 
However, other studies show that polyamines can sensitize E. coli, S. aureus, Salmonella 
and P. aeruginosa to most β-lactams effectively increasing susceptibility against these 
and other drugs (886, 893).  The reduction in MIC suggested that any possible decrease 
in permeability, caused by polyamine inhibition of porin transport, did not play a major 
role or was not enough of a factor to generate resistance against most β-lactams in those 
studies (886, 893). 
 Porins blockage by polyamines in P. aeruginosa does appear to be a factor 
contributing to resistance at least against imipenem (886). Kwon and Lu showed that 
while polyamines increased susceptibility against most β-lactams (decreased MIC), the 
MIC against imipenem is increased in the presence of polyamines (886, 893). This 
increase appeared to occur by blockage of the OprD porin. Inhibition of OprD activity 
may explain the results of the present work showing that the MIC against all 
carbapenems tested is increased in the presence of polyamines. However, MICs of 
various other non-carbapenem β-lactams such as ceftazidime and piperacillin, were also 
slightly altered in this study. These β-lactams, however, are not known to use the OprD 
porin for passage into the cell. Thus, if polyamines affect susceptibility by blocking of 
porins, they may be able to block more than one type of porin besides OprD. In the 
present study, spermidine however, appears to be more effective at blocking OprD than 
other porins, since it is the carbapenem MIC that is mostly altered. Alternatively, 
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although permeability may be an issue contributing to resistance, other polyamine 
intracellular effects may be responsible for the increase in MIC observed. Future studies 
may elucidate on the expression of poxB in the presence of polyamines and the 
mechanism by which polyamines are able to induce resistance against the carbapenems. 
 
3.5 Concluding Remarks   
 
 Regulation of class D chromosomal β-lactamases has only been previously 
described in Ralstonia pickettii and Aeromonas spp. (567, 730). In R. pickettii, the 
induction of two chromosomally encoded β-lactamases, OXA-22 and OXA-60, requires 
the regulatory element Rp3 encoded upstream of blaOXA-60 and divergently transcribed 
(730).  Aeromonas spp. can produce two–three inducible and unlinked β-lactamases, one 
of which is an oxacillinase (566, 734-736).  Expression of all is coordinately regulated by 
a two-component system, BlrAB, encoded immediately upstream of the blaOXA gene 
(567, 739). Unpublished studies from our lab showed a two-component system, MifSR, 
encoded upstream of poxAB and divergently transcribed, played no role in poxB 
expression or carbapenem resistance.  
 Previous work suggested the transcriptional regulator AmpR may be involved in 
the regulation of the pox operon (710). Our transcription studies reveal poxB mRNA 
levels increase in the absence of AmpR. The increase in pox mRNA levels, however, do 
not translate into quantifiable changes at the protein levels as measured by PoxB β-
lactamase activity. Additionally, binding of AmpR to the pox promoter was not detected 
indicating a possible indirect regulation by AmpR.  As genes can often regulate their own 
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synthesis and that of the operon they are encoded in, the activity of Ppox was investigated 
in the presence of PoxA. PoxA was found to decrease Ppox was activity when expressed in 
trans from an IPTG inducible promoter. This finding suggests PoxA is capable of 
regulating the expression of the pox operon. Autoregulation by PoxA may account for the 
low PoxB activity that is normally observed.   
  Interestingly, this work has unexpectedly connected the role of the small, essential 
molecules polyamines with carbapenem resistance. Specifically, a genome search for pox 
regulators identified Tn insertions in two polyamine transport genes leading to increased 
Ppox activity. Although the link between polyamine transport and pox expression is not yet 
clear, polyamines were found to drastically raise MICs against carbapenems leading to 
clinical resistant phenotypes. Whether or not the polyamine-induced carbapenem 
resistance is connected to enhanced pox expression, polyamine research may be a new 
and worthwhile area of study in the lab. 
 
3.6 Acknowledgments  
  
 We would like to thank Dr. Stephen Lory for kindly providing mini-transposon 
strains for mutagenesis and Camille de Rimonteil for the invaluable help with the 
transposon mutagenesis project. This study was supported in part by the National 
Institutes of Health –Minority Biomedical Research Support SCORE (SC1AI081376; 
KM), Research Initiative for Scientific Enhancement graduate student fellowship 
(NIH/NIGMS R25 GM61347; DZ), and Florida International University Teaching 
Assistantship (DZ).  
162 
 
 
Chapter 4 
 
 
 
 
 
Structural and functional characterization of Pseudomonas aeruginosa global 
regulator AmpR 
 
 
 
As published in the Journal of Bacteriology 
 
November 2014 
 
Volume 196, Pages 3890-3902 
 
Copyright © The American Society for Microbiology 
 
 
 
Olivier Caille, Diansy Zincke, Massimo Merighi, Deepak Balasubramanian, Hansi 
Kumari, Kok-Fai Kong, Eugenia Silva-Herzog, Giri Narasimhan, Lisa Schneper, Stephen 
Lory, Kalai Mathee 
 
 
 
Author contributions:  
O.C. and D.Z. contributed equally to the paper. O.C., D.Z., M.M., D.B., H.K., K-F.K., 
E.S-H., G.N., L.S., S.L., and K.M. designed research; O.C., D.Z., M.M., D.B., H.K., K-
F.K., E.S-H., N.A.N., and L.S. performed research; O.C., D.Z., M.M., D.B., H.K., K-
F.K., E.S-H., G.N., L.S., S.L., and K.M. analyzed data; and O.C., D.Z., and K.M. wrote 
the paper.  
 
163 
 
4.1  Abstract 
 
 Pseudomonas aeruginosa is a dreaded pathogen in many clinical settings. Its 
inherent and acquired antibiotic resistance thwarts therapy. In particular, derepression of 
the AmpC β-lactamase is a common mechanism of β-lactam resistance among clinical 
isolates. The inducible expression of ampC is controlled by the global LysR-type 
transcriptional regulator (LTTR) AmpR.  In the present study we investigated the genetic 
and structural elements that are important for ampC induction. Specifically, the ampC 
(PampC) and ampR (PampR) promoters and the AmpR protein were characterized. The 
transcription start sites (TSSs) of the divergent transcripts were mapped using 5’ rapid 
amplification of cDNA ends-PCR (RACE-PCR), and strong σ54 and σ70 consensus 
sequences were identified at PampR and PampC, respectively. Sigma factor RpoN was found 
to negatively regulate ampR expression possibly through promoter blocking. Deletion 
mapping revealed the minimal PampC extends 98-bp upstream of the TSS. Gel shifts using 
membrane fractions showed AmpR binds to PampC in vitro whereas in vivo binding was 
demonstrated using ChIP-qPCR. Additionally, site-directed mutagenesis of the AmpR 
helix-turn-helix (HTH) motif identified residues critical for binding and function (Ser38, 
and Lys42), and critical for function but not binding (His39). Amino acids Gly102 and 
Asp135, previously implicated in the repression state of AmpR in the enterobacteria, 
were also shown to play a structural role in P. aeruginosa AmpR. Alkaline phosphatase 
fusion and shaving experiments suggest that AmpR is likely to be membrane associated. 
Lastly, in vivo cross-linking study shows that AmpR dimerizes. In conclusion, a potential 
membrane-associated AmpR dimer regulates ampC expression by direct binding.  
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Abbreviations: EMSA, electrophoretic mobility shift assay; HTH, helix-turn-helix; 
LTTR, LysR-type transcriptional regulator; PG, peptidoglycan; RACE-PCR, rapid 
amplification of cDNA ends-PCR; TSS, transcriptional start site 
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4.2 Introduction 
 
 Pseudomonas aeruginosa, a Gram-negative opportunistic pathogen, causes severe 
and life-threatening infections in susceptible individuals. This pathogen is primarily 
associated with morbidity and mortality in patients with cystic fibrosis, a deadly genetic 
disease (742). The bacterium’s innate ability to counteract the action of antibiotics often 
complicates treatment strategies.  Intrinsic resistance is conferred by its low membrane 
permeability, the expression of efflux pumps and hydrolyzing enzymes, the alteration of 
antimicrobial targets and the ability to form biofilm (246, 436, 781). In particular, 
resistance to β-lactam antibiotics is mediated by the expression and overproduction of a 
chromosomally-encoded class C β-lactamase AmpC (379-381).  
 Ambler class C β-lactamases were first described in members of the 
Enterobacteriaceae family where expression is either constitutively low or inducible (375, 
376, 630, 894).  In species where expression is inducible, such as Citrobacter freundii 
and Enterobacter cloacae, the induction requires β-lactam challenge and the presence of 
a transcriptional regulator AmpR (375, 712, 895, 896).  AmpR is a member of the LysR 
family of transcriptional regulators and as such is a DNA-binding protein with a 
predicted helix-turn-helix (HTH) motif at the N-terminus and an inducer-binding domain 
at the C-terminus (856, 897). Comprehensive studies in the Enterobacteriaceae have 
established the critical role of AmpR as the regulator of ampC expression and the 
paradigm of β-lactamase induction. 
 In the Enterobacteriaceae, ampC inducibility is intimately linked to the recycling 
of the peptidoglycan (PG) of the murein sacculus (713, 716, 718, 721).  During normal 
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physiological growth, N-actylglucosaminyl-1,6-anhydromuropeptides (GlcNAc-1,6-
anhydro-MurNAc tri, tetra, and pentapeptides) are continuously being released from the 
murein sacculus due to remodeling (716, 718).  The permease, AmpG, transports the 
metabolites into the cytoplasm where the glycosidase NagZ removes the GlcNAc moiety 
and the amidase AmpD removes the stem peptides from either the incoming GlcNAc-1,6-
anhydro-MurNAc-peptides or from the NagZ-processed product (716, 717, 719, 898-
901). The resulting muramyl peptides are recycled back into the PG biosynthetic pathway 
to form the PG precursor UDP-MurNAc-pentapeptide (902).  It has been proposed that 
during normal cell growth, the cytosolic concentrations of UDP-MurNAc-pentapeptide 
maintain AmpR in an inactive conformation that represses the expression of ampC (716, 
718).  In the presence of β-lactams, however, there is an excessive breakdown of murein 
leading to accumulation of 1,6-anhydromuropeptides in the cytoplasm, which in turn 
overwhelm the hydrolytic activity of AmpD (714, 716, 718, 903).  The increased number 
of AmpD-unprocessed muramyl peptides presumably displaces the repressor UDP-
MurNAc-pentapeptide from AmpR and induce a conformational change in the protein to 
promote expression of ampC (714, 718, 903).    
 All amp gene homologs (ampC, ampR, ampD and ampG) have been identified 
and studied in P. aeruginosa (643, 710, 711, 776, 782, 904-906). Whether a similar 
induction mechanism is employed by P. aeruginosa is not yet known, however, recent 
work illustrates significant departures from the classical enterobacterial induction system. 
In particular, there are three ampD homologs in P. aeruginosa that are responsible for a 
stepwise up-regulation mechanism leading to constitutive β-lactamase hyperexpression 
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(246, 643, 904).  Additionally, P. aeruginosa harbors two AmpG homologs, PA4218 
(AmpP) and PA4393 (AmpG) that appear to be required for induction of ampC (837, 
906). Further, our lab has shown that P. aeruginosa AmpR is a global transcriptional 
regulator involved in the control of amp and various other genes (710, 842-844). 
 AmpR exhibits high sequence identity with its counterparts in C. freundii and E. 
cloacae, and as in the Enterobacteriaceae, ampR is located immediately upstream of 
ampC and divergently transcribed (711, 776). Such similarities suggest a common 
regulatory mechanism among the species, however, the P. aeruginosa ampR-ampC 
intercistronic region bears little resemblance to that of the enterobacteria.  In vitro studies 
using crude extracts have shown P. aeruginosa AmpR binds to this region, but the exact 
binding site and the identity of the amino acids involved in the interaction have not yet 
been determined (776).  In essence, not much is known about the structural elements that 
are critical to the functioning of P. aeruginosa AmpR as regulator of β-lactamase 
expression.   
 In the present work, we define some of the genetic elements in the ampR-ampC 
intergenic region including the ampR and ampC transcriptional start sites, as well as, the 
minimal length of the ampC promoter needed for induction of the ampC system. We 
further show AmpR specifically binds to the 193-bp PampC fragment identified by 
promoter mapping as being required for induction. We also identify amino acids in the 
AmpR HTH motif that are critical for the interaction with the promoter.  Additionally, we 
examine the role of two amino acids, Gly102 and Asp135, previously implicated in the 
repression state of AmpR from the Enterobacteriaceae. Lastly, we show that P. 
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aeruginosa AmpR likely functions as dimers as previously seen for C. freundii and is 
potentially a membrane protein. 
 
4.3 Materials and Methods 
 
4.3.1 Bacterial strains, plasmids and media.  Bacterial strains, plasmids and primers 
employed in this study are shown in Table S1 of the Supplemental Material.  E. coli and 
P. aeruginosa were routinely cultured in Luria-Bertani medium (10 g tryptone, 5 g yeast 
extract, and 5 g NaCl, per liter).  Pseudomonas Isolation Agar (Difco) was used with LB 
at a 1:1 ratio in triparental mating experiments. Antibiotics were used at the following 
concentrations (per milliliter): ampicillin (Ap) at 100 µg, tetracycline (Tc) at 15 µg, and 
gentamycin (Gm) at 15 µg for E. coli; Gm and Tc each at 75 µg for P. aeruginosa. 
PA0ΔampC and PA0ΔampR strains used in this work were previously constructed using 
overlap extension PCR and homologous recombination (760, 843). 
 
4.3.2 PampC promoter deletions.  To characterize the minimal promoter necessary for full 
activity, 5’-end deletions of PampC were constructed and transcriptionally fused to a 
promoterless lacZ.  Briefly, 352-, 193-, 171-, 151-, 130-, 111-, 90-, 70-, and 51-bp 
fragments were generated by PCR with the following primer pairs respectively: 
SBJ03ampCRFor-OCPampCRevBc, OCPampCFor193-OCPampCRevBc, OCPampCFor173-
OCPampCRevBc, OCPampCFor151-OCPampCRevBc, OCPampCFor131-OCPampCRevBc, 
OCPampCFor111-OCPampCRevBc, OCPampCFor91-OCPampCRevBc, OCPampCFor71-
OCPampCRevBc, and OCPampCFor51-OCPampCRevBc (Table S1, Supplemental material). 
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The fragments were sequenced, then cloned into the EcoRI-BamHI sites of the integrative 
vector mini-CTX-lacZ and integrated into PA01.   
 
4.3.3 Construction of His-tagged AmpR.  Primers OCAmpR-His-For and OCAmpR-
His-Rev (Table S1) were used to amplify PA01 genomic ampR.  The 933-bp amplicon, 
carrying a His6 sequence at the 3’-end was cloned into pBluescriptSK(+) and sequenced 
(Table S1). The fragment was subsequently subcloned into the EcoRI-BamHI sites of 
pMMB67EH-Gm, a broad-host range expression vector (763). His-tagged AmpR was 
shown to be functional by β-lactamase assay and E-test (Text S1 and Table S2, 
Supplemental material).   
 
4.3.4 Expression and purification of AmpR-His6. AmpR-His6 was purified according 
to standard protocols.  Briefly, stationary-phase cultures of PA0ΔampR (pAmpR-His6) 
were diluted to an OD600 of 0.02 in 2 liters of LB broth and incubated with shaking at 
37°C until the culture density reached an OD600 of 0.2. Cells were then induced with 1 
mM of isopropyl β-D-1-thiogalactopyranoside (IPTG) and incubated for an additional six 
hours before harvesting.  The cells were recovered by centrifugation at 6,000 X g for 10 
minutes at 4°C and resuspended in 25 ml of lysis buffer (20 mM HEPES pH8, 0.5 M 
NaCl, 10% glycerol, 1 mM PMSF, 2 pellets of EDTA-free protease inhibitor cocktail 
tablets complete, 100 μl of 0.1 mg ml-1 of lysozyme and 5 μl of DNase1). Following 
disruption of the cells on ice with sonication (20-s pulse ON and 20-s pulse OFF for 20 
minutes, amplitude 50%), the cell lysate was centrifuged at 10,000 X g for 10 minutes at 
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4°C.  The supernatant was further ultracentrifuged at 36, 000 rpm for 1 h at 4°C.   
Membranes pellets were resuspended in 20 ml of solubilization buffer (20 mM HEPES 
pH8, 0.5 M NaCl, 10% glycerol, 5 mM imidazole, 1 mM PMSF, 2 pellets of EDTA-free 
Protease Inhibitor cocktail tablets complete, and 2 % of CHAPS) and loaded onto a 
HisTrap FF 1 ml column.  AmpR-His6 was eluted with buffer B (20 mM HEPES pH8, 
0.5 M NaCl, 10% glycerol, 500 mM imidazole and 0.6% of CHAPS) by using an FPLC 
chromatograph (Akta, Amersham Biosciences). About 20 ml were recovered and 
dialyzed to remove imidazole.  This AmpR preparation was used to make AmpR-specific 
antibodies.  
 
4.3.5 Construction of P. aeruginosa AmpR HTH and point mutants. Site-directed 
mutagenesis was used to replace various amino acid residues in AmpR.  Briefly, Ser38, 
His39, Lys42, Ser43, and Glu46 were replaced with Ala; Gly102 and Asp135 were 
replaced with Glu and Asn, respectively.  Substitutions were constructed by PCR using 
the following primer pairs: AmpRSer38AlaFor-AmpRSer38AlaRev, AmpRHis39AlaFor-
AmpRHis39AlaRev, AmpRLys42AlaFor-AmpRLys42AlaRev, AmpRSer43AlaFor-
AmpRSer43AlaRev, AmpRGlu46AlaFor-AmpRGlu46AlaRev, AmpRGly102GluFor-
AmpRGly102GluRev, and AmpRAsp135AsnFor-AmpRAsp135AsnRev (Table S1, 
Supplemental material).   
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4.3.6 Membrane fraction purification. Preliminary studies showed pAmpR-His6 
expression and β-lactamase induction were achieved with a 2-hour incubation at a 1 mM-
IPTG concentration. Thus, PA0ΔampR (pAmpR-His6) cells at OD600 of 0.2 were induced 
with 1 mM of IPTG and incubated for two hours before harvesting for membrane 
fractionation.  For β-lactamase induction, cells were further treated with 200 µg ml-1 of 
penicillin G an hour after IPTG addition.  Cells were recovered by centrifugation at 6,000 
X g for 10 minutes at 4°C and resuspended in 50 ml of lysis buffer (20 mM HEPES pH8, 
0.1 M NaCl, 1 mM EDTA, 1 mM PMSF, and 50 μl of DNase1).  Following disruption of 
the cells on ice with sonication (15 cycles of 10 second pulse ON and 30 S pulse OFF, 
amplitude 40%), the cell lysate was centrifuged at 5,000 rpm for 10 minutes at 4°C.  The 
supernatant was ultracentrifuged at 36,000 rpm (Rotor Ti70) for one hour at 4°C and the 
pellets were resuspended with 2 ml of membrane buffer (25% sucrose, 20 mM Tris pH8, 
and 0.5 mM PMSF).  Two-hundred milliliters of membrane fractions were aliquoted and 
stored at -80°C.  
 
4.3.7 Electrophoretic mobility shift assay (EMSA). The 193-bp PCR fragment 
containing the ampR-ampC intergenic region plus a small part of ampR ORF was used to 
perform EMSA.  Ten pmol of this fragment were radiolabelled at the 5’ end by 
incubation with T4 polynucleotide kinase (NEB) and [γ-32P]ATP  (3,000 Ci mmol-1; 
Perkin Elmer).  The labeled fragment was diluted to a final concentration 100 nM and 
unincorporated nucleotides were removed by sephadex G-25 (Biorad) spin 
chromatography.  DNA binding reactions containing 50 fmol of 
32
P-labeled DNA probe 
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and varying amounts of total protein membrane fractions were incubated for 20 minutes 
and loaded thereafter in a non-denaturating 5% PAGE.  Radioactive signals were 
detected by scanning a phosphostorage cassette with the GE Healthcare Typhoon 9400 
scanner.   
 For competition assays, 50 fmol of the 193-bp 
32
P-labeled probe were mixed with 
the unlabeled 193-bp fragment in 10-, 100- and 500-fold molar excess in the EMSA 
assay.  For nonspecific assays, 50 fmol of the 193-bp 
32
P-labeled probe were mixed with 
a PCR-amplified 233-bp fragment (alg44) in 10-, 100- and 500-fold molar excess in the 
EMSA assay.   
 
4.3.8 5’ RACE PCR.  The ampC and ampR TSSs were mapped using a classical 5’ 
RACE-PCR on total mRNAs extracted from PA01, PA0ΔampR and PA0ΔampC (907). 
Stationary-phase cultures of PA01, PA0ΔampR and PA0ΔampC were diluted to an OD600 
of 0.02 and incubated with shaking at 37°C until the cultures reached an OD600 of 0.6.  
The cultures were then induced with 200 µg ml
-1
 of penicillin G for one hour and 
subsequently blocked on ice for 15 minutes with 1/5
th
 of the final culture volume in 5% 
acidic phenol-95% ethanol, pH 4. One milliliter of the cells were recovered by 
centrifugation and resuspended with 3 mg ml
-1
 of lysozyme (Tris EDTA, pH 8).  RNA 
was then extracted according to the RNeasy mini kit protocol (Qiagen), treated with 10 U 
of RQ1 DNase (Promega) for one hour, extracted with phenol/chloroform/isoamyl 
alcohol (25:24:1) and chloroform, precipitated and dried. Superscript III (Invitrogen) was 
then used to reverse transcribe 10 µg of RNA as previously described (907) using primers 
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5RA-PampC233 and 5RA-PampR229 for determination of the ampC and ampR TSS, 
respectively. In the first round of PCR amplification (Pfu, Stratagen), primers Qt, Q0, and 
5RA-PampC154 were used for ampC TSS determination, while Qt, Q0, and 5RA-PampR169 
were used for determination of the ampR TSS.  In the second round of PCR amplification 
(Pfu, Stratagen), primer pairs Qi-5RA-PampC113, and Qi-5RA-PampR99 were used for 
ampC and ampR TSS determination, respectively (Table S1). PCR products were cloned 
into TOPO (Invitrogen), blue colonies were selected for screening and clones were 
sequenced. 
 
4.3.9 qPCR analysis of ampR and ampC mRNAs. Total RNA was extracted from 
PA01, PA0ΔrpoN and PA0ΔrpoN (pRpoN) in the presence and absence of the inducer 
(0.2 µg ml
-1
 imipenem) using the RNeasy mini kit (Qiagen).  RNA was reverse 
transcribed into cDNA with Superscript III (Invitrogen) and an (NS)5 random primer 
using standard methods (764). For qPCR, the ABI 7500 (Applied Biosystems) cycler was 
used with Power SYBR Green PCR Master Mix with ROX (Applied Biosystems). The 
reading was normalized to clpX (PA1802), whose expression remains constant in all the 
samples and conditions tested. Melting curves were generated to ensure primer 
specificity. Gene expression of each sample was normalized to PA01 uninduced value, to 
see the effect of induction and mutation at the same time. Primer pairs 
DBS_QRTAmpRFwd-DBS_QRTAmpRRev and qRT_ampCF-qRT_ampCR were used 
for the real time amplification of ampR and ampC, respectively.  
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4.3.10 Construction of VSV-G-tagged AmpR.  A 540-bp fragment corresponding to the 
3' end of ampR, minus the stop codon, was amplified using primers DB_ampR3’_F and 
DB_ampR3’_R.  The amplicon was cloned into pP30ΔFRT-MvaT-V (908), a replication-
incompetent vector in P. aeruginosa, such that the 3’ end of ampR was fused in frame 
with three alanines and the VSV-G tag (YTDIEMNRLGK). The construct was then was 
introduced into PA01 as single copy by mating and clones were selected for gentamycin 
resistance. 
 
4.3.11 Chromatin immunoprecipitation quantitative PCR (ChIP-qPCR). Cells 
harboring the VSV-G-tagged AmpR were harvested after sub-MIC β-lactam exposure 
(843) and treated with formaldehyde to cross-link proteins with DNA as previously 
described (908). DNA was sheared by sonication to an average length of 0.5-1.0 kb and 
AmpR was immunoprecipitated with anti-VSV-G agarose beads (BETHYL Laboratories, 
Inc.).  ChIP-qPCR was performed using Power SYBR Green PCR Master Mix (Applied 
Biosystems) with primers DBS_ChIP_ampCF and DBS_ChIP_ampCR.  Fold enrichment 
was normalized to clpX (PA1802). 
 
4.3.12 Protein cross-linking. PA0ΔampR (pAmpR-His6) was grown to an OD600 of 0.3 
and induced with 1 mM IPTG for 2 hours.  Cells were grown for two additional hours in 
the presence and absence of β-lactam antibiotics (0.1 µg ml-1 of imipenem).  Cultures 
were then treated with 0.1% formaldehyde for 20 and 40 minutes at room temperature.  
Crude extracts containing 10 µg of total protein were separated on an SDS-
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polyacrylamide gel and AmpR was visualized using anti-His antibody.  The blot was 
subsequently stripped and reprobed using anti-σ70 antibody (NeoClone).  
 
4.3.13 Polyclonal anti-AmpR-His6 antibody production. Purified AmpR-His6 was 
used as antigen to raise anti-AmpR-His6 rabbit polyclonal antibodies (Covance, 
Princeton, NJ). AmpR-His6 antibody was affinity-purified as previously described (909).   
 
4.3.14 Western Blotting and EMSA of HTH mutants. Concentration of purified 
AmpR-His6 was determined by the bicinchoninic acid (BCA) method (910).  A 
calibration Western blot was generated using FujiFilm LAS-3000 imager to correlate 
intensities with the concentration of purified AmpR-His6. Membrane fractions were 
purified from PA0∆ampR pAmpR-HTH mutants and their concentrations were 
determined using the BCA method, whereas the exact quantity of AmpR was deduced 
from Western blotting.  Preliminary gel shifts with increasing concentrations of 
membrane fractions of AmpR-HTH mutants showed that a 0.4 mg ml
-1
 is sufficient to 
shift the 193-bp PampC PCR fragment (Data not shown).  For a second gel shift, a 0.4 mg 
ml
-1
 of total membrane fraction (8.44 ng of AmpR), recovered from PA0ΔampR 
overexpressing AmpR HTH mutants in the presence and absence of 200 µg ml
-1
 
penicillin G, was hybridized with the 193-bp PCR fragment spanning the ampC-ampR 
intergenic region (Fig. 7).  As this concentration was not enough to visualize AmpR, a 
higher quantity (33 ng) was used for Western blotting of the HTH mutants to show that 
the amount of AmpR-His6 is equivalent under all conditions and thus in the EMSA 
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experiment (Data not shown).  Further, the stability of AmpR-His6 mutants was verified 
by Western using equal amounts of total protein with AmpR-specific antibodies (Figure 
4.8).  Sigma
70 
(NeoClone) was used as control to show the same amount of total protein 
was loaded per sample. All Western blots were developed according to standard 
protocols.  Briefly, proteins were transferred to a PVDF membrane (Bio-Rad) and 
blocked with TBST (TBS 0.1 % Tween) and 5 % non-fat dry milk at 4°C overnight or for 
four hours, followed by rinsing with the same solution and probing with rabbit anti-
AmpR antibody (1:3000). Membranes were subsequently washed with TBST, incubated 
with goat anti-rabbit IgG (H+L)-horseradish peroxidase-conjugated antibody (1:5000) 
(Bio-Rad), rinsed and developed using Enhanced Chemiluminescence Western Blotting 
Substrate (Pierce).   
 
4.3.15 β-galactosidase assay. β-galactosidase assays were performed as previously 
described (854).  
 
4.3.16 AmpR-LacZ and -PhoA fusion construction and analysis.  The topology of 
AmpR was investigated using phoA and lacZ fusions.  The plasmid pSJ01 (710) carrying 
a 1220-bp fragment containing ampR was digested at HindIII, HincII and PstI, 
corresponding to the amino acid positions, Gln15, Val134 and Gln186, respectively (Fig. 
S2A). The resultant fragments were ligated in-frame upstream of phoA and lacZ-
containing plasmids, pTrcphoA and pTrclacZ (Table S1, Supplemental material), (911).  
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The phoA and lacZ activities were qualitatively determined in E. coli according to 
standard protocols (854).  
 
4.3.17 Protease protection (shaving) assay. A stationary-phase culture of PA0ΔampR 
(pAmpR-His6) was diluted to an OD600 of 0.02 and incubated with shaking at 37°C until 
the culture reached an OD600 of 0.4.  The cells were then induced with 1 mM IPTG for 
four hours and chloramphenicol (500 µg ml
-1
) was added 30 minutes prior to harvesting 
to stop protein synthesis.  The cells were harvested by centrifugation and resuspended in 
40 mM Tris-Cl pH 8.0, 0.5 M sucrose.  Spheroplasts were obtained by adding 1 mg ml
-1
 
of lysozyme and 4 mM EDTA for 10 minutes in a 30°C water bath followed by the 
addition of 20 mM MgCl2.  The formation of spheroplasts was monitored by light 
microscopy.  Spheroplasts were harvested by centrifugation at 4,000 X g for 10 minutes 
and resuspended in 40 mM Tris-Cl pH 8.0, 0.5 M sucrose.  Proteinase K (10 µg ml
-1
) was 
added to 1 ml aliquot of the spheroplasts and incubated in a 30°C water bath.  Samples 
were taken at different time points and added to 2 mM PMSF and 4X SDS PAGE Sample 
Buffer.  Samples were then boiled for 5 minutes and ran in a 4-20% SDS-PAGE 
(Criterion Biorad). Proteins were transferred to a nitrocellulose membrane (Biorad) and 
identified using AmpR (Covance), σ70 (NeoClone) and His-tag (Qiagen) antibodies. The 
immunoblot was developed using SuperSignal West Pico Chemiluminescent Substrate 
(Thermo Scientific).  
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4.4 Results and Discussion 
 
4.4.1 Analysis of the P. aeruginosa ampC-ampR regulatory region. P. aeruginosa 
AmpR shares high identity with its homologs in C. freundii and E. cloacae (58.3 and 
62.5%, respectively), as well as, the same gene organization, with ampR located upstream 
of ampC and divergently transcribed (711, 776). The P. aeruginosa ampR-ampC 
intercistronic region, however, shares no significant similarities with that of C. freundii 
and E. cloacae, with the exception of an inverted 38-bp sequence that in C. freundii is 
protected by AmpR (711, 840). The lack of conservation in the promoter region could 
point to different sigma factor requirements and/or different regulatory mechanisms. To 
elucidate the transcriptional regulatory elements of P. aeruginosa ampC and ampR, their 
148-bp intergenic region was characterized.  
 The transcriptional start sites (TSS) were determined using 5’ RACE-PCR on 
total mRNAs isolated from PA01, PA0ΔampR and PA0ΔampC (Figure 4.1). A strong 
similarity to RpoN (σ54) sigma factor sequences was detected at -12 and -24 positions of 
the ampR TSS, whereas strong σ70 promoter sequences were observed at the -10 and -35 
positions of ampC. Alignment of the C. freundii, E. cloacae and P. aeruginosa intergenic 
region reveals a fair conservation for the ampC -10 and -35. However, there is a 
downstream shift in the P. aeruginosa ampR TSS that could contribute to the change in 
sigma factor control observed here (Figure S1, Supplemental material). 
 The presence of putative -12 and -24 recognition sequences in the ampR promoter 
(PampR) suggested that its expression might be RpoN or σ
54
-dependent.  Quantitative real-
time PCR was used to validate this hypothesis.  Total RNA was extracted from β-lactam  
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induced and uninduced PA01, PA0ΔrpoN and PA0ΔrpoN (pRpoN) strains and reverse 
transcribed into cDNA using standard methods (764).  In the wild-type, exposure to β-
lactams increased ampR and ampC expression approximately 100-fold over the 
uninduced samples (normalized to 1) (Figure 4.2). A further, significant increase in 
expression of both genes was observed in PA0ΔrpoN upon β-lactam challenge that could 
be rescued by pRpoN.  In the absence of β-lactams, a small, but significant reduction in 
expression was observed in the PA0ΔrpoN that could not be complemented.  
 In spite of the presence of a probable binding site on PampR, σ
54
 is not required for 
ampR expression. The significant increase in the absence of rpoN and in the presence of 
the β-lactams suggests σ54 negatively impacts ampR expression. RpoN may exert this 
negative effect indirectly by enabling transcription of a negative regulator or directly by 
competing for the RNA polymerase holoenzyme with another sigma factor.  
Alternatively, P. aeruginosa RpoN can directly repress transcription by blocking 
promoter access to a different sigma factor in a phenomenon referred to as σ-factor 
antagonism as previously reported (912).  Specifically, σ54 has been shown to repress σ22-
dependent transcription from PalgD by directly binding to the overlapping promoter 
sequences in the absence of an external stimulus (912).  Similarly, σ-factor antagonism 
has also been reported in E. coli, where mutagenesis of a σ54-dependent promoter created 
a new TSS with σ70 requirement that exhibited decreased transcriptional activity in the 
presence of σ54 (913). 
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Figure 4.2.  RpoN downregulates P. aeruginosa ampR expression in the presence of β-
lactams.  RNA was isolated from PA01, PA0ΔrpoN and PA0ΔrpoN(pRpoN) in the 
presence and absence of β-lactams, reversed transcribed to cDNA and tested by qPCR 
with ampC (grey bars) and ampR (black bars) specific primers, as described in the 
Experimental Procedures. Values were normalized to the expression of the wild-type 
uninduced sample and represent the mean (±SD) of two experiments conducted in 
triplicates.  * p-value< 0.001 for  both ampR and ampC expression in induced PA01 
versus expression in uninduced PA01, ** p-value< 0.005 for ampR and ampC expression 
in induced PA0ΔrpoN versus expression in PA01 induced as determined by unpaired t-
test.   
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 A model of repression by σ54 through promoter blocking is conceivable, where in 
the absence of some external stimuli, in this case β-lactams, σ54 binds PampR and prevents 
access and thus transcription by the sigma factor.  In the presence of the inducer, 
however, σ54 may be partially or completely displaced by the sigma-RNA polymerase 
complex to promote ampR transcription. Thus, the loss of rpoN leads to complete de-
repression of ampR expression in the induced condition. 
 Lastly and very interestingly, the expression of ampC followed a pattern similar 
to that of ampR in all backgrounds. Previously, ampR expression in P. aeruginosa was 
shown to be low and not significantly induced upon exposure to the β-lactam 
benzylpenicillin (710). Similarly, expression from the C. freundii ampR promoter in E. 
coli was found to be constitutive in the presence and absence of the inducer (6-
aminopenicillanic acid) (840). In E. cloacae, induction with cefoxitin significantly 
increased transcription of ampC but had no effect on ampR expression (895). Recent 
work from our lab however, showed that in the presence of very powerful known 
inducers, namely imipenem and meropenem, expression of both ampC and ampR is 
equally and very significantly induced in wild-type P. aeruginosa (760).  In light of such 
results, it is not surprising that our current data shows that wild-type P. aeruginosa has 
similar ampC and ampR mRNA levels in the presence of imipenem. Similar induction 
profiles in the absence of rpoN suggest that the ampC and ampR promoters can reach 
their full induction potential upon removal of the restricting negative effect imposed by 
RpoN. It is not clear how exactly RpoN, or its absence, can accomplish this, but it is 
worth noting that in the ampC and ampR TSSs, the -12 sequence of ampR overlaps the -
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10 sequence of ampC. Thus, if σ54 is in fact blocking promoter access to RNA 
polymerase, it could be blocking access to both the ampR and ampC promoters until such 
time as inducers lead to its partial or complete displacement from the intergenic region. 
Further studies are needed to elucidate the mechanism of ampC and ampR 
downregulation by RpoN. 
 
4.4.2 Mapping of P. aeruginosa PampC. To map the minimal promoter needed for AmpR-
dependent activity, a series of 5’-end deletions of PampC were transcriptionally fused to 
the promoterless lacZ gene of the integrative vector mini-CTX-lacZ  (853). The activity 
of each promoter deletion was then analyzed in PA01 by assaying β-galactosidase 
activity in the presence and absence of 200 µg ml
-1
 of penicillin G. The minimum length 
of the promoter needed for full PampC activity is 193-bp (Figure 4.3). This fragment 
consists of the full ampR-ampC intergenic region plus small parts of the ampR (22 bp) 
and ampC (23 bp) ORFs. The high activity seen with the 193-bp fragment in the absence 
of β-lactams as compared to the wild-type may be the result of the partial or complete 
removal of the repressor-binding site.  Subsequent loss of a 22-bp ampR fragment from 
the 5’ end of the 193-bp segment resulted in a 2-fold decrease in induction likely 
indicating partial removal of the activator-binding site. This 22-bp fragment 
corresponding to the beginning of the ampR ORF seems to be necessary for full induction 
of PampC. In silico analysis reveals that this segment is very well conserved among other 
species but has no real identifiable features. Induction was abolished with a further 20-bp 
deletion (151-bp fragment).  Thus, the 42-bp region (denoted red in Figures 4.1 and 4.3),  
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Figure 4.3. Mapping of the minimal P. aeruginosa ampC promoter. 5’-end deletions of 
PampC were constructed and transcriptionally fused to a promoterless lacZ gene in the 
integrative vector mini-CTX-lacZ as described in the Materials and Methods. Constructs 
were introduced into PA01 for integration at the attB site to generate single-copy 
promoter fusions.  Promoter activities are expressed in Miller units.  The +1 denotes the 
ampC transcriptional start site.  The 42-bp segment, missing from the 151-bp construct, 
that appears to be necessary for activator binding, is depicted in red at the 5’ end of the 
193-bp fragment. * p-value< 0.05 as compared to uninduced PA0attB::PampC352-lacZ; ** 
p-value< 0.05 versus uninduced PA0attB::PampC171-lacZ as determined by unpaired t-test 
using ANOVA. 
 
present at the 5’ end of the 193-bp fragment but deleted from the 151-bp construct, 
demarcates the outer bounds of the functional promoter needed for activation of PampC. 
Since this 42-bp fragment includes the AmpR box, an in silico derived putative AmpR-
binding site (Figure 4.1), this region could be critical for activator binding.  
 
4.4.3 P. aeruginosa AmpR binds to PampC. Previously, P. aeruginosa AmpR has been 
shown to bind PampC using AmpR-overexpressing E. coli whole cell extracts (776). 
Similarly, crude preparations of C. freundii AmpR were also shown to retard a radio-
labeled ampR-ampC intergenic region (840). Since preliminary work from our lab 
suggested that P. aeruginosa AmpR is likely to be a membrane-associated protein (See 
Localization studies of P. aeruginosa AmpR section below and Figure. S2), we tested the 
ability of PA01 membrane fractions to bind PampC. EMSA was performed using AmpR-
His6 enriched membrane fractions and a [γ-
32
P] ATP radiolabeled PampC fragment. Shift 
was observed with increasing concentrations of total membrane protein up to 0.4 mg ml
-1
 
(Figure 4.4). The binding was competed-out by mixing labeled DNA with unlabeled 
promoter DNA in 100-fold molar excess confirming AmpR binding to PampC (Figure 4.4). 
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Additionally, competition with a nonspecific, unlabeled fragment (233-bp alg44 PCR 
fragment) mixed in 10-, 100-, and 500-fold molar excess with the labeled PampC fragment, 
failed to displace AmpR-His6 from PampC illustrating the binding specificity. 
  
Figure 4.4.  P. aeruginosa AmpR binds PampC.  Fifty fmol of a 193-bp radio-labeled 
PampC fragment (Lane 1) spanning the ampC-ampR promoter region were mixed with 
increasing concentrations of AmpR-His6 enriched membrane fractions extracted from 
PA0ΔampR (pAmpR-His6 ) in the presence of 200 µg ml
-1
 of penicillin G (Lanes 2 to 6).  
Competition assays were carried out with the cold PampC fragment in 10- (Lane 7), 100- 
(Lane 8) and 500-fold (Lane 9) molar excess.  To characterize the binding specificity, a 
nonspecific fragment (233-bp alg44 PCR fragment) was mixed in 10- (Lane 10), 100- 
(Lane 11) and 500-fold (Lane 12) molar excess with the radio-labeled reaction mix.  Lane 
13 is the control showing the 193-bp radio-labeled PampC fragment in the presence of 
membrane fractions extracted from PA0∆ampR containing the plasmid backbone alone.   
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 To determine if AmpR interacts with PampC in vivo, ChIP-qPCR was employed 
(908). A functional VSV-G-tagged AmpR (Table S3, Supplemental material) was 
introduced into PA01 as single copy and then immunoprecipitated with anti-VSV-G 
antibody. Sequence-specific primers were used to detect the presence of PampC DNA with 
qPCR. Promoter occupancy was detected in the presence and absence of β-lactams as 
expected of LTTRs (856) (Fold enrichment over clpX control- Uninduced: 10.6±1.73, 
Induced: 13.3±4.63; Fold enrichment for negative control target aprX- Uninduced: 
1.30±0.02, Induced: 1.34±0.22). AmpR thus binds PampC in vivo in the presence and 
absence of the inducer. 
 
4.4.4 HTH is important for AmpR function. The majority of prokaryotic DNA-binding 
proteins, including LTTRs, use the HTH motif to interact with DNA (897, 914). In 
LTTRs, this domain is often found at the N-terminus (856, 897). The canonical HTH 
motif is comprised of three helical bundles where the second and third helices interact 
with the DNA, and the third makes the essential contacts with the major groove to 
provide recognition (897, 914, 915).  A multiple alignment of the AmpR family HTH 
motif shows the highest degree of conservation is found in the first two helices, with the 
most variation in the third helix that provides specificity (Figure S3, Supplemental 
material). Although P. aeruginosa AmpR has been shown to bind the ampR-ampC 
intercistronic region (776), the amino acids involved in the interaction have not been 
identified.      
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 An amphipathic wheel of the third helix (residues Gln34 to Leu48), generated 
using DNASTAR Protean, identified polar and charged amino acids potentially facing the 
major groove of the DNA (Figure 4.5). Point mutations corresponding to these residues 
were generated by site-directed mutagenesis of AmpR-His6. Residues Ser38, His39, 
Lys42, Ser43, and Glu46 were thus replaced with alanine and the mutants were 
overexpressed in PA01 and PA0ΔampR strains carrying the chromosomal PampC-lacZ 
fusion (Figure 4.6). The PampC activity observed in PA01 is the result of both ampR 
alleles, from the chromosome (ampRchr) and from the plasmid (ampRpls), whereas in 
PA0ΔampR only ampRpls contributes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5.  Analysis of the third helix of the P. aeruginosa AmpR HTH motif.  An 
amphipathic wheel of the third helix (residues Q34 to L48) was generated using 
DNASTAR Protean in order to identify polar and charged amino acids likely facing the 
major groove of the DNA. The AmpR residues Ser38, His39, Lys42, Ser43, and Glu46, 
were identified as amino acids likely to interact with the DNA and were thus targeted for 
mutagenesis.  They are indicated by the black arrows and denoted as S5, H6, K9, S10 and 
E13 in the helical wheel, respectively. The N-terminal sequence of P. aeruginosa AmpR 
illustrates the HTH motif and the location of the above amino acids (in red) in the third 
helix of AmpR.   
189 
 
 
Figure 4.6.  Functional analysis of the P. aeruginosa AmpR HTH motif.  Site-directed 
mutagenesis was used to replace Ser38, His39, Lys42, Ser43, and Glu46 with Ala in 
AmpR-His6. The mutant proteins were overexpressed in PA01 and PA0ΔampR strains 
carrying a single copy of the PampC-lacZ fusion integrated at the attB site.  β-galactosidase 
activity was quantified in the presence and absence of β-lactams.  * p-value< 0.05 versus 
uninduced PA01 vector control; ** p-value< 0.005 versus induced PA01 vector control 
as determined by unpaired t-test using ANOVA. 
 
 Alanine substitutions at Ser43 and Glu46 did not affect the ability of AmpR to 
activate PampC in PA0ΔampR (Figure 4.6). In addition, both AmpRSer43Ala and 
AmpRGlu46Ala were able to bind PampC in the presence and absence of β-lactams (Figure 
4.7). These two findings suggest Ser43 and Glu46 are not critical for AmpR function. 
However, expression of AmpRSer43Ala and AmpRGlu46Ala in PA01 that carries AmpRchr, 
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significantly increased PampC activity by more than 2-fold in the presence of inducers 
suggesting a possible interaction between chromosomal encoded AmpRchr and the 
variants (Figure 4.6). In particular, the Ser43Ala substitution increased basal levels in the 
absence of inducers, while leading to hyperinduction in the presence of β-lactams. 
Similarly, significant activation of PampC in PA01 in the presence of AmpR-His6 further 
strengthens the idea that AmpR functions as a multimer.  
 
Figure 4.7.  Electromobility shift assay of P. aeruginosa AmpR HTH mutants.  A 50 
fmol of the 193-bp radio-labeled PampC fragment (Lane 1) were mixed with membrane 
fractions recovered from PA0∆ampR in the absence (Lanes 2 to 8) and presence of β-
lactams (Lanes 9 to 15) and carrying pMMB67EH-Gm (Lanes 3 & 10), pAmpR-His6 
(Lanes 2 & 9), pAmpR-His6(His39Ala) (Lanes 4 & 11), pAmpR-His6(Ser38Ala) (Lanes 5 & 
12), pAmpR-His6(Lys42Ala) (Lanes 6 & 13),  pAmpR-His6(Ser43Ala) (Lanes 7 & 14),  and 
pAmpR-His6(Glu46Ala) (Lanes 8 & 15).  
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 AmpR mutant proteins failed to activate PampC when Ser38, His39, or Lys42 were 
substituted with alanine. These three residues are thus essential for AmpR activity and are 
presumably involved in the binding to PampC.  A multiple alignment reveals Ser38 and 
Lys42 are well-conserved in members of the AmpR family as expected of amino acids 
that play a critical role in the functionality of a protein (Figure S3, Supplemental 
material).   
 The loss of PampC activity in AmpRSer38Ala, AmpRHis39Ala and AmpRLys42Ala could 
be attributed to the destabilization of the proteins. Their expression was thus analyzed 
using Western blotting with anti-AmpR antibody (Figure 4.8). Interestingly, not only are 
these three mutant AmpR proteins made, it appears that they, and in particular 
AmpRSer38Ala and AmpRLys42Ala, are made in large quantities. These amino acid 
substitutions, therefore, appear to stabilize rather than destabilize the proteins. Thus, we 
argued that the loss of PampC activity may be due to their inability to bind DNA.  Gel-
shifts revealed that AmpRSer38Ala failed to bind to PampC while AmpRLys42Ala bound very 
poorly correlating well with the loss of PampC transcriptional activity (Figure 4.7). 
Surprisingly, the His39Ala substitution did not prevent AmpR from binding to PampC in 
the presence or absence of β-lactams, although it clearly prevented it from activating 
transcription from PampC (Figures 4.6 and 4.7).  AmpRHis39Ala is thus a positive control 
mutant that can bind DNA but cannot activate transcription from the promoter to which it 
binds.   
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Figure 4.8. Stability of P. aeruginosa AmpR mutant proteins.  Total protein extracts 
were recovered from AmpR HTH and point mutants after a 1½-hour incubation with 1 
mM of IPTG.  The stability of each mutant was verified by Western blotting using 
AmpR-specific antibodies.  Equal amounts of total membrane protein were loaded per 
well; σ70 was used as a loading control and detected with anti-σ70 antibody.  
 
 Positive control (pc) mutants are proteins that are defective in transcriptional 
activation but retain the ability to bind DNA. The pc phenotype is caused by the 
disruption of favorable protein-protein interactions between the activator protein and the 
RNA polymerase (916-918). Several pc mutants of other proteins have been 
characterized with mutations in or near the DNA-binding domain (916-921). Mutations 
away from this region have also been reported (922). In particular, mutations in the 
DNA-binding region have been mapped to the second helix of the HTH motif and to the 
junction between the second and third helix of the same domain in the activator proteins 
λ cI, 434 cI, and P22 c2 (916-919).  AmpRHis39Ala is different from previously reported pc 
mutants in that its mutation is found in the helix of the DNA-binding domain that is 
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thought to directly interact with the major groove of the DNA (helix 3), and not in the 
helix which usually lies across the major groove (helix 2), and makes contacts with the 
DNA backbone. Although it is not clear whether this third helix can contact the RNA 
polymerase, it may interact with other sites in the nearby helix to indirectly affect 
transcription. Our work here does not reveal how the disruption of His39 affects 
activation of transcription, but merely that it is required for it.   
 In the present work we show that the highly conserved residues Ser38 and Lys42 
(not conserved in Klebsiella pneumoniae), in the HTH motif are critical for binding and 
function of AmpR. The less conserved His39 is also necessary for promoter activation 
but not for binding to the DNA.  
 
4.4.5. Gly102 and Asp135 are critical for AmpR function. Previous work identified C. 
freundii ampR mutants that constitutively express β-lactamase (839, 923). Specifically, a 
change in Gly102 to Glu (Gly102Glu) resulted in high constitutive β-lactamase 
expression in an inducer-independent manner, while a Gly102Asp substitution yielded a 
similar but less pronounced phenotype (839, 923). In addition, Asp135 was also found to 
play a role in the function of C. freundii and E. cloacae AmpR (923, 924). The 
expression of C. freundii AmpRAsp135Tyr led to constitutive β-lactamase hyperexpression 
in an ampG mutant background. In E. cloacae AmpR Asp135 substitutions to Val or Asn 
resulted in higher β-lactamase activity in the presence and absence of inducers and 
contributed to increased β-lactam resistance in two different E. coli backgrounds (923, 
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924). Gly102 and Asp135, thus appear to play important roles in the activation/repression 
state of AmpR in, at least, the Enterobacteriaceae.  
 To investigate the role of these amino acids, P. aeruginosa AmpR Gly102 and 
Asp135 were replaced with Glu and Asn, respectively. The two mutant AmpR proteins 
were overexpressed in PA01 and PA0ΔampR strains carrying PampC-lacZ (Figure 4.9). 
Unlike in C. freundii, in P. aeruginosa the Gly102Glu substitution resulted in the loss of 
PampC activity in the presence and absence of β-lactams. The loss of activity is due to 
destabilization of the protein (Figure 4.8), suggesting a structural role for Gly102 in P. 
aeruginosa AmpR.   
 On the other hand, the Asp135Asn substitution led to an inducer-independent 
increase in PampC transcriptional activity in both PA01 and PA0ΔampR with no 
concomitant increase in the amount of protein being made (Figures 4.8 and 4.9). Thus, 
we postulate that the Asp135Asn substitution in the effector binding domain appears to 
stabilize the active conformation effectively turning AmpR into a constitutive activator of 
ampC transcription. The Asp135Asn substitution has also been reported in AmpR from a 
P. aeruginosa clinical variant that exhibited hyper-constitutive β-lactamase expression 
and high resistance to β-lactams (722). The importance of Asp135 corroborates the 
previous work in E. cloacae and C. freundii (923, 924). Gly102, on the other hand, 
clearly plays different roles in the P. aeruginosa and C. freundii AmpR proteins. 
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Figure 4.9.  Activity of the P. aeruginosa ampC promoter in the presence of AmpR-
His6(Gly102Glu) and AmpR-His6(Asp135Asn) mutants.  Site-directed mutagenesis was used to 
replace Gly102 and Asp135 of P. aeruginosa AmpR with Glu and Asn, respectively.  
Mutant AmpRs were expressed in wild-type PA01 and PA0ΔampR strains carrying 
PampC-lacZ.  β-galactosidase activity was quantified in the presence and absence of β-
lactams and is represented in Miller units. * p-value<0.01 versus induced PA0∆ampR 
pAmpR-His6; ** p-value<0.01 versus induced PA0attB::mini-CTX-lacZ; *** p-
value<0.001 versus induced PA0∆ampR pAmpR-His6 as determined by unpaired t-test 
using ANOVA.  
 
4.4.6 Cross-linking studies suggest P. aeruginosa AmpR dimerizes. The PampC activity 
in the presence of both ampRchr and ampRpls is always considerably higher than that in 
PA01 and PA0∆ampR (ampRpls) (Figure 4.6). These findings suggest a possible 
interaction between the wild-type and His-tagged AmpR. This is not surprising as LTTRs 
exist and/or function as dimers or tetramers (856, 897, 925-929). To determine if in fact 
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P. aeruginosa AmpR can dimerize, proteins from PA0ΔampR (pAmpR-His6) were cross-
linked and AmpR was visualized with anti-His antibody.  The detection of a 64-kD and a 
32 kD species in cross-linked and non-cross-linked samples, respectively, suggests that 
AmpR dimerizes in vivo (Figure 4.10). Only the monomeric form of σ70 was detected 
after stripping and reprobing the blot. Our findings corroborate previous work in C. 
freundii where both AmpR and its effector binding domain were shown to dimerize in 
solution and in the crystallized form, respectively (930, 931). 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10. P. aeruginosa AmpR appears to dimerize in vivo. A fresh culture of 
PA0ΔampR strain harboring pAmpR-His6 was treated with 0.1% formaldehyde for 20 
and 40 minutes at room temperature to achieve protein cross-linking. Crude extracts 
containing 10 µg of total protein were separated on an SDS-polyacrylamide gel and 
AmpR was visualized using anti-His antibody.  The blot was later stripped and reprobed 
using anti-σ70 antibody.  Monomeric AmpR is detected in non-cross-linked samples at 
zero time point, while AmpR dimeric entities (64KDa) are detected 20 and 40 minutes 
after protein cross-linking. 
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4.4.7. Localization studies of P. aeruginosa AmpR.  Although it is generally accepted 
that AmpR is a cytoplasmic protein, our bioinformatics analyses suggested that AmpR 
may be membrane associated. More specifically, a Kyte-and-Doolittle hydrophobicity 
plot (932) and the topology prediction softwares TopPred2 (933), DAS (934), MEMSAT 
(935), TMpred (936), and SCAMPI (937) suggested the presence of a transmembrane 
domain somewhere between amino acids 92 and 114 of P. aeruginosa AmpR.  The 
crystal structure of C. freundii AmpR, however, reveals this segment is near the protein-
protein interface of the dimer and thus unlikely to traverse the membrane (930).  
 In order to localize AmpR, phoA and lacZ were fused in-frame at amino acid 
positions Glu15, Val134 and Gln185 (Figure S2A, Supplemental material). Fusions at 
Glu15 were LacZ-positive and PhoA-negative, whereas fusions at Val134 and Gln185 
were PhoA-positive and LacZ-negative suggesting AmpR may traverse the inner 
membrane with the N and C termini in the cytoplasm and periplasm, respectively (Figure 
4.11). Since this data is only qualitative, localization of P. aeruginosa AmpR was further 
investigated with a protease protection assay using a C-terminal His-tagged AmpR that 
was shown to be functional (Table S2, Supplemental material).  Full length AmpR (32 
kDa) was detected in whole cell extracts, as well as, in spheroplasts preparations treated 
with Proteinase K (0-min incubation) that were immediately processed for 
immunoblotting (Figure S2B, Supplemental material). Incubations with Proteinase K of 5 
minutes or longer resulted in the visible reduction of full length AmpR and the 
appearance of the degradation product (10-kDa fragment). However, slight degradation 
of σ70 was observed.  The evidence provided here is suggestive of AmpR being an inner 
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membrane-associated protein. If confirmed, this would be an important finding and could 
have major implications regarding the regulation of two ampD amidase homologs that 
have now been localized to the periplasm (938, 939). The identity of the muramyl-
peptides that are important for regulating AmpR will further confirm its localization and 
is the subject of ongoing work in the lab. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11. AmpR model. A three-dimensional structure of AmpR was generated using 
RasMol (http://www.umass.edu/microbio/rasmol/). The topology of AmpR was 
investigated by introducing phoA and lacZ fusions at amino acid positions Glu15, 
Val134, and Gln185. Fusions at Glu15 were LacZ positive but PhoA negative, whereas 
fusions at Val134 and Gln185 were PhoA positive and LacZ negative. 
 
 Although the majority of purified LTTRs appear to be soluble cytoplasmic 
proteins, the nodulation factor, NodD, from Rhizobium species appears to be a peripheral 
membrane protein associated with the inner leaflet of the cytoplasmic membrane (940). A 
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few membrane-bound non-LTTRs have also been reported, such as the Salmonella 
enterica serovar Typhimurium acid-sensing CadC, the streptococcal CpsA involved in 
regulation of capsule production, and the Vibrio cholera toxin activator, ToxR (941-943). 
Since these proteins act as both signal sensor and response regulator, they form a simple 
but sophisticated form of transmembrane signaling system.  
 
4.5 Concluding Remarks 
 
 The role of AmpR as regulator of ampC expression has been clearly established in 
both the Enterobacteriaceae and P. aeruginosa. Our recent work has further redefined 
AmpR as a major global regulator, playing an important role in acute infections through 
its regulation of virulence, biofilm formation, quorum sensing and non-β-lactam 
resistance (710, 841-844).  Regulation of ampC, however, remains one of its most critical 
roles, as AmpC derepression is a prevalent mechanism of β-lactam resistance in P. 
aeruginosa.  
 In the present work we characterize some of the genetic and structural elements 
necessary for induction of ampC and important for the functioning of AmpR as regulator 
of AmpC β-lactamase expression. The presence of strong σ54 consensus sequences in the 
ampR promoter led us investigate its possible involvement in the regulation of ampR. 
However, contrary to what was expected, RpoN was not required for ampR expression in 
the conditions tested. Instead, RpoN was found to downregulate expression of both ampR 
and ampC, although the exact mechanism is yet unknown.  
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 Like other LTTRs, AmpR has two important regions critical for its functioning as 
activator/repressor of ampC expression: the HTH motif for binding to DNA and the 
effector binding domain for ligand interaction. Analysis of polar and charged amino acids 
on the AmpR HTH revealed two residues, Ser38 and Lys42, important for binding of 
AmpR to the promoter region and consequently for ampC promoter activation. A third 
residue, His39, was shown to be important for function but not for binding to PampC. In 
the effector binding domain, we examined the role of two amino acids, Gly102 and 
Asp135, previously shown to be important for maintaining AmpR in an inactive 
conformation in the enterobacteria.  In P. aeruginosa, Gly102 appears to be responsible 
for maintaining a stable structural conformation, while Asp135 is responsible for keeping 
AmpR in an inactive state that represses ampC expression. Additionally, our work 
suggests that AmpR dimerizes and that it is likely to be membrane associated.  This is the 
first comprehensive look at the P. aeruginosa AmpR and the promoter elements that it 
regulates.  
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Chapter 5 
 
 
 
 
General Discussion and Summary 
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5.1 Overview  
 
 The Infectious Diseases Society of America classified Pseudomonas aeruginosa 
as one of the troublesome ESKAPE
1
 pathogens that, along with Enterococcus faecium, 
Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, and 
Enterobacter spp., causes the majority of nosocomial infections and effectively evades 
the action of antibiotics (944, 945). The intractability of P. aeruginosa is owned to its 
intrinsic low membrane permeability, the presence of multidrug efflux pumps that can 
export more than one type of antimicrobial, and the expression of β-lactamases, enzymes 
which can hydrolyze and inactivate the commonly used β-lactam antibiotics (246, 270, 
317, 549, 946). In addition, P. aeruginosa can evolve resistance after treatment with 
antibiotics through mutations in resistance genetic determinants or their regulator-
encoding genes (247, 313, 336, 749, 947-949).  
 P. aeruginosa also has an innate ability to acquire resistance genes from the 
environment and is often a natural reservoir of multiple plasmid-encoded β-lactamases 
(549, 950). Chromosomally, P. aeruginosa carries AmpC, a class C β-lactamase that 
plays a major role in intrinsic resistance against penicillin- and cephalosporin-type β-
lactams (711). Mutational derepression of this enzyme, whereby AmpC is produced at 
high levels irrespective of the presence or absence of β-lactams, is currently one of the 
most common mechanisms of β-lactam resistance in the clinical setting (379, 380, 722, 
749).  
                                                 
 
1
 ESKAPE is an acronym for the six pathogens, Enterococcus faecium, Staphylococcus aureus, Klebsiella 
pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp., which are 
currently a major problem in the hospital setting. 
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 This dissertation delved into the role of a second chromosomally encoded β-
lactamase in P. aeruginosa termed PoxB. This work established PoxB is an oxacillinase-
type β-lactamase with a narrow spectrum of hydrolysis that includes the carbapenems 
imipenem, meropenem and doripenem. The currently available β-lactamase inhibitors did 
not significantly affect PoxB activity as commonly seen for class D enzymes. In addition, 
PoxB was shown to form a two-gene operon with the upstream open reading frame poxA, 
whose expression exerted negative control on the pox promoter. The transcriptional 
regulator AmpR negatively impacted pox expression but this regulation did not occur by 
binding to the promoter. A mutant transposon library, constructed to screen for regulators 
of pox expression, identified two clones with insertions in genes involved in polyamine 
transport.  Polyamines coincidently were shown to provide resistance against imipenem 
and meropenem. In summary, two chromosomal-encoded β-lactamases with 
complementing hydrolytic spectrums have the potential to provide P. aeruginosa with 
resistance against most classes of β-lactams including the penicillins, cephalosporins and 
carbapenems. 
 
5.2 PoxB is a chromosomal-encoded class D carbapenemase. Class D β-lactamases are 
predominantly found in P. aeruginosa and in A. baumannii, but have also been reported 
in Escherichia coli, K. pneumoniae, and Proteus mirabilis, among others (606, 685). 
Three distinct oxacillinase categories are now recognized: the narrow-spectrum, the 
extended-spectrum and the carbapenem-hydrolyzing oxacillinases (680). Carbapenem-
hydrolyzing class D β-lactamases (CHDLs), are widespread in the nosocomial pathogen 
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A. baumannii but have also been occasionally reported in K. pneumoniae and 
Acinetobacter spp., as well as and in a few of the Enterobacteriaceae (680, 685). CHDLs 
are less common in P. aeruginosa and to date only three CHDLs have been reported 
there: OXA-40, OXA-198 and, of course, OXA-50 or PoxB (549, 740, 741, 951, 952). 
 Specifically, a plasmidic carbapenemase was detected in two unrelated imipenem-
resistant P. aeruginosa isolates from northern Spain where OXA-40-producing A. 
baumannii were found to be common (951, 953, 954). The nucleotide sequence in fact 
showed 100% identity to the previously described blaOXA-40 from an A. baumannii isolate 
endemic to this area (951). Thus, one of the first OXA-type carbapenemases detected in 
P. aeruginosa was termed OXA-40 (954). Similarly, OXA-198 was identified in the 
imipenem-resistant clinical isolate PA41437 (952). OXA-198 was encoded in a plasmid-
borne integron but was not closely related to other OXA enzymes. Biochemically, OXA-
198 behaved similarly to other CHDLs, exhibiting a strong affinity for carbapenems but 
low rate of hydrolysis (952). Its expression in a heterologous host provided resistance 
against ticarcillin and decreased susceptibility against piperacillin, cefepime, and the 
carbapenems and but not against aztreonam and extended-spectrum cephalosporins (952). 
Although the clinical strain PA41437 was resistant to imipenem and displayed a high 
minimum inhibitory concentration (MIC) against meropenem (12 µg/ml), OXA-198 
expression in trans only decreased susceptibility against these drugs, suggesting other 
mechanisms of resistance were operating in the PA41437. Sequencing of oprD revealed a 
number of mutations and an 88-bp deletion in this strain (952).  
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 To our knowledge PoxB (OXA-50), is the first carbapenem-hydrolyzing class D 
β-lactamase reported in P. aeruginosa (740, 741). Similar to OXA-198, OXA-50 is only 
weakly related to other class D enzymes, displaying 43-47% homology to CHDLs from 
the OXA-23 and OXA-229 group found in A. baumannii and Acinetobacter spp.  Unlike 
the other two OXA enzymes reported in P. aeruginosa, OXA-50 is carried on the 
chromosome and ubiquitously found in environmental and clinical P. aeruginosa isolates 
(740). The goal of this dissertation was to characterize the naturally occurring class D β-
lactamase PoxB and determine its contribution to intrinsic resistance in P. aeruginosa.  
 Since the class C, chromosomal encoded AmpC β-lactamase is known to play a 
major a role in both the intrinsic and acquired resistance against β-lactams in P. 
aeruginosa, the role of PoxB was investigated in strains carrying clean deletions of the β-
lactamase-encoding genes (PA0∆ampC, PA0∆poxB and PA0∆ampC∆poxB). This work 
clearly showed AmpC confers protection against penicillins and cephalosporins. 
Specifically, an ampC deletion rendered strains susceptible to the aminopenicillins 
(ampicillin and amoxicillin) but produced only a small decrease in MIC for imipenem 
and doripenem (Chapter 2, Table 2.2). Overexpression of AmpC in PA0∆ampC restored 
resistance against the aminopenicillins and additionally provided resistance or 
significantly increased MICs (decreased susceptibility) against the cephalosporins and the 
rest of the penicillins (Chapter 2, Table 2.3). A slight decrease in susceptibility was also 
observed against doripenem but not against imipenem or meropenem suggesting the 
carbapenems are not good substrates of the AmpC β-lactamase.  
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 The role of PoxB, on the other hand, was not readily observed in the natural 
background. For instance, a poxB deletion failed to alter susceptibility in the presence or 
absence of ampC (Chapter 2, Table 2.2). Similarly, the amount β-lactamase activity 
produced by a poxB deletion strain (PA0∆poxB) was comparable to that of wild-type 
PA01 (Chapter 2, Figure 2.3). PA0∆ampC, on the other hand, failed to produce any 
detectable β-lactamase activity in the presence or absence of chromosomal poxB. This 
suggests that the activity detected in wild-type and poxB deletion strains was due to the 
presence of AmpC. PoxB thus appears to be expressed at very low, marginal levels in the 
lab strain PA01 under the tested experimental conditions.  
 Expression of poxB from an IPTG-inducible promoter in an ampC-deficient strain 
(PA0∆ampC) or in an ampCpoxB deletion strain (PA0∆ampC∆poxB), however, increased 
the MIC, thereby decreasing susceptibility, against the carbapenems doripenem and 
meropenem, but produced little to no change against the penicillins and cephalosporins 
(Chapter 2, Table 2.3). It is well-documented that clinical strains can develop resistance 
to imipenem after treatment with said carbapenem (304, 313, 314, 955). Mutations, 
deletions and insertions usually occur in oprD, encoding an outer membrane porin 
specific for the uptake of imipenem, and result in impaired/lost function of the porin 
(313, 315, 947, 955).  Similarly, in our studies loss of the outer membrane porin, OprD, 
specific for the uptake of imipenem, extended the hydrolysis spectrum of PoxB to include 
imipenem and enhanced the carbapenem-hydrolyzing phenotype leading to clinical 
intermediate and resistant phenotypes (Chapter 2, Table 2.4). Thus, PoxB is a 
carbapenem-hydrolyzing class D β-lactamase.  
208 
 
 In agreement with our studies, previous work by Girlich et. al examining the 
biochemical properties of PoxB, failed to detect hydrolysis of oxacillin, cloxacillin, 
cefepime, cefotaxime, ceftazidime and aztreonam, among others (741). Hydrolysis of 
various other penicillins and cephalosporins, however, was detected, as well as of 
nitrocefin, meropenem and imipenem. PoxB, however, displayed low affinity, high Km, 
for most β-lactams tested, with the exception of imipenem and nitrocefin for which Km 
values of 20 and 200 µM were obtained, respectively (741). Hydrolysis of both imipenem 
and meropenem, nonetheless, was very low, with meropenem exhibiting even weaker 
hydrolysis than that of imipenem. PoxB expression did afford the cell decreased 
susceptibility against meropenem in the previous and present study (741). In the current 
work, PoxB expression additionally increased MIC against doripenem, and in the absence 
of OprD against imipenem. Protection against imipenem was not previously detected in 
the work of Girlich et. al despite PoxB exhibiting high affinity for this β-lactam, as 
experiments were conducted in oprD
+ 
strains. 
 The current study further tested the effect of class A β-lactamase inhibitors, 
tazobactam, sulbactam and clavulanic acid, on the activity of PoxB (Chapter 2, Figures 
2.7 and 2.8). These compounds did not significantly affect PoxB activity and thus were 
considered poor inhibitors and likely also poor substrates of the enzyme. That OXA-50 is 
resistant to inhibition is not surprising as in general, class D enzymes are not significantly 
inhibited by clavulanic acid, sulbactam, and tazobactam (428, 467). Exceptions include 
OXA-53 (956), OXA-18 (957) and OXA-45 (958) all inhibited by clavulanic acid, OXA-
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12 (735) inhibited by both clavulanic acid and tazobactam, and OXA-2 and its point 
mutant OXA-32 that are susceptible to inhibition by tazobactam (959).  
 Avibactam, a new non-β-lactam-type inhibitor, was also a poor inhibitor of PoxB 
(Chapter 2, Table 2.6). Avibactam has been shown to successfully inhibit class A and C 
enzymes, but has generally lacked activity against A. baumannii isolates expressing 
OXA-type β-lactamases (804, 805). Significant activity has been observed against the 
CHDL OXA-48, but a kinetics study showed that the rate of inhibition was lower than 
that for class A and C enzymes (805, 816). Thus inhibition of class D enzymes still 
remains a problem in the clinical setting where the commercially available inhibitors are 
not generally active against OXA enzymes. In this respect, OXA-50 is a typical class D 
β-lactamase.  In vitro inhibition by NaCl, often used as a defining characteristic of most 
oxacillinases, was also observed for PoxB. This inhibition, although readily detected in 
crude extracts from PoxB-expressing cells, was only slightly noticeable by the broth 
microdilution method (Chapter 2, Figures 2.9 and 2.11).  
 In summary, although exhibiting relatively low homology to other class D 
enzymes, in most respects, PoxB is a typical class D carbapenemase. In general, CHDLs 
do not significantly hydrolyze extended-spectrum cephalosporins but do exhibit some 
level of hydrolysis against the penicillins, mainly benzylpenicillin, ampicillin, piperacillin 
and ticarcillin (680, 693, 960). Additionally, CHDLs display low Km values for 
imipenem, lower than for other β-lactams, suggesting very high affinity for this substrate 
(680, 685, 960). Hydrolysis rates for both imipenem and meropenem, however, remain 
very low.  
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 In its natural host and under the conditions tested, poxB seems to be expressed at 
very low levels which do not contribute to the intrinsic resistance of PA01. This raises the 
question of the natural role of this operon in P. aeruginosa. Does the poxAB operon play 
a yet unidentified role besides that of resistance? Further, we know that increasing the 
expression of PoxB can lead to decreased susceptibility or resistance against the 
carbapenems, but the relevance of OXA-50 in the clinical setting is not yet known.   
 Although poxB expression appears to be constitutive and unregulated, it is 
possible that mutations in the promoter region or insertion elements could lead to its 
expression in a way that contributes to resistance as seen in other bacteria. For example, 
A. baumannii often carries the chromosomal ampC but lacking ampR, expression is 
normally non-inducible (961, 962). Ceftazidime resistance in this pathogen however, has 
been linked to increased expression of ampC due to the presence of the upstream 
insertion element ISAba1 with strong promoter sequences (963, 964). ISAba1 was absent 
from ceftazidime-susceptible strains (724, 965). This insertion sequence seems to be 
prevalent in carbapenem-resistant A. baumannii isolates where it has been reported in 
association with blaOXA-51-like and blaOXA-23-like genes (700, 725, 727). Although ISAba1 
has not been reported in P. aeruginosa, promoter sequences in ISPa12 have been found 
to drive expression of the extended-spectrum β-lactamase-encoding gene blaPER-1 in P. 
aeruginosa, Providencia stuartii, A. baumannii and Salmonella enterica serovar 
Typhimurium (728). Similarly, expression of the extended-spectrum β-lactamase-
encoding gene, blaVEB-1, in ceftazidime-resistant P. aeruginosa isolates was found to be 
driven by promoter sequences within the upstream-located IS1999 (966). Thus, 
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upregulation of gene expression by insertion sequences is a plausible mechanism of PoxB 
overexpression. 
 As a sole mechanism of resistance, poxB expression may be easy to overlook as 
the changes in MIC against carbapenems may not be substantial. Moreover, carbapenem 
resistance is often linked to mutations or insertions in oprD, and screening of the poxB 
ORF and its promoter are not routinely done. This work showed that, when combined, 
the concerted expression of poxB and the loss of oprD can lead to resistance and/or 
significant MIC changes. Thus, although constitutively expressed in PA01, the role of 
PoxB in P. aeruginosa in the clinical setting may currently be overlooked.  
 
5.3 Regulation of poxB. After establishing the role of PoxB as a carbapenem-
hydrolyzing class D β-lactamase, its regulation was investigated (Chapter 3). As previous 
work pointed to the involvement of the transcriptional regulator AmpR (710), expression 
of poxB was examined by RT-PCR in the presence and absence of ampR (Figure 3.3). A 
small but significant increase in expression was observed in the absence of ampR and in 
the presence of β-lactams suggesting AmpR normally acts to downregulate poxB 
expression. Similarly, promoter studies using reporter strains carrying Ppox-lacZ fusions 
were in agreement with the mRNA data (Figure 3.8). Specifically, induction of poxB 
could be achieved only in the absence of ampR and in the presence of β-lactams (Chapter 
3). Interestingly these changes could not be observed at the protein level in terms of β-
lactamase activity.  
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 AmpR is an interesting candidate for regulator of pox expression.  As a LysR-type 
transcriptional regulator, AmpR carries an N-terminal HTH motif to interact with DNA 
and an effector binding domain in the C-terminus for ligand interaction (852, 856, 897). 
As detailed in Chapter 4 of this dissertation, AmpR activates transcription of ampC in the 
presence of β-lactams but maintains expression at low basal levels in the absence of such 
compounds, thus acting as both a negative and positive regulator of ampC expression 
(710, 711, 776). AmpR has additionally been shown to have an extensive regulon that 
includes a number of characterized and putative transcriptional and sigma factors, as well 
as genes involved in quorum sensing and virulence (710, 841, 843). That the regulon of 
AmpR includes transcriptional regulatory proteins suggests AmpR-dependent expression 
may occur by indirect regulation. Our EMSA studies in fact, failed to show binding of 
AmpR to the pox promoter (Figure 3.5), suggesting regulation by AmpR is indirect.  
 In an effort to identify possible pox regulators, a genome-wide approach was 
undertaken using the reporter strains PA0::Ppox-lacZ and PA0∆ampR::Ppox-lacZ (Chapter 
3, Section 3.4.5). The strains were mutagenized with a random mariner transposon (Tn) 
in order to identify clones with increased or decreased lacZ expression indicative of 
altered pox promoter expression. This study generated a wealth of clones that are still 
being screened and evaluated. Two noteworthy clones however, identified based on their 
increased lacZ expression, had insertions in spuE (PA0301) and PA0322, genes involved 
in a characterized and a putative polyamine uptake system, respectively. 
 Polyamines (putrescine, cadaverine, spermidine, spermine) are essential 
molecules found in all domains of life (845, 847). Bacteria can synthesize, catabolize and 
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uptake these molecules for a number of diverse processes as described in Chapter 3 (845, 
847, 878). Interestingly, polyamines have been found to sensitize a number of bacterial 
species to multiple β-lactams including penicillins, cephalosporins and monobactams 
(886, 893). This sensitization did not appear to occur by an increase in outer membrane 
permeability as expected of polyamines given their cationic nature. On the other hand, 
polyamines provided resistance against the β-lactam imipenem in P. aeruginosa 
seemingly through blockage of OprD, the major route of entry for imipenem into the cell 
(893).  
 In order to determine if the increased lacZ expression in mutants containing Tn 
insertions in spuE and PA0322, was due to an increase in pox expression, the 
susceptibility of the mutants to carbapenems was investigated in the presence and 
absence of polyamines (Chapter 3, Table 3.7). Our studies show that polyamines 
significantly increased MICs, or decreased susceptibility, against ceftazidime, piperacillin 
and the carbapenems, but not against aztreonam, in both unmutagenized and Tn-
mutagenized strains. This increased in MIC is likely the result of blockage of OprD as 
well as other porins, as ceftazidime and piperacillin are not known to use the OprD porin 
for passage into the cell. If resistance is occurring by blocking of porins, then the 
polyamines do not necessarily need to come into the cell to exert their action. This would 
explain why polyamines could raise MICs in what appear to be a strain-independent 
manner. The resistance provided was independent of polyamine uptake pathways and as 
such the spuE and PA0322 Tn insertions did not affect susceptibility. That the polyamine 
spermidine (10 mM) could induce resistance against both imipenem and meropenem 
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(>32 µg/ml) likely suggests that polyamines more efficiently block OprD than other 
porins and that meropenem and imipenem preferentially enter the cell via this route.  
 Alternatively, although the function of these genes may be impaired, since there 
are other polyamine transport systems, both putative and characterized, the disruptions 
imposed by the Tn insertions could potentially be overcome by other such systems.  
Thus, polyamines could still enter the cell to exert their action, e.g., modulation of gene 
expression. For instance, SpuE is a periplasmic binding protein that specifically binds 
spermidine, but the spuABCDEFGH gene cluster that encodes it also encodes SpuD, 
another periplasmic binding protein that although preferentially binds to putrescine, can 
also bind and transport spermidine (864, 883). Thus, this system is also likely involved in  
the uptake and transport of both spermidine and putrescine. The presence of 
spuABCDEFGH probably also compensates for the loss of PA0322 a putative, not yet 
proven putrescine transporter. Other putative polyamine transport and utilization systems 
are also encoded in the general vicinity of the spu gene cluster. The redundancy of such 
system may illustrate how essential these molecules are for survival. 
 It is worth noting that the Tn insertion into spuE likely also led to disruption of 
transcription for the rest of the operon, spuFGH, encoding the ATPase for transport and 
the two permeases, respectively. Since the Tn contained an outwardly-directed promoter 
and the insertion occurred with the promoter in the direction of transcription of these 
genes, it is likely that transcription of these downstream ORFs did occur. As experiments 
revealed in Chapter 3, the outward-facing promoter of this mariner transposon was very 
strong.  
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 An alternative explanation for the polyamine-dependent MIC increase could be 
the induction of genes that themselves confer resistance, such as those involved in efflux. 
Although polyamines have not been shown to induce expression of efflux pumps, 
spermidine did provide resistance against cationic peptides and quinolones by inducing 
expression of oprH-phoPQ and the LPS modification operon (885). It is likely we don’t 
yet know all the current targets of polyamines. 
 The β-lactamase profiles of spuE (PA0301) and PA0322 Tn mutants were not 
altered as compared to wild-type as would be expected if such insertions affected pox 
expression. Although the increased lacZ expression phenotype displayed by these 
mutants appears to be unconnected to Ppox expression, that we have stumbled upon yet 
another condition that contributes to carbapenem resistance is very interesting. To 
conclusively prove pox involvement, the transcript levels would have to be quantified in 
spuE and PA0322 mutants. 
 
5.4 Future directions. Previous studies showed poxB is ubiquitous in P. aeruginosa 
clinical and environmental isolates (741), yet its expression and contribution to β-lactam 
resistance has not been analyzed in such backgrounds. Traditionally, carbapenem 
resistance in P. aeruginosa has been provided by the loss of OprD and the expression of 
class B β-lactamases, especially the VIM and IMP-types (549, 947, 955, 967-969). OXA-
50, however, is not routinely screened for and thus its true contribution in the clinical 
setting is unknown.  
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 Future studies should elucidate on the role of PoxB in clinical isolates, especially 
for those that are shown to be carbapenem non-susceptible (intermediate and resistant 
phenotypes). Using PCR-based methods, the gold standard for identifying β-lactamases, 
the presence of metallo-β-lactamases and OXA-type enzymes, including OXA-50, could 
be detected.  Since the mere presence of PoxB does not imply its expression, its mRNA 
levels should be quantified. Alternatively, the actual protein could be quantified by doing 
Western blot. Sequencing of the oprD ORF should also be done in carbapenem non-
susceptible isolates to determine contribution of this porin to resistance.  
 Another area of this research to expand could involve identification of other 
potential roles for PoxB and the pox operon besides that of resistance. Phenotypic 
microarrays (Biolog, Hayward, CA) could help identify other such functions. Such arrays 
typically measure the rate of respiration over a period of time under a number of 
environmental conditions including ranges of salinity, pH, nitrogen, carbon, phosphorus 
and sulfur sources, as well as many antimicrobial drugs and chemical compounds. In this 
respect two strains will be critical: poxB and poxAB deletion mutants.  
 A phenotypic microarray has been carried out in PA0∆poxA and pointed to a 
growth defect in the presence of NaNO3, leading us to investigate morphology in anoxic 
and oxic environments. While the NaNO3 phenotype could not be reproduced, we did 
observed PoxA-expressing strains were able to bind the dye Congo red (CR) better 
presumably because of increased production of an extracellular polymeric substance. The 
CR-binding phenotype was not reproducible or readily observed in liquid media as is 
often seen with strains that overproduce Pel and Psl polysaccharides. Thus, it is likely 
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that the CR-binding phenotype is due to production of a polysaccharide or a CR-binding 
substance other than Pel or Psl.  In order to rule out the involvement of Pel or Psl 
polysaccharides, expression of some of the genes of pel an psl operons could be 
quantified by RT-PCR. Additionally, the carbohydrate composition of the CR-binding 
substance being produced in PoxA-expressing cells could be investigated by gas 
chromatography/mass spectrometry as previously described (768, 825). 
 Although screening and confirmation of the Tn mutant library was well 
underway, more than 50% of the library still remains to be screened and/or evaluated. 
Thus, a continuing project could involve further screening with the clones that still 
remain to be investigated. Although the relationship between pox expression and 
polyamine transport identified by the transposon screening is not yet clear, polyamine-
induced resistance and susceptibility in P. aeruginosa is by itself an interesting and 
worthy area of study. A microarray could elucidate on the targets of these essential 
molecules and the link to carbapenem resistance. 
 Carbapenem resistance has become an increasing problem in the nosocomial 
pathogen A. baumannii with the predominant mechanism of resistance being the 
expression of OXA enzymes (622, 692, 708, 709, 726, 820). Carbapenems are often the 
drug of choice for treating organisms expressing extended-spectrum β-lactamases 
(ESBLs) which can hydrolyze penicillins and cephalosporins. There is a real concern that 
treatment with such compounds can lead to ESBLs that additionally can hydrolyze 
carbapenems. Thus, there is a need to develop effective class D β-lactamase inhibitors. 
Although not yet prevalent in P. aeruginosa, CHDLs have the potential to become 
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widespread, as they have in the closely related Pseudomonadales species A. baumannii, 
given its genomic plasticity and ability to acquire resistance genes from the environment. 
P. aeruginosa already carries PoxB, a chromosomal carbapenem-hydrolyzing β-
lactamase, ubiquitous in clinical and environmental isolates, and with the potential to 
become yet another tool in the arsenal of this intractable pathogen against the β-lactam 
antibiotics. 
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Table S1: Bacterial strains, plasmids, and primers used in this study 
Strains/ Plasmids Relevant phenotype and genotype Source 
Escherichia coli   
E. coli  DH5α F
-
Φ80lacZΔM15 Δ (lacZYA-argF)U169 deoR recA1 
endA1 hsdR17 (rk
-
 mk
+
) phoA supE44 λ
- thi-1 gyrA96 
relA1 
New 
England 
Biolabs 
   
Pseudomonas aeruginosa  
PA01 Wild-type  (762) 
PA06358 PA0rpoN , PA01 containing in-frame deletion of a 
0.9-kb fragment from the rpoN gene (PA4462) 
(970) 
PKM106 PA0attB::mini-CTX-lacZ; TcR This study 
PKM107 PA0attB::PampC352-lacZ; TcR  This study 
PKM108 PA0attB::PampC193-lacZ; TcR  This study 
PKM109 PA0attB::PampC171-lacZ; TcR  This study 
PKM110 PA0attB::PampC151-lacZ; TcR  This study 
PKM111 PA0attB::PampC-130-lacZ; TcR  This study 
PKM112 PA0attB::PampC-111-lacZ; TcR  This study 
PKM113 PA0attB::PampC90-lacZ; TcR  This study 
PKM114 PA0attB::PampC70-lacZ; TcR  This study 
PKM115 PA0attB::PampC51-lacZ; TcR  This study 
PKM116 PA0attB::PampR193-lacZ; TcR  This study 
PKM201 PA0ampC , PA01 containing in-frame deletion of 
ampC  
(760) 
PKM315 PA0ampR , PA01 containing in-frame deletion of 
ampR  
(843) 
PKM318 PA0ampRVSV-G; VSV-G tag added in-frame to AmpR This study 
   
Plasmids   
pBSK(+) ApR; ColE1ori lacZα Stratagene 
pEXG2 GmR; pMB1ori sacB (759) 
pP30ΔFRT-MvaT-V GmR; ColE1ori RP4 (mob) aacC1, integration-
proficient vector containing VSV-G epitope tag 
(908) 
pSJ01 ApR, pGEMEX-1 with a 1220-bp EcoRI-BamHI-
flanked fragment containing ampR 
(710) 
pTrcphoA 
ApR, low-copy trc promoter expression vector 
carrying lacIq and phoA 
(911) 
pTrclacZ 
ApR, low-copy trc promoter expression vector 
carrying lacIq and lacZ 
(911) 
Mini-CTX-lacZ Tc
R
; Integration-proficient vector for single-copy 
chromosomal lacZ fusion at the attB site 
(853) 
pMMB67EH-Gm GmR; IncQ, RSF1010, lacIq Ptac expression vector  
with ampR::aacC1 insertion at DraI 
(763) 
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pP30FRT-AmpR-V pP30FRT-MvaT-V digested with HindIII and NotI 
to release mvaT and carrying  540-bp 3’ fragment of 
ampR fused in-frame with VSV-G tag 
This study 
pOC1 TcR; PampC352 fused to the lacZ of mini-CTX-lacZ This study 
pOC2 TcR; PampC193 fused to the lacZ of mini-CTX-lacZ  This study 
pOC3 TcR; PampC171 fused to the lacZ of mini-CTX-lacZ This study 
pOC4 TcR; PampC151 fused to the lacZ of mini-CTX-lacZ This study 
pOC5 TcR; PampC130 fused to the lacZ of mini-CTX-lacZ This study 
pOC6 TcR; PampC111 fused to the lacZ of mini-CTX-lacZ This study 
pOC7 TcR; PampC90 fused to the lacZ of mini-CTX-lacZ This study 
pOC8 TcR; PampC70 fused to the lacZ of mini-CTX-lacZ  This study 
pOC9 TcR; PampC51 fused to the lacZ of mini-CTX-lacZ This study 
pOC10 TcR; PampR193 fused to the lacZ of mini-CTX-lacZ This study 
pOC11 ApR; pBSK-AmpR-His6 (933-bp EcoRI-BamHI 
fragment containing AmpR His-tagged at C-
terminus) 
This study 
pOC12 ApR; pOC11-AmpRSer38Ala  This study 
pOC13 ApR; pOC11-AmpRHis39Ala  This study 
pOC14 ApR; pOC11-AmpRLys42Ala This study 
pOC15 ApR; pOC11-AmpRSer43Ala This study 
pOC16 ApR; pOC11-AmpRGlu46Ala This study 
pOC17 ApR; pOC11-AmpRGly102Glu This study 
pOC18 ApR; pOC11-AmpRAsp135Asn This study 
pOC19 
GmR; pMMB67EHGM containing  933-bp EcoRI-
BamHI ampR-His6 fragment from pOC11 
pAmpR-
His6,  This 
study 
pOC20 GmR; pMMB67EHGM with EcoRI-BamHI fragment  
containing AmpR-His6- Ser38Ala from pOC12 
This study 
pOC21 GmR; pMMB67EHGM with EcoRI-BamHI fragment  
containing AmpR-His6- His39Ala from pOC13 
This study 
pOC22 GmR; pMMB67EHGM with EcoRI-BamHI fragment  
containing AmpR-His6-Lys42Ala from pOC14 
This study 
pOC23 GmR; pMMB67EHGM with EcoRI-BamHI fragment  
containing AmpR-His6-Ser43Ala from pOC15 
This study 
pOC24 GmR; pMMB67EHGM with EcoRI-BamHI fragment  
containing AmpR-His6-Glu46Ala from pOC16 
This study 
pOC25 GmR; pMMB67EHGM with EcoRI-BamHI fragment  
containing AmpR-His6-Gly102Glu from pOC17 
This study 
pOC26 GmR; pMMB67EHGM with EcoRI-BamHI fragment  
containing AmpR-His6-Asp135Asn from pOC18 
This study 
pKK862 ApR, pTrclacZ derivative with a 1220-bp fragment 
containing ampR and the lacZ gene at HindIII site 
This study 
pKK863 ApR, pTrcphoA derivative with a 1220-bp fragment 
containing ampR and the phoA gene at HindIII site 
This study 
pKK864 ApR, pTrclacZ derivative with a 1220-bp fragment 
containing ampR and the lacZ gene at HincII site 
This study 
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pKK865 ApR, pTrcphoA derivative with a 1220-bp fragment 
containing ampR and the phoA gene at HincII site 
This study 
pKK866 ApR, pTrclacZ derivative with a 1220-bp fragment 
containing ampR and the lacZ gene at PstI site  
This study 
pKK867 ApR, pTrcphoA derivative with a 1220-bp fragment 
containing ampR and the phoA gene at PstI site 
This study 
   
Primers   
DZampCUF1 5’-GGAATTCAAGACGATGCTCCGGGTCAGTG-3’ (760) 
DZampCUR1 
5’-GATACCAGATTCCCCTGCCTGTCTAGCTAGCTAGA 
ATGCTC-3’ 
(760) 
DZampCDF2 
5’-CTAGCTAGCTAGAATGCTCAAGCGCGCTCGCGAGG  
GCGA CGGA-3’ 
(760) 
DZampCDR2 5’-CGGGATCCGACCCTGCATACCATCAAGG-3’ (760) 
KMampRUF1 5’-GGAATTCAGCCTGGAACTTCCGCAATCTCGACG 
AGA-3’ 
(843) 
KMampRUR1 5’GAGCATTCTAGCTAGCTAGGTTCGCCACCGAAGT  
GAGTACC-3’ 
(843) 
KMampRDF2 5’-CTAGCTAGCTAGAATGCTCAATGGGGTCGAACCAA 
TCTCT GCTCC-3’ 
(843) 
KMampRDR2 5’ CGGGATCCGATGCTCGGGTTGGAATAGA-3’ (843) 
OCAmpR-His-For 
5’-ACAGAATTCGAAGGAGATATACCTTGGTTCGACCC 
CATTT GCC-3’ 
This study 
OCAmpR-His-Rev 
5’-GAGGATCCTTAGTGATGATGATGATGATGTCTCCC 
CCGCGCCTCAACGGCAGCC-3’ 
This study 
SBJ03ampCRFor 
5’-GGAATTCTGAGGCCGCGCGGCAGACGCTTGAACA-
3’ 
This study 
OCPampC For193 5’-CGGGAATTCGCGGCAAATGGGGTCGAACC-3’ This study 
OCPampC For173 5’-CGGGAATTCTCTCTGCTCCAAATTTTTCT-3’ This study 
OCPampC For151 5’-CGGGAATTCAATGGCTGCCGCGAGTATTCG-3’ This study 
OCPampC For131 5’-CGGGAATTCTCGTTTGCCGCAAATCCTGC-3’ This study 
OCPampC For111 5’-CGGGAATTCGCAAGCCTAGATTTTCCCCG-3’ This study 
OCPampC For91 5’-CGGGAATTCCCCGCCGATCAAGGAGCGCT-3’ This study 
OCPampC For71 5’-CGGGAATTCCCCGGGGCGGTTTCTCATGC-3’ This study 
OCPampC For51 5’-CGGGAATTCAGCCAACGACAAAGGACGC-3’ This study 
OCPampC RevBc 5’-CGGGGATCCTCAGGGGAATCTGGTATCGCG-3’C This study 
OCPampR Rev193 5’-CGGGGATCCGCGGCAAATGGGGTCGAACC-3’ This study 
OCPampR ForEc 5’-CGGGAATTCCAGGGGAATCTGGTATCGCGC-3’ This study 
alg44 For 5’-CGAAGCCCAGCGCCAGTTCG-3’ This study 
alg44 Rev 5’-GGTCCACCGAGCGCACCTGG-3’ This study 
AmpRSer38AlaFor 5’-ACCCAGGCGGCGGTCGCCCACCAGGTGAAGAGC-3’ This study 
AmpRSer38AlaRev 5’-GCTCTTCACCTGGTGGGCGACCGCCGCCTGGGT-3’ This study 
AmpRHis39AlaFor 5’-CAGGCGGCGGTCAGCGCCCAGGTGAAGAGCCTC-3’ This study 
AmpRHis39AlaRev 5’-GAGGCTCTTCACCTGGGCGCTGACCGCCGCCTG-3’ This study 
AmpRLys42AlaFor 5’-GTCAGCCACCAGGTGGCGAGCCTCGAGGAGCGT-3’ This study 
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AmpRLys42AlaRev 5’-ACGCTCCTCGAGGCTCGCCACCTGGTGGCTGAC-3’ This study 
AmpRSer43AlaFor 5’-AGCCACCAGGTGAAGGCCCTCGAGGAGCGTCTC-3’ This study 
AmpRSer43AlaRev 5’-GAGACGCTCCTCGAGGGCCTTCACCTGGTGGCT-3’ This study 
AmpRGlu46AlaFor 5’-GTGAAGAGCCTCGAGGCGCGTCTCGGCGTGGCC-3’ This study 
AmpRGlu46AlaRev 5’-GGCCACGCCGAGACGCGCCTCGAGGCTCTTCAC-3’ This study 
AmpRGly102GluFor 
5’-
CACCGTCGGCGCGGTCGAAACCTTCACGGTCGGTT-3’ 
This study 
AmpRGly102GluRev 
5’-
AACCGACCGTGAAGGTTTCGACCGCGCCGACGGTG-3’ 
This study 
AmpRAsp135Asn 
For 
5’-CCCACAACAACCGCGTCAACATCGCCGCCGAGGG-
3’ 
This study 
AmpRAsp135Asn 
Rev 
5’-CCCTCGGCGGCGATGTTGACGCGGTTGTTGTGGG-
3’ 
This study 
5RA-PampC233 5’-GGGTCTCCGGCGTCACCCGG-3’ This study 
5RA-PampC154 5’-GGCTACGGCCAGGCCCGG-3’ This study 
5RA-PampC113 5’-CCGGTTGTACGGCGGCGTCG-3’ This study 
5RA-PampR229 5’-GCAGGCCGGCGATGCGGTCG-3’ This study 
5RA-PampR169 5’-GGTCAGCATGAGGCCGCGCG-3’ This study 
5RA-PampR99 5’-CCTGGTGGCTGACCGCCGCC-3’ This study 
Qt 
 5’- 
GCCAGGTGAGCAGGAGTGACGGGAATTCAGCTGGAT 
CCTGCACCCTTTTTTTTTTTTTTTTTT-3’ 
(764) 
Q0 5’- GCCAGGTGAGCAGGAGTGACG-3’  (764) 
Qi 5’-GGAATTCAGCTGGATCCTGCACCC-3’ (764) 
DBS_ChIP_ampCF 5’-GGTCGAACCAATCTCTGCTCCAAA-3’ (841) 
DBS_ChIP_ampCR 5’-TTGTCGTTGGCTGCATGAGAAACC-3’ (841) 
DBS_qRT_clpXF 5'-TGCGATTACGATGTGGAGA-3' (843) 
DBS_qRT_clpXR 5'-CCCTCGATGAGCTTCAGCA-3' (843) 
DBS_QRTAmpRFwd 5’-CATTGGCCTTCATCACCGGTTGTA-3’ (760) 
DBS_QRTAmpRRev 5’-GGTTTCTCATGCAGCCAACGACAA-3’ (760) 
qRT_ampCF 5'-CGCCGTACAACCGGTGAT-3'  (971) 
qRT_ampCR 5'-CGGCCGTCCTCTTTCGA-3'  (971) 
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His-tagged AmpR is functional. PA0ΔampR was complemented with the vector, 
pMMB67EH-Gm, or with the His-tagged AmpR.  β-lactamase assays show that in the 
absence of AmpR there is low constitutive ampC expression (Table S2).  However, 
overexpression of AmpR-His6 in PA0ΔampR in the presence of β-lactams restores the β-
lactamase activity to that of the wild-type induced strain. Additionally, the inherently 
resistant PA01 strain shows a significant increase in sensitivity to both amoxicillin and 
ampicillin when ampR is deleted, as determined by E-test (Table S2).  The resistance is 
restored upon complementation with AmpR-His6. The AmpR-His6 construct thus 
complements the ampR deletion and retains its native function. 
 
Table S2: Complementing assays showing His-tagged AmpR is functional. 
Strains 
Minimum Inhibitory 
Concentration (µg ml-1) * 
β-Lactamase Specific Activity 
(nmol min
-1
 mg protein
-1
) † 
Amoxicillin 
Ampicillin-
Sulbactam 
- β-lactam + β-lactam 
PA01 >256 >256 0.040 + 0.012 0.872 + 0.032 
PA0∆ampR (pVector)^ 7 14 0.035 + 0.007 0.031 + 0.011 
PA0∆ampR (pAmpR-
His6) 
>256 >256 0.042 + 0.002 1.295 + 0.008 
*Etests were performed in the presence of 1 mM of IPTG. 
^The vector used to construct pAmpR-His6 was pMMB67EH-Gm. 
†Cultures were induced with 1 mM of IPTG and β-lactamase activity was quantified in presence and 
absence of β-lactams (penicillin G at 200 µg ml-1 for 1h).  Assays were performed in triplicates using 
sonicated lysate and nitrocefin as a chromogenic substrate. 
 
225 
 
VSV-G-tagged AmpR is functional. The VSV-G-tagged AmpR was introduced into 
PA0ΔampR.  The inherently resistant PA01 strain shows a significant increase in 
sensitivity to both amoxicillin and ampicillin-sublactam when ampR is deleted, as 
determined by E-test (Table S3).  The resistance is restored upon integration of ampR-
VSV-G. The AmpR-VSV-G complements the ampR deletion and retains its native 
function. 
 
Table S3: Complementing assays showing VSV-G-tagged AmpR is functional. 
Strains 
Minimum Inhibitory Concentration (µg ml-1) * 
Amoxicillin Ampicillin-Sulbactam 
PA01 >256 >256 
PA0∆ampR 8 48 
PAO∆ampR::ampR-VSV-G >256 >256 
*MIC was determined by Etest. 
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Figure S1.  Multiple alignment of the ampR-ampC intergenic region. The C. freundii, E. 
cloacae and P. aeruginosa ampR-ampC intergenic regions were aligned using ClustalW2. 
The ampR and ampC ORFs (arrows), TSSs (triangles), and sigma sequences (underlined) 
are depicted in blue and green, respectively.  A downstream shift in the P. aeruginosa 
ampR TSS is likely responsible for the change in sigma factor control observed here.  
Orange arrows denote palindromic sequences. 
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Figure S2.  Localization studies of P. aeruginosa AmpR.  (A) Restriction map and 
topology of AmpR.  The topology of AmpR was investigated by introducing phoA and 
lacZ fusions at the restriction sites HindIII, HincII and PstI restriction sites corresponding 
to amino acid positions Glu15, Val134 and Gln185, respectively.  Fusions at Glu15 were 
LacZ-positive but PhoA-negative, whereas fusions at Val134 and Gln185 were PhoA-
positive and LacZ-negative. (B) Spheroplasts of PA0ΔampR (pAmpR-His6) were 
obtained and treated with 10 µg/ml of Proteinase K for varying lengths of time. Anti-
AmpR antibodies were used to monitor the presence of the full-length AmpR (32 kDA) 
and the shaved product (10 kDa) by Western blotting. The membranes were stripped and 
re-probed with anti-σ70 antibodies. 
  
B 
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Figure S3. Multiple alignment of the AmpR HTH motif.  N-terminal sequences from P. 
aeruginosa, C. freundii, E. cloacae, K. pneumonia, A. tumefaciens, O. anthropic, and L. 
hongkongensis AmpR were aligned using ClustalW2 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/).  Asterisks denote conserved residues that 
do not deviate from those in the reference sequence of P. aeruginosa.  Residues denoted 
in red were replaced with alanine in P. aeruginosa AmpR-His6 by site-directed 
mutagenesis.   
 
SUPPLEMENTAL MATERIALS AND METHODS 
 
β-lactamase assay. The β-lactamase assay was modified from a previously published 
protocol (765).  Briefly, stationary-phase cultures were diluted in 30 ml of LB broth to an 
OD600 of 0.02 and incubated with shaking at 37°C.  At an OD600 of 0.2, cells containing 
the expression plasmid were induced with 1 mM IPTG for an hour.  At an OD600 of 0.6, 
the remaining cultures were induced with 200 µg ml
-1
 of penicillin G for an hour before 
harvesting. Cells were harvested by centrifugation, resuspended in 1 ml of 50 mM of 
sodium phosphate buffer and sonicated on ice for 1 min 20 s (20-sec pulse ON, 20-sec 
pulse OFF, amplitude 30%). The sonicated cells were centrifuged at 10,000 X g at 4°C 
for 30 minutes to collect the β-lactamase-containing supernatant.  A 2-µl aliquot of cell 
lysate is added to nitrocefin (final concentration, 100 µM) in 1 ml of assay buffer.  The 
reaction was incubated at 37°C for 20 minutes and the hydrolysis of nitrocefin was 
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measured spectrophotometrically at 482 nm.  Total protein concentration was determined 
with Bradford on the same supernatant. The activity was expressed as nmol of nitrocefin 
degraded per minute per milligram of total protein. 
 
Minimum Inhibitory concentration (MIC).  The MIC was determined by the E-test 
system according to the manufacturer’s instructions (bioMérieux, Marcy l’Etoile).   
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